<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anti‐seizure medications for neonates with seizures - Abiramalatha, T - 2023 | Cochrane Library</title> <meta content="Anti‐seizure medications for neonates with seizures - Abiramalatha, T - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014967.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Anti‐seizure medications for neonates with seizures - Abiramalatha, T - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014967.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD014967.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Anti‐seizure medications for neonates with seizures" name="citation_title"/> <meta content="Thangaraj Abiramalatha" name="citation_author"/> <meta content="abi_paeds@yahoo.com" name="citation_author_email"/> <meta content="Sivam Thanigainathan" name="citation_author"/> <meta content="All India Institute of Medical Sciences" name="citation_author_institution"/> <meta content="Viraraghavan Vadakkencherry Ramaswamy" name="citation_author"/> <meta content="Ankura Hospital for Women and Children" name="citation_author_institution"/> <meta content="Ronit Pressler" name="citation_author"/> <meta content="Francesco Brigo" name="citation_author"/> <meta content="Hans Hartmann" name="citation_author"/> <meta content="Hannover Medical School" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD014967.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/10/24" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014967.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014967.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014967.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Epilepsy [drug therapy]; Levetiracetam [therapeutic use]; Phenobarbital [therapeutic use]; *Phenytoin [therapeutic use]; Seizures [drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014967.pub2&amp;doi=10.1002/14651858.CD014967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="XHP2gG4h";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD014967\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD014967\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014967\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014967\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","th","ms","hr","fa","id","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD014967.pub2",title:"Anti\\u2010seizure medications for neonates with seizures",firstPublishedDate:"Oct 24, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neonatal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XHP2gG4h&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014967.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014967.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD014967.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD014967.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014967.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD014967.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;riskOfBias2&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of Bias&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD014967.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD014967.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD014967.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD014967.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3035 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD014967.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full#CD014967-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full#CD014967-sec-0251"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full#CD014967-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full#CD014967-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full#CD014967-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full#CD014967-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full#CD014967-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full#CD014967-sec-0245"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/appendices#CD014967-sec-0256"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2"> Risk of bias </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/supinfo/CD014967-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/supinfo/CD014967-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Anti‐seizure medications for neonates with seizures</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/information#CD014967-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Thangaraj Abiramalatha</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/information#CD014967-cr-0005">Sivam Thanigainathan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/information#CD014967-cr-0006">Viraraghavan Vadakkencherry Ramaswamy</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/information#CD014967-cr-0007">Ronit Pressler</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/information#CD014967-cr-0008">Francesco Brigo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014967.pub2/information#CD014967-cr-0009">Hans Hartmann</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/information/en#CD014967-sec-0273">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 24 October 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD014967.pub2">https://doi.org/10.1002/14651858.CD014967.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD014967-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014967-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD014967-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014967-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014967-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD014967-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014967-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD014967-abs-0001" lang="en"> <section id="CD014967-sec-0001"> <h3 class="title" id="CD014967-sec-0001">Background</h3> <p>Newborn infants are more prone to seizures than older children and adults. The neuronal injury caused by seizures in neonates often results in long‐term neurodevelopmental sequelae. There are several options for anti‐seizure medications (ASMs) in neonates. However, the ideal choice of first‐, second‐ and third‐line ASM is still unclear. Further, many other aspects of seizure management such as whether ASMs should be initiated for only‐electrographic seizures and how long to continue the ASM once seizure control is achieved are elusive. </p> </section> <section id="CD014967-sec-0002"> <h3 class="title" id="CD014967-sec-0002">Objectives</h3> <p>1. To assess whether any ASM is more or less effective than an alternative ASM (both ASMs used as first‐, second‐ or third‐line treatment) in achieving seizure control and improving neurodevelopmental outcomes in neonates with seizures. We analysed EEG‐confirmed seizures and clinically‐diagnosed seizures separately. </p> <p>2. To assess maintenance therapy with ASM versus no maintenance therapy after achieving seizure control. We analysed EEG‐confirmed seizures and clinically‐diagnosed seizures separately. </p> <p>3. To assess treatment of both clinical and electrographic seizures versus treatment of clinical seizures alone in neonates. </p> </section> <section id="CD014967-sec-0003"> <h3 class="title" id="CD014967-sec-0003">Search methods</h3> <p>We searched MEDLINE, Embase, CENTRAL, Epistemonikos and three databases in May 2022 and June 2023. These searches were not limited other than by study design to trials. </p> </section> <section id="CD014967-sec-0004"> <h3 class="title" id="CD014967-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) that included neonates with EEG‐confirmed or clinically diagnosed seizures and compared (1) any ASM versus an alternative ASM, (2) maintenance therapy with ASM versus no maintenance therapy, and (3) treatment of clinical or EEG seizures versus treatment of clinical seizures alone. </p> </section> <section id="CD014967-sec-0005"> <h3 class="title" id="CD014967-sec-0005">Data collection and analysis</h3> <p>Two review authors assessed trial eligibility, risk of bias and independently extracted data. We analysed treatment effects in individual trials and reported risk ratio (RR) for dichotomous data, and mean difference (MD) for continuous data, with respective 95% confidence interval (CI). We used GRADE to assess the certainty of evidence. </p> </section> <section id="CD014967-sec-0006"> <h3 class="title" id="CD014967-sec-0006">Main results</h3> <p>We included 18 trials (1342 infants) in this review.</p> <p><b>Phenobarbital versus levetiracetam as first‐line ASM in EEG‐confirmed neonatal seizures (one trial)</b> </p> <p>Phenobarbital is probably more effective than levetiracetam in achieving seizure control after first loading dose (RR 2.32, 95% CI 1.63 to 3.30; 106 participants; moderate‐certainty evidence), and after maximal loading dose (RR 2.83, 95% CI 1.78 to 4.50; 106 participants; moderate‐certainty evidence). However, we are uncertain about the effect of phenobarbital when compared to levetiracetam on mortality before discharge (RR 0.30, 95% CI 0.04 to 2.52; 106 participants; very low‐certainty evidence), requirement of mechanical ventilation (RR 1.21, 95% CI 0.76 to 1.91; 106 participants; very low‐certainty evidence), sedation/drowsiness (RR 1.74, 95% CI 0.68 to 4.44; 106 participants; very low‐certainty evidence) and epilepsy post‐discharge (RR 0.92, 95% CI 0.48 to 1.76; 106 participants; very low‐certainty evidence). The trial did not report on mortality or neurodevelopmental disability at 18 to 24 months. </p> <p><b>Phenobarbital versus phenytoin as first‐line ASM in EEG‐confirmed neonatal seizures (one trial)</b> </p> <p>We are uncertain about the effect of phenobarbital versus phenytoin on achieving seizure control after maximal loading dose of ASM (RR 0.97, 95% CI 0.54 to 1.72; 59 participants; very low‐certainty evidence). The trial did not report on mortality or neurodevelopmental disability at 18 to 24 months. </p> <p><b>Maintenance therapy with ASM versus no maintenance therapy in clinically diagnosed neonatal seizures (two trials)</b> </p> <p>We are uncertain about the effect of short‐term maintenance therapy with ASM versus no maintenance therapy during the hospital stay (but discontinued before discharge) on the risk of repeat seizures before hospital discharge (RR 0.76, 95% CI 0.56 to 1.01; 373 participants; very low‐certainty evidence). Maintenance therapy with ASM compared to no maintenance therapy may have little or no effect on mortality before discharge (RR 0.69, 95% CI 0.39 to 1.22; 373 participants; low‐certainty evidence), mortality at 18 to 24 months (RR 0.94, 95% CI 0.34 to 2.61; 111 participants; low‐certainty evidence), neurodevelopmental disability at 18 to 24 months (RR 0.89, 95% CI 0.13 to 6.12; 108 participants; low‐certainty evidence) and epilepsy post‐discharge (RR 3.18, 95% CI 0.69 to 14.72; 126 participants; low‐certainty evidence). </p> <p><b>Treatment of both clinical and electrographic seizures versus treatment of clinical seizures alone in neonates (two trials)</b> </p> <p>Treatment of both clinical and electrographic seizures when compared to treating clinical seizures alone may have little or no effect on seizure burden during hospitalisation (MD ‐1871.16, 95% CI ‐4525.05 to 782.73; 68 participants; low‐certainty evidence), mortality before discharge (RR 0.59, 95% CI 0.28 to 1.27; 68 participants; low‐certainty evidence) and epilepsy post‐discharge (RR 0.75, 95% CI 0.12 to 4.73; 35 participants; low‐certainty evidence). The trials did not report on mortality or neurodevelopmental disability at 18 to 24 months. </p> <p>We report data from the most important comparisons here; readers are directed to Results and Summary of Findings tables for all comparisons. </p> </section> <section id="CD014967-sec-0007"> <h3 class="title" id="CD014967-sec-0007">Authors' conclusions</h3> <p>Phenobarbital as a first‐line ASM is probably more effective than levetiracetam in achieving seizure control after the first loading dose and after the maximal loading dose of ASM (moderate‐certainty evidence). Phenobarbital + bumetanide may have little or no difference in achieving seizure control when compared to phenobarbital alone (low‐certainty evidence). Limited data and very low‐certainty evidence preclude us from drawing any reasonable conclusion on the effect of using one ASM versus another on other short‐ and long‐term outcomes. </p> <p>In neonates who achieve seizure control after the first loading dose of phenobarbital, maintenance therapy compared to no maintenance ASM may have little or no effect on all‐cause mortality before discharge, mortality by 18 to 24 months, neurodevelopmental disability by 18 to 24 months and epilepsy post‐discharge (low‐certainty evidence). </p> <p>In neonates with hypoxic‐ischaemic encephalopathy, treatment of both clinical and electrographic seizures when compared to treating clinical seizures alone may have little or no effect on seizure burden during hospitalisation, all‐cause mortality before discharge and epilepsy post‐discharge (low‐certainty evidence). </p> <p>All findings of this review apply only to term and late preterm neonates.</p> <p>We need well‐designed RCTs for each of the three objectives of this review to improve the precision of the results. These RCTs should use EEG to diagnose seizures and should be adequately powered to assess long‐term neurodevelopmental outcomes. We need separate RCTs evaluating the choice of ASM in preterm infants. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD014967-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014967-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD014967-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD014967-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014967-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014967-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD014967-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/id#CD014967-abs-0013">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ms#CD014967-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD014967-abs-0014">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD014967-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014967-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD014967-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD014967-abs-0002" lang="en"> <h3>Medication to treat fits in newborn babies</h3> <p><b>Review questions</b> </p> <p>What medication can be used effectively and safely to treat seizures in newborns?</p> <p>How long should the medication for seizures be continued once started?</p> <p>Should we treat seizures that are seen only on the EEG?</p> <p><b>Note:</b> </p> <p><i>EEG is a test to analyse the electrical activity of the brain. It identifies seizure activity as well.</i> </p> <p><i>Phenobarbital and levetiracetam are anti‐seizure medications used in newborns.</i> </p> <p><i>'Maintenance treatment' refers to continuing the anti‐seizure medication at a smaller dose, once seizures are stopped with a larger dose of the medication.</i> </p> <p><b>Key messages</b> </p> <p>Phenobarbital is probably more effective than levetiracetam in achieving seizure control in newborns. However, we are uncertain about the effect of phenobarbital compared to levetiracetam on other outcomes. </p> <p>Maintenance treatment with anti‐seizure medication during hospital stay and treating seizures only identified on EEG may or may not result in better outcomes in newborns. </p> <p><b>Background</b> </p> <p>Newborns are more prone to develop seizures when compared to older children and adults. The brain damage caused by seizures in newborns is associated with cerebral palsy, intellectual disability, learning problems and a tendency to develop epilepsy in the future. There are only a few options for medications to treat seizures in newborns, and we do not know which is the ideal medication to use first, second or third. Similarly, whether to treat the seizures that are seen only on EEG and how long to continue the anti‐seizure medication is also not clear. </p> <p><b>What did we want to find?</b> </p> <p>We looked for evidence from studies that assessed one medication versus another to treat seizures in newborns, studies that evaluated whether maintenance doses of anti‐seizure medication should be continued or not, and studies that assessed whether to treat seizures that were identified only on EEG. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that evaluated the effects of medications on treating seizures in newborns. We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We identified 18 trials (including 1342 newborns).</p> <p>Phenobarbital is probably more effective than levetiracetam in achieving seizure control in newborns. However, we are uncertain about the effect of phenobarbital on other outcomes such as death before discharge, requirement for invasive ventilation, sleepiness and epilepsy after discharge. </p> <p>Maintenance therapy with anti‐seizure medication during hospital stay compared to no maintenance therapy may or may not result in better outcomes for newborns. Similarly, treating seizures only identified on EEG may or may not result in better outcomes. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We are moderately confident that phenobarbital is better than levetiracetam in achieving seizure control. The confidence for the estimates of all other comparisons and outcomes is low to very low. More studies are needed to synthesise strong evidence on medications to treat seizures in newborns. </p> <p><b>How up‐to‐date is this evidence?</b> </p> <p>Evidence is up‐to‐date as of June 2023.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD014967-sec-0251" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD014967-sec-0251"></div> <h3 class="title" id="CD014967-sec-0252">Implications for practice</h3> <section id="CD014967-sec-0252"> <p>Phenobarbital is probably more effective than levetiracetam in achieving seizure control after the first loading dose and after the maximal loading dose (moderate‐certainty evidence). Phenobarbital may be more effective than phenytoin in achieving seizure control after the first loading dose (low‐certainty evidence). However, as the latter finding is based on trials that utilised clinical diagnosis of seizures, this needs to be confirmed by a well‐powered RCT evaluating EEG‐confirmed seizures. Phenobarbital + bumetanide may have little or no difference in achieving seizure control when compared to phenobarbital alone (low‐certainty evidence). Limited data and very low‐certainty evidence preclude us from drawing any reasonable conclusion on the effect of using one ASM versus another on other short‐ and long‐term outcomes. </p> <p>In neonates with HIE, treatment of both clinical and electrographic seizures when compared to treating clinical seizures alone may have little or no effect on mortality before hospital discharge, seizure burden during hospitalisation, and the proportion of infants who develop epilepsy post‐discharge (low‐certainty evidence). </p> <p>In neonates who achieve seizure control after the first loading dose of phenobarbital, maintenance therapy with ASM when compared to no maintenance ASM may have little or no effect on mortality before hospital discharge, mortality by 18 to 24 months, neurodevelopmental disability by 18 to 24 months, and proportion of infants with epilepsy post‐discharge (low‐certainty evidence). </p> <p>All findings of this review apply only to term and late preterm neonates.</p> <p>We identified 23 studies that were registered as ongoing. However, most of these were either entered into the registry five to 10 years ago without follow‐up, or results were not published in spite of the apparently achieved sample size. We identified one study investigating treatment duration that may change the conclusions of this review (<a href="./references#CD014967-bbs2-0072" title="NCT04320940. Efficacy and safety of intravenous phenobarbital in neonatal seizures. clinicaltrials.gov/ct2/show/NCT04320940 (first received 25 March 2020). [CENTRAL: CN-02089336] ">NCT04320940</a>). </p> </section> <h3 class="title" id="CD014967-sec-0253">Implications for research</h3> <section id="CD014967-sec-0253"> <p>We need well‐designed RCTs evaluating the effect of one ASM versus another to improve the precision of the results. These RCTs should use EEG to diagnose seizures, as clinical diagnosis of seizures is prone to errors and inaccurate. These studies should be adequately powered to assess the effect of ASMs on long‐term neurodevelopmental outcomes. As seizures are not uncommon in preterm neonates, we need separate RCTs evaluating the choice of ASM in this vulnerable population. </p> <p>Similarly, the other two questions 'whether to treat only‐electrographic seizures with ASM or not' and 'whether to give routine maintenance therapy with ASM after achieving seizure control with loading doses of ASM' are very pertinent for the clinical management of neonates with seizures. We need further RCTs on these to evaluate the effect of ASM on short‐ and long‐term outcomes with more precision. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD014967-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD014967-sec-0008"></div> <div class="table" id="CD014967-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates with EEG‐confirmed seizures<br/><b>Setting:</b> Neonatal intensive care unit<br/><b>Intervention:</b> phenobarbital as first‐line ASM<br/><b>Comparison:</b> levetiracetam as first‐line ASM </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with levetiracetam as first‐line ASM</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with phenobarbital as first‐line ASM</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after the first loading dose of ASM </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>359 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>834 per 1000</b><br/>(586 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.32</b><br/>(1.63 to 3.30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after the maximal loading dose of ASM </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>283 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>801 per 1000</b><br/>(504 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.83</b><br/>(1.78 to 4.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality or neurodevelopment disability at 18 to 24 months' corrected age ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality before hospital discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b><br/>(3 to 197) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.30</b><br/>(0.04 to 2.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Requirement of mechanical ventilation</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>375 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>454 per 1000</b><br/>(285 to 716) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.21</b><br/>(0.76 to 1.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who develop sedation or drowsiness</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>190 per 1000</b><br/>(74 to 486) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.74</b><br/>(0.68 to 4.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who develop epilepsy post‐discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>481 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>443 per 1000</b><br/>(231 to 847) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b><br/>(0.48 to 1.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438900176882570386" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438900176882570386</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by one level for serious imprecision due to small small size not meeting the 'Optimal Information Size' criteria<br/><sup>b</sup> Downgraded by one level for indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs as well.<br/><sup>c</sup> Downgraded by two levels for very serious imprecision due to very low sample size and event rate not meeting the 'Optimal Information Size' criteria </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014967-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ Phenobarbital versus levetiracetam as first‐line ASM for clinically diagnosed neonatal seizures</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbital versus levetiracetam as first‐line ASM for clinically diagnosed neonatal seizures</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> clinically diagnosed neonatal seizures<br/><b>Setting:</b> Neonatal intensive care unit<br/><b>Intervention:</b> phenobarbital as first‐line ASM<br/><b>Comparison:</b> levetiracetam as first‐line ASM </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with levetiracetam as first‐line ASM</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with phenobarbital as first‐line ASM</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after first loading dose of ASM</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>443 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>306 per 1000</b><br/>(244 to 381) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.69</b><br/>(0.55 to 0.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>286<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after maximal loading dose of ASM</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>777 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>451 per 1000</b><br/>(365 to 559) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.58</b><br/>(0.47 to 0.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality or neurodevelopment disability at 18 to 24 months' corrected age ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported in any included trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality before hospital discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>116 per 1000</b><br/>(67 to 200) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.41</b><br/>(0.82 to 2.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>452<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d,</sup><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Requirement of mechanical ventilation</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b><br/>(3 to 49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.20</b><br/>(0.50 to 9.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>394<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,</sup><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who develop sedation or drowsiness</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b><br/>(36 to 292) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.88</b><br/>(0.66 to 5.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c,</sup><sup>d,</sup><sup>e,</sup><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who develop epilepsy post discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>133 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b><br/>(7 to 659) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.50</b><br/>(0.05 to 4.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>f,</sup><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_442643727142716799" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_442643727142716799</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for very serious risk of bias due to 'high risk of bias' in 2 trials and some concerns in the other trial<br/><sup>b</sup> Downgraded by one level for serious imprecision due to small sample size not meeting the 'Optimal Information Size' criterion<br/><sup>c</sup> Downgraded by two levels for very serious risk of bias due to high risk of bias in all included studies<br/><sup>d</sup> Downgraded by one level for serious indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs as well<br/><sup>e</sup> Downgraded by one level for serious imprecision due to low event rate not meeting the 'Optimal Information Size' criteria <br/><sup>f</sup> Downgraded by two levels for very serious imprecision due to single digit event rate<br/><sup>g</sup> Downgraded by one level for serious inconsistency due to substantial heterogeneity<br/><sup>h</sup> Downgraded by two levels for very serious risk of bias due to high risk of bias in the only included study </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014967-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings table ‐ Phenobarbital versus phenytoin as first‐line ASM for EEG‐confirmed neonatal seizures</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbital versus phenytoin as first‐line ASM for EEG‐confirmed neonatal seizures</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates with EEG‐confirmed seizures<br/><b>Setting:</b> Neonatal intensive care unit<br/><b>Intervention:</b> phenobarbital as first‐line ASM<br/><b>Comparison:</b> phenytoin as first‐line ASM </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with phenytoin as first‐line ASM</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with phenobarbital as first‐line ASM</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after the first loading dose of ASM ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial did not report this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after the maximal loading dose of ASM </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>448 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>435 per 1000</b><br/>(242 to 771) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.97</b><br/>(0.54 to 1.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial did not report this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438951560046041157" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438951560046041157</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for very serious risk of bias due to high risk of bias in the only included trial<br/><sup>b</sup> Downgraded by two levels for very serious imprecision due to very low sample size and event rate not meeting the 'Optimal Information Size' criteria </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014967-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings table ‐ Phenobarbital versus phenytoin as first‐line ASM for clinically diagnosed neonatal seizures</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbital versus phenytoin as first‐line ASM for clinically diagnosed neonatal seizures</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates with clinically diagnosed seizures<br/><b>Setting:</b> Neonatal intensive care unit<br/><b>Intervention:</b> phenobarbital as first‐line ASM<br/><b>Comparison:</b> phenytoin as first‐line ASM </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with phenytoin as first‐line ASM</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with phenobarbital as first‐line ASM</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after first loading dose of ASM</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>356 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>683 per 1000</b><br/>(498 to 939) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.92</b><br/>(1.40 to 2.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after maximal loading dose ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neither of the two included trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neither of the two included trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality before hospital discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>211 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>281 per 1000</b><br/>(167 to 477) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.33</b><br/>(0.79 to 2.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c,</sup><sup>d,</sup><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Requirement of mechanical ventilation</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 7.13</b><br/>(0.38 to 134.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,</sup><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who develop sedation or drowsiness</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 23.00</b><br/>(1.41 to 375.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,</sup><sup>f,</sup><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438949398863786458" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438949398863786458</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by one level for serious risk of bias as the trial contributing &gt; 50% weighting to the estimate has a high risk of overall bias<br/><sup>b</sup> Downgraded by one level for serious inconsistency as there was considerable heterogeneity (I2 = 96%)<br/><sup>c</sup> Downgraded by one level for serious inconsistency as there was substantial heterogeneity (I2=82%)<br/><sup>d</sup> Downgraded by one level for serious indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs as well<br/><sup>e</sup> Downgraded by one level for serious imprecision for sample size and event rate not meeting the 'Optimal Information Size' criteria <br/><sup>f</sup> Downgraded by two levels for very serious imprecision due to very low sample size and event rate not meeting the 'Optimal Information Size' criteria<br/><sup>g</sup> Downgraded by two levels for very serious risk of bias due to high risk of bias in the only included trial </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014967-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings table ‐ Phenobarbital versus Lorazepam as first‐line ASM for clinically diagnosed neonatal seizures</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbital versus Lorazepam as first‐line ASM for clinically diagnosed neonatal seizures</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Neonates with clinically diagnosed seizures<br/><b>Setting:</b> Neonatal intensive care unit<br/><b>Intervention:</b> Phenobarbital as first‐line ASM<br/><b>Comparison:</b> Lorazepam as first‐line ASM </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Lorazepam as first‐line ASM</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Phenobarbital as first‐line ASM</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after the first loading dose of ASM </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>889 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>631 per 1000</b><br/>(471 to 836) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.71</b><br/>(0.53 to 0.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after the maximal loading dose of ASM ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality before hospital discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>194 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>342 per 1000</b><br/>(154 to 768) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.76</b><br/>(0.79 to 3.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who develop sedation or drowsiness</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>314 per 1000</b><br/>(75 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5.66</b><br/>(1.35 to 23.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438956545731624502" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438956545731624502</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for very serious risk of bias due to high risk of bias in the only included trial<br/><sup>b</sup> Downgraded by one level for serious imprecision for sample size and event rate not meeting the 'Optimal Information Size' criteria<br/><sup>c</sup> Downgraded by one level for serious indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs as well<br/><sup>d</sup> Downgraded by two levels for very serious imprecision due to very low sample size and event rate not meeting the 'Optimal Information Size' criteria </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014967-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings table ‐ Phenytoin versus lorazepam as first‐line ASM for clinically diagnosed neonatal seizures</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenytoin versus lorazepam as first‐line ASM for clinically diagnosed neonatal seizures</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates with clinically diagnosed seizures<br/><b>Setting:</b> Neonatal intensive care unit<br/><b>Intervention:</b> phenytoin as first‐line ASM<br/><b>Comparison:</b> lorazepam as first‐line ASM </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with lorazepam as first‐line ASM</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with phenytoin as first‐line ASM</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after the first loading dose of ASM </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>889 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>684 per 1000</b><br/>(533 to 880) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.77</b><br/>(0.60 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after the maximal loading dose of ASM ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality before hospital discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>194 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>86 per 1000</b><br/>(23 to 305) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.44</b><br/>(0.12 to 1.57) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who develop sedation or drowsiness</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b><br/>(1 to 229) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.21</b><br/>(0.01 to 4.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438956906630512363" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438956906630512363</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for very serious risk of bias due to high risk of bias in the only included trial<br/><sup>b</sup> Downgraded by one level for serious imprecision for sample size and event rate not meeting the 'Optimal Information Size' criteria<br/><sup>c</sup> Downgraded by one level for serious indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs as well.<br/><sup>d</sup> Downgraded by two levels for very serious imprecision due to very low sample size and event rate not meeting the 'Optimal Information Size' criteria </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014967-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Summary of findings table ‐ Phenobarbital + bumetanide versus phenobarbital alone for EEG‐confirmed neonatal seizures</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbital + bumetanide versus phenobarbital alone for EEG‐confirmed neonatal seizures</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates with EEG‐confirmed seizures<br/><b>Setting:</b> Neonatal intensive care unit<br/><b>Intervention:</b> phenobarbital + bumetanide<br/><b>Comparison:</b> phenobarbital alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with phenobarbital alone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with phenobarbital + bumetanide</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after the first loading dose of ASM </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>313 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>297 per 1000</b><br/>(116 to 750) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b><br/>(0.37 to 2.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after the maximal loading dose of the ASM ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality before hospital discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>188 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b><br/>(4 to 326) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.20</b><br/>(0.02 to 1.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive impairment at 18‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>159 per 1000</b><br/>(39 to 645) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.53</b><br/>(0.13 to 2.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Requirement of mechanical ventilation</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who develop epilepsy post‐discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>308 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>348 per 1000</b><br/>(132 to 914) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b><br/>(0.43 to 2.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438957230819281917" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438957230819281917</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for very serious imprecision due to very low sample size and event rate not meeting the 'Optimal Information Size' criteria<br/><sup>b</sup> Downgraded by one level for serious indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs as well </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014967-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Summary of findings table ‐ Lignocaine versus benzodiazepines as second‐line ASM for EEG‐confirmed neonatal seizures</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lignocaine versus benzodiazepines as second‐line ASM for EEG‐confirmed neonatal seizures</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates with EEG‐confirmed seizures<br/><b>Setting:</b> Neonatal intensive care unit<br/><b>Intervention:</b> lignocaine as second‐line ASM<br/><b>Comparison:</b> benzodiazepines as second‐line ASM </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with benzodiazepines as second‐line ASM</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with lignocaine as second‐line ASM</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after first loading dose of ASM ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after maximal loading dose of ASM</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 8.17</b><br/>(0.52 to 128.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality or neurodevelopmental disability at 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b><br/>(710 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/>(0.71 to 1.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality before hospital discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>333 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b><br/>(83 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.20</b><br/>(0.25 to 5.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurodevelopmental disability at 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>600 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>600 per 1000</b><br/>(216 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/>(0.36 to 2.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438957465149804345" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438957465149804345</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for very serious risk of bias due to high risk of bias in the only included trial<br/><sup>b</sup> Downgraded by two levels for very serious imprecision due to very low sample size and event rate not meeting the 'Optimal Information Size' criteria<br/><sup>c</sup> Downgraded by one level for serious indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs as well </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014967-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Summary of findings table ‐ Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates with clinically diagnosed seizures<br/><b>Setting:</b> Neonatal intensive care unit<br/><b>Intervention:</b> maintenance ASM after achieving seizure control<br/><b>Comparison:</b> no maintenance ASM after achieving seizure control </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no maintenance ASM after achieving seizure control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with maintenance ASM after achieving seizure control</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants with repeat seizure before hospital discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>353 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>268 per 1000</b><br/>(198 to 356) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.76</b><br/>(0.56 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>373<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neither of the two included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality before hospital discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>96 per 1000</b><br/>(54 to 170) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.69</b><br/>(0.39 to 1.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>373<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality at 18‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>121 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>113 per 1000</b><br/>(41 to 315) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b><br/>(0.34 to 2.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurodevelopmental disability at 18‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>35 per 1000</b><br/>(5 to 240) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b><br/>(0.13 to 6.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who develop epilepsy post‐discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>106 per 1000</b><br/>(23 to 491) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.18</b><br/>(0.69 to 14.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438158727822576253" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438158727822576253</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by one level for risk of bias due to 'some concerns' in the risk of bias in both the included studies<br/><sup>b</sup> Downgraded by two levels for very serious imprecision due to very low sample size and event rate not meeting the 'Optimal Information Size' criteria </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014967-tbl-0010"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Summary of findings table ‐ Treatment of clinical and electrographic seizures versus treatment of clinical seizures alone in neonates</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Treatment of clinical and electrographic seizures versus treatment of clinical seizures alone in neonates</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates<br/><b>Setting:</b> Neonatal intensive care unit<br/><b>Intervention:</b> treatment of clinical and electrographic seizures<br/><b>Comparison:</b> treatment of clinical seizures alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with treatment of clinical seizures alone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with treatment of clinical and electrographic seizures</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seizure burden during hospitalisation</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean seizure burden during hospitalisation was <b>0</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>1871.16 lower</b><br/>(4525.05 lower to 782.73 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality before hospital discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>345 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>203 per 1000</b><br/>(97 to 438) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.59</b><br/>(0.28 to 1.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who develop epilepsy post‐discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>133 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><br/>(16 to 631) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.75</b><br/>(0.12 to 4.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438901735468111265" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438901735468111265</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for very serious imprecision due to very low sample size and event rate not meeting the 'Optimal Information Size' criteria </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD014967-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD014967-sec-0009"></div> <section id="CD014967-sec-0010"> <h3 class="title" id="CD014967-sec-0010">Description of the condition</h3> <p>The term 'seizure' is defined as a transient occurrence of signs or symptoms, due to abnormal excessive or synchronous neuronal activity in the brain (<a href="./references#CD014967-bbs2-0093" title="FisherRS , vanEmdeBW , BlumeW , ElgerC , GentonP , LeeP , et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia2005;46(4):470-2. [DOI: 10.1111/j.0013-9580.2005.66104.x] [PMID: 15816939]">Fisher 2005</a>). However, this definition does not include electrographic‐only seizures. The American Clinical Neurophysiology Society (ACNS) defines electrographic seizures in neonates based on electroencephalogram (EEG) as "a sudden, abnormal EEG event, defined by a repetitive and evolving pattern with a minimum 2 μV peak‐to‐peak voltage and duration of at least 10 seconds" (<a href="./references#CD014967-bbs2-0135" title="PresslerRM , CilioMR , MizrahiEM , MoshéSL , NunesML , PlouinP , et al. The ILAE classification of seizures and the epilepsies: modification for seizures in the neonate. Position paper by the ILAE Task Force on Neonatal Seizures. Epilepsia2021;62(3):615-28. [DOI: 10.1111/epi.16815] [PMID: 33522601]">Pressler 2021</a>; <a href="./references#CD014967-bbs2-0158" title="TsuchidaTN , WusthoffCJ , ShellhaasRA , HahnCD , SullivanJE , NguyenS , et al, American Clinical Neurophysiology Society Critical Care Monitoring Committee. American Clinical Neurophysiology Society standardized EEG terminology and categorization for the description of continuous EEG monitoring in neonates: report of the American Clinical Neurophysiology Society Critical Care Monitoring Committee. Journal of Clinical Neurophysiology: Official Publication of the American Electroencephalographic Society.2013;30(2):161-73. [DOI: 10.1097/WNP.0b013e3182872b24] [PMID: 23545767]">Tsuchida 2013</a>). The incidence of neonatal seizures ranges from 1.5 to 5.5 per 1000 live births in term infants and 11 to 19 per 1000 live births in preterm infants (<a href="./references#CD014967-bbs2-0082" title="BuraniqiE , SansevereAJ , KapurK , BerginAM , PearlPL , LoddenkemperT . Electrographic seizures in preterm neonates in the neonatal intensive care unit. Journal of Child Neurology2017;32(10):880-5. [DOI: 10.1177/0883073817713918] [PMID: 28691593]">Buraniqi 2017</a>; <a href="./references#CD014967-bbs2-0114" title="LanskaMJ , LanskaDJ , BaumannRJ , KryscioRJ . A population-based study of neonatal seizures in Fayette County, Kentucky. Neurology1995;45(4):724-32. [DOI: 10.1212/wnl.45.4.724] [PMID: 7723962]">Lanska 1995</a>; <a href="./references#CD014967-bbs2-0139" title="RonenGM , PenneyS , AndrewsW . The epidemiology of clinical neonatal seizures in Newfoundland: a population-based study. Journal of Pediatrics1999;134(1):71-5. [DOI: 10.1016/s0022-3476(99)70374-4] [PMID: 9880452]">Ronen 1999</a>; <a href="./references#CD014967-bbs2-0141" title="SalibaRM , AnnegersJF , WallerDK , TysonJE , MizrahiEM . Incidence of neonatal seizures in Harris County, Texas, 1992-1994. American Journal of Epidemiology1999;150(7):763-9. [DOI: 10.1093/oxfordjournals.aje.a010079] [PMID: 10512430]">Saliba 1999</a>; <a href="./references#CD014967-bbs2-0161" title="VasudevanC , LeveneM . Epidemiology and aetiology of neonatal seizures. Seminars in Fetal &amp; Neonatal Medicine2013;18(4):185-91. [DOI: 10.1016/j.siny.2013.05.008] [PMID: 23746578]">Vasudevan 2013</a>). The clinical manifestations of neonatal seizures are motor (clonic, tonic, myoclonic, spasms or automatisms), non‐motor (autonomic or behavioural arrest) or a combination of both (sequential) (<a href="./references#CD014967-bbs2-0135" title="PresslerRM , CilioMR , MizrahiEM , MoshéSL , NunesML , PlouinP , et al. The ILAE classification of seizures and the epilepsies: modification for seizures in the neonate. Position paper by the ILAE Task Force on Neonatal Seizures. Epilepsia2021;62(3):615-28. [DOI: 10.1111/epi.16815] [PMID: 33522601]">Pressler 2021</a>). </p> <p>Hypoxic‐ischaemic encephalopathy (HIE), a form of neonatal encephalopathy caused by perinatal asphyxia, is the most common cause of neonatal seizures. The other major causes are focal ischaemic lesions (stroke), intracranial haemorrhage, central nervous system (CNS) infections, CNS malformations, inborn errors of metabolism and genetic causes (<a href="./references#CD014967-bbs2-0114" title="LanskaMJ , LanskaDJ , BaumannRJ , KryscioRJ . A population-based study of neonatal seizures in Fayette County, Kentucky. Neurology1995;45(4):724-32. [DOI: 10.1212/wnl.45.4.724] [PMID: 7723962]">Lanska 1995</a>; <a href="./references#CD014967-bbs2-0139" title="RonenGM , PenneyS , AndrewsW . The epidemiology of clinical neonatal seizures in Newfoundland: a population-based study. Journal of Pediatrics1999;134(1):71-5. [DOI: 10.1016/s0022-3476(99)70374-4] [PMID: 9880452]">Ronen 1999</a>; <a href="./references#CD014967-bbs2-0156" title="TekgulH , GauvreauK , SoulJ , MurphyL , RobertsonR , StewartJ , et al. The current etiologic profile and neurodevelopmental outcome of seizures in term newborn infants. Pediatrics2006;117(4):1270-80. [DOI: 10.1542/peds.2005-1178] [PMID: 16585324]">Tekgul 2006</a>). Though most neonatal seizures are acutely provoked (i.e. they are caused by an acute brain insult), 10% to 20% are the first manifestation of epilepsy (<a href="./references#CD014967-bbs2-0148" title="ShellhaasRA , WusthoffCJ , TsuchidaTN , GlassHC , ChuCJ , MasseySL , et al, Neonatal Seizure Registry. Profile of neonatal epilepsies: characteristics of a prospective US cohort. Neurology2017;89(9):893-9. [DOI: 10.1212/WNL.0000000000004284] [PMID: 28733343]">Shellhaas 2017</a>). </p> <p>A newborn infant's brain is more vulnerable to developing seizures compared to the brain of older children and adults. This is due to the imbalance between excitatory and inhibitory neurotransmitters; there is excessive excitatory glutamate activity and deficient inhibitory gamma‐aminobutyric acid (GABA) activity in the immature neonatal brain. Moreover, GABA exerts a paradoxical excitatory action in the neonatal brain due to delayed expression of potassium chloride co‐transporter 2 (KCC2) receptors, which result in high intracellular chloride concentration and depolarisation (<a href="./references#CD014967-bbs2-0088" title="DzhalaVI , StaleyKJ . Excitatory actions of endogenously released GABA contribute to initiation of ictal epileptiform activity in the developing hippocampus. Journal of Neuroscience: The Official Journal of the Society for Neuroscience2003;23(5):1840-6. [DOI: 10.1523/JNEUROSCI.23-05-01840.2003] [PMID: 12629188]">Dzhala 2003</a>; <a href="./references#CD014967-bbs2-0089" title="DzhalaVI , TalosDM , SdrullaDA , BrumbackAC , MathewsGC , BenkeTA , et al. NKCC1 transporter facilitates seizures in the developing brain. Nature Medicine2005;11(11):1205-13. [DOI: 10.1038/nm1301] [PMID: 16227993]">Dzhala 2005</a>; <a href="./references#CD014967-bbs2-0106" title="HuttenlocherPR , deCourtenC , GareyLJ , Van der LoosH . Synaptogenesis in human visual cortex--evidence for synapse elimination during normal development. Neuroscience Letters1982;33(3):247-52. [DOI: 10.1016/0304-3940(82)90379-2] [PMID: 7162689]">Huttenlocher 1982</a>; <a href="./references#CD014967-bbs2-0110" title="KhazipovR , KhalilovI , TyzioR , MorozovaE , Ben-AriY , HolmesGL . Developmental changes in GABAergic actions and seizure susceptibility in the rat hippocampus. European Journal of Neuroscience2004;19(3):590-600. [DOI: 10.1111/j.0953-816x.2003.03152.xAbstract] [PMID: 14984409]">Khazipov 2004</a>; <a href="./references#CD014967-bbs2-0153" title="TakashimaS , ChanF , BeckerLE , ArmstrongDL . Morphology of the developing visual cortex of the human infant: a quantitative and qualitative Golgi study. Journal of Neuropathology and Experimental Neurology1980;39(4):487-501. [DOI: 10.1097/00005072-198007000-00007] [PMID: 7217997]">Takashima 1980</a>). </p> <p>Neonatal seizures are diagnosed either clinically, or by recording the electrical activity of the brain using an EEG. Recent evidence suggests that clinical diagnosis of seizures is not reliable (<a href="./references#CD014967-bbs2-0118" title="MaloneA , RyanCA , FitzgeraldA , BurgoyneL , ConnollyS , BoylanGB . Interobserver agreement in neonatal seizure identification. Epilepsia2009;50(9):2097-101. [DOI: 10.1111/j.1528-1167.2009.02132.x] [PMID: 19490044]">Malone 2009</a>; <a href="./references#CD014967-bbs2-0132" title="PellegrinS , MunozFM , PadulaM , HeathPT , MellerL , TopK , et al, Brighton Collaboration Neonatal Seizures Working Group. Neonatal seizures: case definition &amp; guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine2019;37(52):7596-609. [DOI: 10.1016/j.vaccine.2019.05.031] [PMID: 31783981]">Pellegrin 2019</a>; <a href="./references#CD014967-bbs2-0151" title="SoulJS , PresslerR , AllenM , BoylanG , RabeH , PortmanR , et al, International Neonatal Consortium. Recommendations for the design of therapeutic trials for neonatal seizures. Pediatric Research2019;85(7):943-54. [DOI: 10.1038/s41390-018-0242-2] [PMID: 30584262]">Soul 2019</a>). It is now believed that all, or nearly all, seizures have an EEG correlate, while half of all seizures have no clinical correlate (<a href="./references#CD014967-bbs2-0127" title="NashKB , BonifacioSL , GlassHC , SullivanJE , BarkovichAJ , FerrieroDM , et al. Video-EEG monitoring in newborns with hypoxic-ischemic encephalopathy treated with hypothermia. Neurology2011;76(6):556-62. [DOI: 10.1212/WNL.0b013e31820af91a] [PMID: 21300971]">Nash 2011</a>). Continuous, video‐assisted recording of conventional electroencephalography (cEEG) is considered the gold standard for diagnosing and monitoring neonatal seizures (<a href="./references#CD014967-bbs2-0084" title="ClancyRR . The contribution of EEG to the understanding of neonatal seizures. Epilepsia1996;37(Suppl 1):S52-9. [DOI: 10.1111/j.1528-1157.1996.tb06022.x] [PMID: 8647052]">Clancy 1996</a>; <a href="./references#CD014967-bbs2-0121" title="McCoyB , HahnCD . Continuous EEG monitoring in the neonatal intensive care unit. Journal of Clinical Neurophysiology: Official Publication of the American Electroencephalographic Society2013;30(2):106-14. [DOI: 10.1097/WNP.0b013e3182872919] [PMID: 23545760]">McCoy 2013</a>; <a href="./references#CD014967-bbs2-0164" title="WusthoffCJ . Diagnosing neonatal seizures and status epilepticus. Journal of Clinical Neurophysiology: Official Publication of the American Electroencephalographic Society2013;30(2):115-21. [DOI: 10.1097/WNP.0b013e3182872932] [PMID: 23545761]">Wusthoff 2013</a>). Amplitude‐integrated EEG (aEEG) is an alternative, though it may not detect all seizures due to the limited number of scalp electrodes and modification of signals (<a href="./references#CD014967-bbs2-0098" title="GlassHC , WusthoffCJ , ShellhaasRA . Amplitude-integrated electro-encephalography: the child neurologist's perspective. Journal of Child Neurology2013;28(10):1342-50. [DOI: 10.1177/0883073813488663] [PMID: 23690296]">Glass 2013</a>). Automated seizure detection using machine learning technology is increasingly used in neonatal intensive care units (NICUs) to improve the seizure detection rate (<a href="./references#CD014967-bbs2-0131" title="PavelAM , RennieJM , deVriesLS , BlennowM , ForanA , ShahDK , et al. A machine-learning algorithm for neonatal seizure recognition: a multicentre, randomised, controlled trial. Lancet. Child &amp; Adolescent Health2020;4(10):740-9. [DOI: 10.1016/S2352-4642(20)30239-X] [PMID: 32861271]">Pavel 2020</a>). However, though EEG confirmation of seizures is considered essential, treatment of seizures based on clinical diagnosis does exist as a practice in many centres, especially in resource‐limited settings. </p> <p>Seizures substantially increase the metabolic demand of the CNS (<a href="./references#CD014967-bbs2-0168" title="YounkinDP , Delivoria-PapadopoulosM , MarisJ , DonlonE , ClancyR , ChanceB . Cerebral metabolic effects of neonatal seizures measured with in vivo 31P NMR spectroscopy. Annals of Neurology1986;20(4):513-9. [DOI: 10.1002/ana.410200412] [PMID: 3789667]">Younkin 1986</a>). This results in a marked decline in brain high‐energy phosphates and glucose, causing neuronal injury by energy deprivation (<a href="./references#CD014967-bbs2-0094" title="FujikawaDG , VannucciRC , DwyerBE , WasterlainCG . Generalized seizures deplete brain energy reserves in normoxemic newborn monkeys. Brain Research1988;454(1-2):51-9. [DOI: 10.1016/0006-8993(88)90802-5] [PMID: 3136858]">Fujikawa 1988</a>). In addition, the cardiorespiratory compromise and fluctuating arterial pressure during a seizure result in hypoxic and ischaemic injury to the brain, causing neuronal cell death (<a href="./references#CD014967-bbs2-0086" title="ClozelM , DavalJL , MoninP , DubrucC , MorselliPL , VertP . Regional cerebral blood flow during bicuculline-induced seizures in the newborn piglet: effect of phenobarbital. Developmental Pharmacology and Therapeutics1985;8(3):189-99. [DOI: 10.1159/000457036] [PMID: 4006653]">Clozel 1985</a>; <a href="./references#CD014967-bbs2-0122" title="McDonaldJW , JohnstonMV . Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Research. Brain Research Reviews1990;15(1):41-70. [DOI: 10.1016/0165-0173(90)90011-c] [PMID: 2163714]">McDonald 1990</a>). The neuronal injury caused by seizures often results in long‐term neurological sequelae such as cerebral palsy, cognitive impairment, learning disabilities and future epilepsy (<a href="./references#CD014967-bbs2-0133" title="PisaniF , PiccoloB , CantalupoG , CopioliC , FuscoC , PelosiA , et al. Neonatal seizures and postneonatal epilepsy: a 7-y follow-up study. Pediatric Research2012;72(2):186-93. [DOI: 10.1038/pr.2012.66] [PMID: 22580721]">Pisani 2012</a>; <a href="./references#CD014967-bbs2-0140" title="RonenGM , BuckleyD , PenneyS , StreinerDL . Long-term prognosis inchildren with neonatal seizures: a population-based study. Neurology2007;69(19):1816-22. [DOI: 10.1212/01.wnl.0000279335.85797.2c] [PMID: 17984448]">Ronen 2007</a>; <a href="./references#CD014967-bbs2-0167" title="YildizEP , TatliB , EkiciB , EraslanE , AydinliN , CaliskanM , et al. Evaluation of etiologic and prognostic factors in neonatal convulsions. Pediatric Neurology2012;47(3):186-92. [DOI: 10.1016/j.pediatrneurol.2012.05.015] [PMID: 22883283]">Yildiz 2012</a>). </p> </section> <section id="CD014967-sec-0011"> <h3 class="title" id="CD014967-sec-0011">Description of the intervention</h3> <p>Once the immediately correctable causes of neonatal seizures, such as hypoglycaemia and hypocalcaemia, are addressed, there are several options for anti‐seizure medications (ASMs). Phenobarbitone, phenytoin and levetiracetam are the commonly used ASMs in neonates (<a href="./references#CD014967-bbs2-0149" title="SlaughterLA , PatelAD , SlaughterJL . Pharmacological treatment of neonatal seizures: a systematic review. Journal of Child Neurology2013;28(3):351-64. [DOI: 10.1177/0883073812470734] [PMID: 23318696]">Slaughter 2013</a>; <a href="./references#CD014967-bbs2-0160" title="Van RooijLG , Hellström-WestasL , De VriesLS . Treatment of neonatal seizures. Seminars in Fetal &amp; Neonatal Medicine2013;18(4):209-15. [DOI: 10.1016/j.siny.2013.01.001] [PMID: 23402893]">Van Rooij 2013</a>). Drugs such as lidocaine and midazolam are used as infusions for seizures that are refractory (difficult to control) (<a href="./references#CD014967-bbs2-0074" title="AbendNS , Gutierrez-ColinaAM , MonkHM , DlugosDJ , ClancyRR . Levetiracetam for treatment of neonatal seizures. Journal of Child Neurology2011;26(4):465-70. [DOI: 10.1177/0883073810384263] [PMID: 21233461]">Abend 2011</a>; <a href="./references#CD014967-bbs2-0095" title="FürwentschesA , BussmannC , RamantaniG , EbingerF , PhilippiH , PöschlJ , et al. Levetiracetam in the treatment of neonatal seizures: a pilot study. Seizure2010;19(3):185-9. [DOI: 10.1016/j.seizure.2010.01.003] [PMID: 20133173]">Fürwentsches 2010</a>; <a href="./references#CD014967-bbs2-0149" title="SlaughterLA , PatelAD , SlaughterJL . Pharmacological treatment of neonatal seizures: a systematic review. Journal of Child Neurology2013;28(3):351-64. [DOI: 10.1177/0883073812470734] [PMID: 23318696]">Slaughter 2013</a>; <a href="./references#CD014967-bbs2-0160" title="Van RooijLG , Hellström-WestasL , De VriesLS . Treatment of neonatal seizures. Seminars in Fetal &amp; Neonatal Medicine2013;18(4):209-15. [DOI: 10.1016/j.siny.2013.01.001] [PMID: 23402893]">Van Rooij 2013</a>). Newer drugs, such as topiramate and bumetanide, have also been explored for the treatment of neonatal seizures (<a href="./references#CD014967-bbs2-0097" title="GlassHC , PoulinC , ShevellMI . Topiramate for the treatment of neonatal seizures. Pediatric Neurology2011;44(6):439-42. [DOI: 10.1016/j.pediatrneurol.2011.01.006] [PMID: 21555055]">Glass 2011</a>; <a href="./references#CD014967-bbs2-0108" title="JensenFE . Neonatal seizures: an update on mechanisms and management. Clinics in Perinatology2009;36(4):881-900, vii. [DOI: 10.1016/j.clp.2009.08.001] [PMID: 19944840]">Jensen 2009</a>; <a href="./references#CD014967-bbs2-0134" title="PresslerRM , BoylanGB , MarlowN , BlennowM , ChironC , CrossJH , et al. Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial. Lancet. Neurology2015;14(5):469-77. [DOI: 10.1016/S1474-4422(14)70303-5] [PMID: 25765333]">Pressler 2015</a>). </p> <p>Anti‐seizure medications act through various mechanisms, the main ones being blockage of voltage‐gated ion channels, GABA‐mediated neuronal inhibition, and blockage of glutamatergic excitatory pathways. Barbiturates and benzodiazepines enhance GABA‐mediated inhibition by modulating the permeability of chloride channels. Vigabatrin potentiates GABA inhibition by blocking GABA transaminase, the GABA‐degrading enzyme. Gabapentin acts by enhancing GABA‐mediated inhibition and possibly also by inactivating sodium channels. It has been suggested that drugs that act through GABA may be less effective in neonatal seizures because of the paradoxical chloride response in GABA receptors, and the overall reduced GABA receptor expression in neonates (<a href="./references#CD014967-bbs2-0087" title="DulacO , MilhM , HolmesGL . Brain maturation and epilepsy. Handbook of Clinical Neurology2013;111:441-6. [DOI: 10.1016/B978-0-444-52891-9.00047-6] [PMID: 23622192]">Dulac 2013</a>; <a href="./references#CD014967-bbs2-0108" title="JensenFE . Neonatal seizures: an update on mechanisms and management. Clinics in Perinatology2009;36(4):881-900, vii. [DOI: 10.1016/j.clp.2009.08.001] [PMID: 19944840]">Jensen 2009</a>). However, this has never been confirmed in humans. </p> <p>Phenytoin, carbamazepine and lamotrigine cause blockage of voltage‐gated sodium channels and inhibit repetitive neuronal firing. Levetiracetam and brivaracetam act by binding to the synaptic vesicle protein, (SV2A) in the brain, resulting in modulation of synaptic neurotransmitter release (<a href="./references#CD014967-bbs2-0075" title="Abou-KhalilB . Levetiracetam in the treatment of epilepsy. Neuropsychiatric Disease and Treatment2008;4(3):507-23. [DOI: 10.2147/ndt.s2937] [PMID: 18830435]">Abou‐Khalil 2008</a>). Valproate acts by multiple mechanisms, such as blocking voltage‐gated sodium channels, interfering with glutamate‐mediated excitation, and increasing GABA concentration in the brain by influencing GABA synthesis and breakdown. Remacemide acts by blocking N‐methyl‐D‐aspartate (NMDA) receptors and voltage‐gated sodium channels. Topiramate acts on multiple sites, including GABA receptors, glutamate receptors, L‐type calcium receptors, and possibly voltage‐gated sodium channels (<a href="./references#CD014967-bbs2-0081" title="BrodieMJ , DichterMA . Antiepileptic drugs. New England Journal of Medicine1996;334(3):168-75. [DOI: 10.1056/NEJM199601183340308] [PMID: 8531974]">Brodie 1996</a>; <a href="./references#CD014967-bbs2-0096" title="GidalBE , PriviteraMD , ShethRD , GilmanJT . Vigabatrin: a novel therapy for seizure disorders. Annals of Pharmacotherapy1999;33(12):1277-86. [DOI: 10.1345/aph.18376] [PMID: 10630829]">Gidal 1999</a>; <a href="./references#CD014967-bbs2-0124" title="MeldrumBS . Update on the mechanism of action of antiepileptic drugs. Epilepsia1996;37(Suppl 6):S4-11. [DOI: 10.1111/j.1528-1157.1996.tb06038.x] [PMID: 8941036]">Meldrum 1996</a>; <a href="./references#CD014967-bbs2-0155" title="TaylorCP , MeldrumBS . Na+ channels as targets for neuroprotective drugs. Trends in Pharmacological Sciences1995;16(9):309-16. [DOI: 10.1016/s0165-6147(00)89060-4] [PMID: 7482996]">Taylor 1995</a>). </p> </section> <section id="CD014967-sec-0012"> <h3 class="title" id="CD014967-sec-0012">How the intervention might work</h3> <p>The aim of treating neonatal seizures with an ASM is to reduce seizure burden and stop progression to status epilepticus with the main aim of stopping seizures. This is assumed to reduce the risk of long‐term neurodevelopmental impairment (<a href="./references#CD014967-bbs2-0163" title="WirrellEC . Neonatal seizures: to treat or not to treat?Seminars in Pediatric Neurology2005;12(2):97-105. [DOI: 10.1016/j.spen.2005.03.004] [PMID: 16114175]">Wirrell 2005</a>; <a href="./references#CD014967-bbs2-0166" title="YagerJY , ArmstrongEA , MiyashitaH , WirrellEC . Prolonged neonatal seizures exacerbate hypoxic-ischemic brain damage: correlation with cerebral energy metabolism and excitatory amino acid release. Developmental Neuroscience2002;24(5):367-81. [DOI: 10.1159/000069049] [PMID: 12640175]">Yager 2002</a>). However, animal experiments indicate that they may cause neuronal apoptosis, and alter neurogenesis and neural cell migration in the developing brain (<a href="./references#CD014967-bbs2-0076" title="BittigauP , SifringerM , GenzK , ReithE , PospischilD , GovindarajaluS , et al. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proceedings of the National Academy of Sciences of the United States of America2002;99(23):15089-94. [DOI: 10.1073/pnas.222550499] [PMID: 12417760]">Bittigau 2002</a>; <a href="./references#CD014967-bbs2-0107" title="IkonomidouC , TurskiL . Antiepileptic drugs and brain development. Epilepsy Research2010;88(1):11-22. [DOI: 10.1016/j.eplepsyres.2009.09.019] [PMID: 19825509]">Ikonomidou 2010</a>). Further, many ASMs cause significant adverse effects. Phenobarbitone and benzodiazepines can cause respiratory depression and hypoventilation requiring ventilatory support; phenytoin can cause arrhythmias leading to circulatory disturbance; lidocaine can lead to hypotension requiring volume or inotropic support; valproate can cause hepatotoxicity; and other adverse effects of ASMs include nephrotoxicity and free‐radical injury (<a href="./references#CD014967-bbs2-0091" title="El-DibM , SoulJS . The use of phenobarbital and other anti-seizure drugs in newborns. Seminars in Fetal &amp; Neonatal Medicine2017;22(5):321-7. [DOI: 10.1016/j.siny.2017.07.008] [PMID: 28811085]">El‐Dib 2017</a>; <a href="./references#CD014967-bbs2-0169" title="YozawitzE , StaceyA , PresslerRM . Pharmacotherapy for seizures in neonates with hypoxic ischemic encephalopathy. Pediatric Drugs2017;19(6):553-67. [DOI: 10.1007/s40272-017-0250-4] [PMID: 28770451]">Yozawitz 2017</a>). </p> <p>Neonatal seizures are difficult to treat with conventional ASMs. This is due to the inadequate development of inhibitory systems and excessive activity of excitatory systems in the developing brain as discussed above, and the lack of novel targets on which these medications can act upon. Studies have shown that neonatal seizures were refractory to first‐line drugs in nearly 50% of cases and that an additional 30% failed to respond even when second‐line drugs were added (<a href="./references#CD014967-bbs2-0078" title="BoylanGB , RennieJM , PresslerRM , WilsonG , MortonM , BinnieCD . Phenobarbitone, neonatal seizures, and video-EEG. Archives of Disease in Childhood. Fetal and Neonatal Edition2002;86(3):F165-170. [DOI: 10.1136/fn.86.3.f165] [PMID: 11978746]">Boylan 2002</a>; <a href="./references#CD014967-bbs2-0079" title="BoylanGB , RennieJM , ChorleyG , PresslerRM , FoxGF , FarrerK , et al. Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study. Neurology2004;62(3):486-8. [DOI: 10.1212/01.wnl.0000106944.59990.e6] [PMID: 14872039]">Boylan 2004</a>). Studies on phenobarbitone and phenytoin have given conflicting evidence about the efficacy of one medication over the other (<a href="./references#CD014967-bbs2-0129" title="PainterMJ , ScherMS , SteinAD , ArmattiS , WangZ , GardinerJC , et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine1999;341(7):485-9. [DOI: 10.1056/NEJM199908123410704] [PMID: 10441604]">Painter 1999</a>; <a href="./references#CD014967-bbs2-0130" title="PathakG , UpadhyayA , PathakU , ChawlaD , GoelSP . Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial. Indian Pediatrics2013;50(8):753-7. [DOI: 10.1007/s13312-013-0218-6] [PMID: 23502660]">Pathak 2013</a>). Further, the risk of uncoupling (the persistence of electrographic seizures after the suppression of clinical seizures) is well documented with both phenobarbitone and phenytoin (<a href="./references#CD014967-bbs2-0143" title="ScherMS , HamidMY , SteppeDA , BeggarlyME , PainterMJ . Ictal and interictal electrographic seizure durations in preterm and term neonates. Epilepsia1993;34(2):284-8. [DOI: 10.1111/j.1528-1157.1993.tb02412.x] [PMID: 8453938]">Scher 1993</a>; <a href="./references#CD014967-bbs2-0144" title="ScherMS , AlvinJ , GausL , MinnighB , PainterMJ . Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology2003;28(4):277-80. [DOI: 10.1016/s0887-8994(02)00621-5] [PMID: 12849880]">Scher 2003</a>). This would increase the burden of unrecognised seizures in centres where continuous cEEG monitoring is not used. </p> <p>Recently, drugs such as levetiracetam, topiramate and bumetanide are being investigated in research trials, with variable benefits. Though these drugs may have the advantage of not causing neuronal apoptosis, data regarding their efficacy, safety and optimal dosing are lacking (<a href="./references#CD014967-bbs2-0083" title="ChaBH , SilveiraDC , LiuX , HuY , HolmesGL . Effect of topiramate following recurrent and prolonged seizures during early development. Epilepsy Research2002;51(3):217-32. [DOI: 10.1016/s0920-1211(02)00157-2] [PMID: 12399072]">Cha 2002</a>; <a href="./references#CD014967-bbs2-0085" title="ClearyRT , SunH , HuynhT , ManningSM , LiY , RotenbergA , et al. Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures. PloS One2013;8(3):e57148. [DOI: 10.1371/journal.pone.0057148] [PMID: 23536761]">Cleary 2013</a>; <a href="./references#CD014967-bbs2-0090" title="DzhalaVI , BrumbackAC , StaleyKJ . Bumetanide enhances phenobarbital efficacy in a neonatal seizure model. Annals of Neurology2008;63(2):222-35. [DOI: 10.1002/ana.21229] [PMID: 17918265]">Dzhala 2008</a>; <a href="./references#CD014967-bbs2-0109" title="KahleKT , BarnettSM , SassowerKC , SJ. Decreased seizure activity in a human neonate treated with bumetanide, an inhibitor of the Na(+)-K(+)-2Cl(-) cotransporter NKCC1. Journal of Child Neurology2009;24(5):572-6. [DOI: 10.1177/0883073809333526] [PMID: 19406757]">Kahle 2009</a>; <a href="./references#CD014967-bbs2-0111" title="KilicdagH , DaglıogluK , ErdoganS , GuzelA , SencarL , PolatS , et al. The effect of levetiracetam on neuronal apoptosis in neonatal rat model of hypoxic ischemic brain injury. Early Human Development2013;89(5):355-60. [DOI: 10.1016/j.earlhumdev.2012.12.002] [PMID: 23266150]">Kilicdag 2013</a>; <a href="./references#CD014967-bbs2-0112" title="Kim J-S, KondratyevA , TomitaY , GaleK . Neurodevelopmental impact of antiepileptic drugs and seizures in the immature brain. Epilepsia2007;48(Suppl 5):19-26. [DOI: 10.1111/j.1528-1167.2007.01285.x] [PMID: 17910577]">Kim 2007</a>; <a href="./references#CD014967-bbs2-0116" title="LiuY , BarksJD , XuG , SilversteinFS . Topiramate extends the therapeutic window for hypothermia-mediated neuroprotection after stroke in neonatal rats. Stroke2004;35(6):1460-5. [DOI: 10.1161/01.STR.0000128029.50221.fa] [PMID: 15105511]">Liu 2004</a>; <a href="./references#CD014967-bbs2-0117" title="LiuY , ShangguanY , BarksJD , SilversteinFS . Bumetanide augments the neuroprotective efficacy of phenobarbital plus hypothermia in a neonatal hypoxia-ischemia model. Pediatric Research2012;71(5):559-65. [DOI: 10.1038/pr.2012.7] [PMID: 22398701]">Liu 2012</a>; <a href="./references#CD014967-bbs2-0119" title="MantheyD , AsimiadouS , StefovskaV , KaindlAM , FassbenderJ , IkonomidouC , et al. Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brain. Experimental Neurology2005;193(2):497-503. [DOI: 10.1016/j.expneurol.2005.01.006] [PMID: 15869952]">Manthey 2005</a>; <a href="./references#CD014967-bbs2-0123" title="McHughDC , LancasterS , ManganasLN . A systematic review of the efficacy of levetiracetam in neonatal seizures. Neuropediatrics2018;49(1):12-7. [DOI: 10.1055/s-0037-1608653] [PMID: 29179233]">McHugh 2018</a>; <a href="./references#CD014967-bbs2-0137" title="RaoLM , HussainSA , ZakiT , ChoA , ChanlawT , GargM , et al. A comparison of levetiracetam and phenobarbital for the treatment of neonatal seizures associated with hypoxic-ischemic encephalopathy. Epilepsy &amp; Behavior2018;88:212-7. [DOI: 10.1016/j.yebeh.2018.09.015] [PMID: 30296665]">Rao 2018</a>; <a href="./references#CD014967-bbs2-0147" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 INVESTIGATORS. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>; <a href="./references#CD014967-bbs2-0154" title="TalosDM , ChangM , KosarasB , FitzgeraldE , MurphyA , FolkerthRD , et al. Antiepileptic effects of levetiracetam in a rodent neonatal seizure model. Pediatric Research2013;73(1):24-30. [DOI: 10.1038/pr.2012.151] [PMID: 23138400]">Talos 2013</a>). </p> </section> <section id="CD014967-sec-0013"> <h3 class="title" id="CD014967-sec-0013">Why it is important to do this review</h3> <p>There is no definitive evidence or guideline on the choice of first‐, second‐ and third‐line ASMs in neonates. Furthermore, it is not clear whether ASMs should be initiated for only electrographic seizures, only clinical seizures, or both electrographic and clinical seizures (<a href="./references#CD014967-bbs2-0077" title="BoothD , EvansDJ . Anticonvulsants for neonates with seizures. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD004218. [DOI: 10.1002/14651858.CD004218.pub2]">Booth 2004</a>; <a href="./references#CD014967-bbs2-0080" title="BoylanGB , StevensonNJ , VanhataloS . Monitoring neonatal seizures. Seminars in Fetal &amp; Neonatal Medicine2013;18(4):202-8. [DOI: 10.1016/j.siny.2013.04.004] [PMID: 23707519]">Boylan 2013</a>; <a href="./references#CD014967-bbs2-0149" title="SlaughterLA , PatelAD , SlaughterJL . Pharmacological treatment of neonatal seizures: a systematic review. Journal of Child Neurology2013;28(3):351-64. [DOI: 10.1177/0883073812470734] [PMID: 23318696]">Slaughter 2013</a>; <a href="./references#CD014967-bbs2-0152" title="SrinivasakumarP , ZempelJ , TrivediS , WallendorfMI , RaoR , SmithB , et al. Treating EEG seizures in hypoxic ischemic encephalopathy: a randomized controlled trial. Pediatrics2015;136(5):e1302-9. [DOI: 10.1542/peds.2014-3777] [PMID: 26482675]">Srinivasakumar 2015</a>; <a href="./references#CD014967-bbs2-0159" title="Van RooijLG , ToetMC , Van HuffelenAC , GroenendaalF , LaanW , ZecicA , et al. Effect of treatment of subclinical neonatal seizures detected with aEEG: randomized, controlled trial. Pediatrics2010;125(2):e358-66. [DOI: 10.1542/peds.2009-0136] [PMID: 20100767]">Van Rooij 2010</a>). Finally, it is unclear how long to continue the ASM for once it is initiated, that is, whether to continue maintenance doses once seizure control is achieved after the loading dose (<a href="./references#CD014967-bbs2-0142" title="SaxenaP , SinghA , UpadhyayA , GuptaP , SharmaS , VishnubatlaS . Effect of withholding phenobarbitone maintenance in neonatal seizures: a randomized controlled trial. Indian Pediatrics2016;53(12):1069-73. [PMID: 27889710]">Saxena 2016</a>). </p> <p>Given the benefits, as well as the potential harm of using ASMs for neonatal seizures, we have undertaken a Cochrane Review that identifies and appraises data from randomised controlled trials, to provide a synthesis of evidence regarding the efficacy and adverse effects of using ASMs in neonatal seizures and their influence on short‐, intermediate‐ and long‐term outcomes. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD014967-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD014967-sec-0014"></div> <p> <ol id="CD014967-list-0001"> <li> <p>To assess whether any anti‐seizure medication (ASM) is more or less effective than an alternative ASM (both ASMs used as first‐, second‐ or third‐line treatment) in achieving seizure control and improving neurodevelopmental outcomes in neonates with seizures. We analysed EEG‐confirmed seizures and clinically‐diagnosed seizures separately. </p> </li> <li> <p>To assess maintenance therapy with ASM versus no maintenance therapy after achieving seizure control. We analysed EEG‐confirmed seizures and clinically‐diagnosed seizures separately. </p> </li> <li> <p>To assess treatment of both clinical and electrographic seizures versus treatment of clinical seizures alone in neonates. </p> </li> </ol> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD014967-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD014967-sec-0015"></div> <section id="CD014967-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD014967-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs), both parallel‐design and cross‐over trials*, in this review. We did not identify any quasi‐ or cluster‐RCTs for inclusion in this review. </p> <p>We included studies on any class of ASMs that are known to be used in neonatal seizures.</p> <p>We excluded studies on the use of vitamins, medical gas or other interventions such as therapeutic hypothermia, which may have a role in seizure control in neonates. We also excluded trials with prophylactic use of ASMs to prevent neonatal seizures or to improve neurodevelopmental outcomes. </p> <p>(*See <a href="#CD014967-sec-0277">Differences between protocol and review</a>.) </p> </section> <section id="CD014967-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included newborn infants of any gestational age, gender or ethnicity who were diagnosed with seizures. We included seizures due to any aetiology and treated with any ASM. We included seizures that were: </p> <p> <ol id="CD014967-list-0002"> <li> <p>clinical with EEG confirmation (EEG‐confirmed clinical seizures or electro‐clinical seizures); </p> </li> <li> <p>clinically diagnosed without EEG confirmation (clinically‐diagnosed seizures);</p> </li> <li> <p>only electrographic without any clinical manifestation (electrographic‐only seizures).</p> </li> </ol> </p> </section> <section id="CD014967-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We compared:</p> <p> <ol id="CD014967-list-0003"> <li> <p>any ASM versus an alternative ASM in EEG‐confirmed neonatal seizures and clinically‐diagnosed neonatal seizures (both ASMs used as first‐, second‐ or third‐line treatment); </p> </li> <li> <p>maintenance therapy with ASM versus no maintenance therapy in EEG‐confirmed neonatal seizures and clinically‐diagnosed neonatal seizures; </p> </li> <li> <p>treatment of both clinical and electrographic seizures versus treatment of clinical seizures alone. </p> </li> </ol> </p> <p>We excluded ASMs used for indications other than neonatal seizures, such as neonatal hyperbilirubinaemia, sedation, or anaesthesia. We analysed EEG‐confirmed seizures and clinically‐diagnosed seizures separately. This was because appropriate diagnosis of seizures is an essential prerequisite to test the efficacy of ASMs (accurate outcome measure). Therefore, trials that included only EEG‐confirmed seizures will provide more reliable data on the outcomes of treatment with ASMs. However, treatment of seizures based on clinical diagnosis is a common practice and could not be excluded, although it is recognised that clinical diagnosis is associated with a high risk of over and under‐diagnosis. Hence, we analysed both EEG‐confirmed seizures and clinically‐diagnosed seizures in separate comparisons. </p> </section> <section id="CD014967-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD014967-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD014967-list-0004"> <li> <p>Proportion of infants who achieve seizure control after first or maximal loading dose of the given ASM; </p> </li> <li> <p>Mortality or neurodevelopmental disability at 18 to 24 months' corrected age. Neurodevelopmental disability was defined as one or more of the following: cerebral palsy on clinical examination; developmental delay more than two standard deviations (SDs) below population mean on a standardised test of development; blindness (visual acuity less than 6/60); deafness (any hearing impairment requiring amplification). </p> </li> </ol> </p> <p>(*<i>The outcomes are reported in different ways in the trials. We have mentioned the changes in the reported outcomes, if any, in the</i><a href="#CD014967-sec-0277">Differences between protocol and review</a>). </p> </section> <section id="CD014967-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD014967-list-0005"> <li> <p>Mortality before hospital discharge or at any time later;</p> </li> <li> <p>Neurodevelopmental disability at 18 to 24 months' corrected age, defined as one or more of the following: cerebral palsy on clinical examination; developmental delay more than two SDs below population mean on a standardised test of development; blindness (visual acuity less than 6/60); deafness (any hearing impairment requiring amplification); </p> </li> <li> <p>Proportion of infants who develop cognitive impairment at two years or more (defined as a cognitive score below 70 measured using a validated assessment tool); </p> </li> <li> <p>Seizure burden (seizure hours per infant, or minutes per hour of monitoring) during hospitalisation; </p> </li> <li> <p>Proportion of infants with one or more of the following adverse effects related to ASM(s) during hospitalisation: </p> <ol id="CD014967-list-0006"> <li> <p>Requirement for mechanical ventilation;</p> </li> <li> <p>Sedation or drowsiness;</p> </li> <li> <p>Arrhythmias causing circulatory disturbance;</p> </li> <li> <p>Bradycardia;</p> </li> <li> <p>Hypotension requiring volume or inotropic support;</p> </li> <li> <p>Shock requiring volume or inotropic support;</p> </li> <li> <p>Hepatotoxicity resulting in discontinuation of therapy;</p> </li> <li> <p>Acute kidney injury (of any stage);</p> </li> <li> <p>Any further individual adverse effects;</p> </li> </ol> </li> <li> <p>Proportion of infants with abnormal background pattern in EEG (as defined by the authors) during the ASM treatment and after stopping the ASM; </p> </li> <li> <p>Duration of hospital stay (days);</p> </li> <li> <p>Proportion of infants with persistent seizures or requiring ASM(s) at discharge (or both); </p> </li> <li> <p>Proportion of infants discharged on gavage feeds;</p> </li> <li> <p>Proportion of infants with abnormal neurological examination at discharge: as defined by trialists based on validated tools, or as hypotonia or muscle weakness; </p> </li> <li> <p>Proportion of infants who develop epilepsy post‐discharge;</p> </li> <li> <p>Time to establish full oral feeds (days);</p> </li> <li> <p>Proportion of infants who required ≥ 3 ASMs.</p> </li> </ol> </p> </section> </section> </section> <section id="CD014967-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>The Cochrane Neonatal Information Specialist, Chris Cooper, wrote and ran search strategies.</p> <section id="CD014967-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases in May 2022 with an update search in June 2023. We searched without restrictions on language, publication year, publication type, or publication status. </p> <p> <ul id="CD014967-list-0007"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), Issue 6, 2023;</p> </li> <li> <p>Ovid MEDLINE, MEDALL (1946 to 06 June 2023);</p> </li> <li> <p>Ovid Embase (1980 to 2023 Week 22);</p> </li> <li> <p>Epistemonikos (registry of systematic reviews) <a href="https://www.epistemonikos.org" target="_blank">https://www.epistemonikos.org,</a> 7 June 2023. </p> </li> </ul> </p> <p>Search strategies are available in <a href="./appendices#CD014967-sec-0257">Appendix 1</a>; <a href="./appendices#CD014967-sec-0264">Appendix 2</a>. </p> </section> <section id="CD014967-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We identified trial registration records using CENTRAL and by independent searches of the following: </p> <p> <ul id="CD014967-list-0008"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>), 7 June 2023; </p> </li> <li> <p>ICTRP‐‐World Health Organization International Clinical Trials Registry Platform (<a href="https://trialsearch.who.int/Default.aspx" target="_blank">https://trialsearch.who.int/Default.aspx</a>), 7 June 2023. </p> </li> </ul> </p> <p>We screened the reference lists of included or related, or both, studies (e.g. in the subject area of our review but not eligible for inclusion), and related systematic reviews (e.g. reviews including the population or intervention examined in our review) for studies not identified by the database searches. </p> </section> </section> <section id="CD014967-sec-0026"> <h3 class="title" id="CD014967-sec-0026">Data collection and analysis</h3> <section id="CD014967-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Search results were managed in Endnote. Duplicates were removed using both Endnote and Covidence. Titles and abstracts were assessed in two ways: using Cochrane's Screen4Me (S4M) system (<a href="https://community.cochrane.org/sites/default/files/uploads/S4M_Users_FAQs.pdf" target="_blank">https://community.cochrane.org/sites/default/files/uploads/S4M_Users_FAQs.pdf</a>) and by author screening. </p> <p>The S4M system includes three levels of assessment for identifying non‐RCT records. Of these three levels, we used two: Known Assessments and RCT Classifier (<a href="./references#CD014967-bbs2-0120" title="MarshallIJ , Noel-StorrA , KuiperJ , ThomasJ , WallaceBC . Machine learning for identifying randomized controlled trials: an evaluation and practitioner's guide. Research Synthesis Methods2018;9(4):602-14. [DOI: 10.1002/jrsm.1287]">Marshall 2018</a>; <a href="./references#CD014967-bbs2-0128" title="Noel-StorrA , DooleyG , WisniewskiS , GlanvilleJ , ThomasJ , CoxS , et al. Cochrane Centralised Search Service showed high sensitivity identifying randomized controlled trials: a retrospective analysis. Journal of Clinical Epidemiology2020;127:142-50. [DOI: 10.1016/j.jclinepi.2020.08.008] [PMID: 32798713]">Noel‐Storr 2020</a>; <a href="./references#CD014967-bbs2-0157" title="ThomasJ , McDonaldS , Noel-StorrA , ShemiltI , ElliottJ , MavergamesC , et al. Machine learning reduced workload with minimal risk of missing studies: development and evaluation of a randomized controlled trial classifier for Cochrane reviews. Journal of Clinical Epidemiology2021;133:140-51. [DOI: 10.1016/j.jclinepi.2020.11.003] [PMID: 33171275]">Thomas 2021</a>). Records remaining after S4M classification were screened independently by two of four authors (TA, ST, VVR and HH). These same authors independently screened the full texts of studies remaining after title/abstract assessment. At any point during the screening process, disagreements were resolved by discussion or by another reviewer. Where a review author was involved in an included study, any decisions regarding inclusion were made by other authors. </p> <p>We collated multiple reports of the same study so that the study, rather than the reference, was the unit of interest in the review. Information about studies is provided in the following tables: <a href="./references#CD014967-sec-0279" title="">Characteristics of included studies</a>; <a href="./references#CD014967-sec-0280" title="">Characteristics of excluded studies</a>; <a href="./references#CD014967-sec-0281" title="">Characteristics of studies awaiting classification</a>); and <a href="./references#CD014967-sec-0282" title="">Characteristics of ongoing studies</a>. </p> <p>We reported the study selection process in sufficient detail to generate a PRISMA flow diagram (<a href="./references#CD014967-bbs2-0115" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ2009;339:b2700. [DOI: doi.org/10.1136/bmj.b2700]">Liberati 2009</a>; <a href="./references#CD014967-bbs2-0125" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006-12. [DOI: 10.1016/j.jclinepi.2009.06.005] [PMID: 19631508]">Moher 2009</a>). </p> </section> <section id="CD014967-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (TA and ST) independently extracted, assessed, and coded all data for each study, using a form designed specifically for this review. We collected information regarding the method of randomisation, masking, intervention, stratification, and whether the trial was single‐ or multi‐centre for each included study. We noted information regarding trial participants, including gestational age, type of seizures, aetiology of seizures, and treatment details. We analysed the clinical outcomes noted above in the <a href="#CD014967-sec-0020">Types of outcome measures</a>. </p> <p>We described ongoing studies identified by our search (when available), detailing the primary author, research question(s), methods, and outcome measures, together with an estimate of the reporting date. We reported such studies in the <a href="./references#CD014967-sec-0282" title="">Characteristics of ongoing studies</a> table. </p> <p>We resolved any disagreements by discussion with a third review author (HH). Should any queries arise or, in cases for which additional data were required, we contacted study investigators/authors for clarification. We replaced any standard error of the mean by the corresponding standard deviation. One review author (TA) entered final data for each study into Review Manager web (<a href="./references#CD014967-bbs2-0138" title="Review Manager Web (RevMan Web). Version 6.3.0. The Cochrane Collaboration, 2023. Available at revman.cochrane.org.">RevMan Web 2023</a>), which the other review author (ST) checked. All review authors reviewed the analysis, results and drafted the manuscript. </p> </section> <section id="CD014967-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The review authors (VVR and RP) independently assessed the risk of bias in all included trials using version 2 of the Cochrane Risk of bias tool (RoB 2) (<a href="./references#CD014967-bbs2-0103" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 6 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>). We resolved any disagreements by discussion or by consulting a third author (TA). </p> <p>We assessed the risk of bias for each study outcome using the following Cochrane RoB 2 criteria: </p> <p> <ol id="CD014967-list-0009"> <li> <p>bias arising from the randomisation process;</p> </li> <li> <p>bias due to deviations from intended interventions;</p> </li> <li> <p>bias due to missing outcome data;</p> </li> <li> <p>bias in measurement of the outcome;</p> </li> <li> <p>bias in selection of the reported result.</p> </li> </ol> </p> <p>For each domain, a series of signalling questions with answers (yes, probably yes, no information, probably no, or no) determined the risk of bias (low risk, some concerns, or high risk). We included relevant text alongside the judgements to provide supporting information for our decisions. We decided the overall risk of bias for an outcome by its performance in all the domains: the overall judgement was 'some concerns' if we assigned a judgement of 'some concerns' for one domain, and 'high risk' if we assigned a judgement of 'some concerns' for multiple domains or 'high risk' for one (or more) domains. </p> </section> <section id="CD014967-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We performed the statistical analyses using Review Manager web (<a href="./references#CD014967-bbs2-0138" title="Review Manager Web (RevMan Web). Version 6.3.0. The Cochrane Collaboration, 2023. Available at revman.cochrane.org.">RevMan Web 2023</a>). We summarised the data in a meta‐analysis if they were sufficiently homogeneous, both clinically and statistically. For dichotomous data, we presented results using risk ratios (RRs) with 95% confidence intervals (CIs). For continuous data, we used the mean difference (MD) when outcomes were measured in the same way between trials. </p> </section> <section id="CD014967-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the participating infant in individually randomised trials. We did not identify any cluster‐randomised trial for inclusion in our review. </p> </section> <section id="CD014967-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We requested additional data from the trialists if data on important outcomes were missing or were reported unclearly. We obtained additional data from the authors of five trials (<a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>; <a href="./references#CD014967-bbs2-0006" title="JindalA , AnguranaSK , SutharR , KumarP , SundaramV . Effect of early withdrawal of phenobarbitone on the recurrence of neonatal seizures: an open-label randomized controlled trial. Epilepsy &amp; Behavior2021;117:107875. [DOI: 10.1016/j.yebeh.2021.107875] [PMID: 33706247]">Jindal 2021</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>; <a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>; <a href="./references#CD014967-bbs2-0015" title="SoulJS , BerginAM , StoppC , HayesB , SinghA , FortunoCR , et al, Boston Bumetanide Trial Group. A pilot randomized, controlled, double‐blind trial of bumetanide to treat neonatal seizures. Annals of Neurology2021;89(2):327-40. [DOI: 10.1002/ana.25959] [PMID: 33201535]">Soul 2021</a>). </p> </section> <section id="CD014967-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We estimated the treatment effects of individual trials and examined heterogeneity amongst trials by inspecting the forest plots and quantifying the impact of heterogeneity using the I² statistic. We interpreted the degree of heterogeneity as follows: </p> <p> <ol id="CD014967-list-0010"> <li> <p>0% to 40% might not be important;</p> </li> <li> <p>30% to 60% may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90% may represent substantial heterogeneity; and</p> </li> <li> <p>75% to 100%, indicating considerable heterogeneity.</p> </li> </ol> </p> <p>We explored the possible causes (e.g. differences in study quality, participants, intervention regimens, or outcome assessments) if we identified substantial heterogeneity (i.e. an I<sup>2</sup> value greater than 50%). </p> </section> <section id="CD014967-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed reporting bias by comparing the studies' stated primary outcomes and secondary outcomes with the reported outcomes. Where study protocols were available, we compared these to the full publications to determine the likelihood of reporting bias. </p> <p>As we included fewer than 10 trials in all the meta‐analyses, we did not examine a funnel plot for possible publication bias. </p> </section> <section id="CD014967-sec-0035"> <h4 class="title">Data synthesis</h4> <p>If we identified multiple studies that we considered to be sufficiently similar, we performed meta‐analysis using Review Manager web (<a href="./references#CD014967-bbs2-0138" title="Review Manager Web (RevMan Web). Version 6.3.0. The Cochrane Collaboration, 2023. Available at revman.cochrane.org.">RevMan Web 2023</a>). We used a fixed‐effect model to combine data where it was reasonable to assume that studies were estimating the same underlying treatment effect. If we deemed meta‐analysis to be inappropriate, we analysed and interpreted individual trials separately. </p> </section> <section id="CD014967-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We explored substantial statistical heterogeneity in the outcomes by visually inspecting the forest plots (<a href="./references#CD014967-bbs2-0104" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>). Where statistical heterogeneity was significant, we interpreted the results of the meta‐analyses accordingly; and we downgraded the certainty of evidence in the summary of findings tables, according to the GRADE recommendations (see Summary of findings and assessment of the certainty of the evidence). </p> <p>Where data were available, we planned to conduct subgroup analyses based on:</p> <p> <ol id="CD014967-list-0011"> <li> <p>gestational age (term infants (born at 37 weeks' gestation or greater) versus preterm infants (born at less than 37 weeks' gestation)); </p> </li> <li> <p>aetiology of seizure (acquired or discrete CNS injury such as hypoxic‐ischaemic encephalopathy, intracranial haemorrhage, stroke or infections versus congenital disorders with ongoing epileptic potential such as metabolic disorders, brain malformations, channelopathies, or other genetic causes). </p> </li> </ol> </p> <p>We did not perform any subgroup analysis as all the included trials were performed on term and late preterm infants, and data based on aetiology of seizures were not available. </p> </section> <section id="CD014967-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>Where we identified substantial heterogeneity, we planned to conduct sensitivity analysis to determine if the findings were affected by inclusion of only those trials considered to have used adequate methodology, i.e. those with a low risk of bias. We planned to report results of sensitivity analyses for primary outcomes only. </p> <p>However, we did not perform any sensitivity analysis, as it was not required.</p> </section> <section id="CD014967-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach, as outlined in the GRADE Handbook (<a href="./references#CD014967-bbs2-0145" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>), to assess the certainty of evidence for the following outcomes for all comparisons: </p> <p> <ol id="CD014967-list-0012"> <li> <p>proportion of infants who achieve seizure control;</p> </li> <li> <p>mortality or neurodevelopmental disability at 18 to 24 months;</p> </li> <li> <p>mortality (at any time);</p> </li> <li> <p>neurodevelopmental disability at 18 to 24 months;</p> </li> <li> <p>proportion of infants who develop cognitive impairment at three years or more;</p> </li> <li> <p>proportion of infants who develop adverse effects of ASM;</p> </li> <li> <p>proportion of infants who develop epilepsy post‐discharge.</p> </li> </ol> </p> <p>(*<i>The outcomes are reported in different ways in the trials. We have mentioned the changes in the reported outcomes, if any, in the</i><a href="#CD014967-sec-0277">Differences between protocol and review</a>.) </p> <p>Two review authors (TA and FB) independently assessed the certainty of the evidence for each of the outcomes above. We resolved any disagreements by discussion with a third author (VVR). We considered evidence from RCTs as being high‐certainty, and downgraded the assessment by one level for serious (or two levels for very serious) limitations based upon the following: design (risk of bias), consistency across studies, directness of the evidence, precision of estimates, and presence of publication bias. We used <a href="./references#CD014967-bbs2-0099" title="GRADEpro GDT. Version accessed 3 May 2023. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a> to create 10 summary of findings tables to report the certainty of the evidence for the following comparisons: </p> <p> <ol id="CD014967-list-0013"> <li> <p>Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures (<a href="./full#CD014967-tbl-0001">summary of findings Table 1</a>); </p> </li> <li> <p>Phenobarbital versus levetiracetam as first‐line ASM for clinically diagnosed neonatal seizures (<a href="./full#CD014967-tbl-0002">summary of findings Table 2</a>); </p> </li> <li> <p>Phenobarbital versus phenytoin as first‐line ASM for EEG‐confirmed neonatal seizures (<a href="./full#CD014967-tbl-0003">summary of findings Table 3</a>); </p> </li> <li> <p>Phenobarbital versus phenytoin as first‐line ASM for clinically diagnosed neonatal seizures (<a href="./full#CD014967-tbl-0004">summary of findings Table 4</a>); </p> </li> <li> <p>Phenobarbital versus lorazepam as first‐line ASM for clinically diagnosed neonatal seizures (<a href="./full#CD014967-tbl-0005">summary of findings Table 5</a>); </p> </li> <li> <p>Phenytoin versus lorazepam as first‐line ASM for clinically diagnosed neonatal seizures (<a href="./full#CD014967-tbl-0006">summary of findings Table 6</a>); </p> </li> <li> <p>Phenobarbital+bumetanide versus phenobarbital alone as first‐line ASM for EEG‐confirmed neonatal seizures (<a href="./full#CD014967-tbl-0007">summary of findings Table 7</a>); </p> </li> <li> <p>Lignocaine versus benzodiazepines as second‐line ASM for EEG‐confirmed neonatal seizures (<a href="./full#CD014967-tbl-0008">summary of findings Table 8</a>); </p> </li> <li> <p>Maintenance therapy with ASM versus no maintenance therapy after achieving seizure control for clinically diagnosed neonatal seizures (<a href="./full#CD014967-tbl-0009">summary of findings Table 9</a>); </p> </li> <li> <p>Treatment of both clinical and electrographic seizures versus treatment of clinical seizures alone in neonates (<a href="./full#CD014967-tbl-0010">summary of findings Table 10</a>). </p> </li> </ol> </p> <p>The GRADE approach results in an assessment of the certainty of a body of evidence in one of the following four grades. </p> <p> <ol id="CD014967-list-0014"> <li> <p>High: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ol> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD014967-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD014967-sec-0039"></div> <section id="CD014967-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD014967-sec-0041"> <h4 class="title">Results of the search</h4> <p>The study selection process is available in <a href="#CD014967-fig-0001">Figure 1</a>. Searches identified 13,009 references. Of these, we processed 10,950 using <a href="https://community.cochrane.org/sites/default/files/uploads/QRG%20Screen4Me_FINAL.pdf" target="_blank">Cochrane's Screen4Me</a> (<a href="#CD014967-fig-0002">Figure 2</a>; <a href="#CD014967-fig-0003">Figure 3</a>). Screen4Me rejected 4475 references as non‐RCTs; of the remaining 8534 references, we removed 3166 duplicates, and screened 5368 references. We excluded 5300 based on title/abstract, and reviewed 68 full texts or trial registry records. We included 18 studies (<a href="./references#CD014967-sec-0279" title="">Characteristics of included studies</a>); excluded 30 (<a href="./references#CD014967-sec-0280" title="">Characteristics of excluded studies</a>); classified two as awaiting assessment (<a href="./references#CD014967-sec-0281" title="">Characteristics of studies awaiting classification</a>); and identified 23 ongoing studies (<a href="./references#CD014967-sec-0282" title="">Characteristics of ongoing studies</a>). </p> <div class="figure" id="CD014967-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram" data-id="CD014967-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram</p> </div> </div> </div> <div class="figure" id="CD014967-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Screen4Me 2022" data-id="CD014967-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Screen4Me 2022</p> </div> </div> </div> <div class="figure" id="CD014967-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Screen4Me 2023" data-id="CD014967-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-FIG-03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Screen4Me 2023</p> </div> </div> </div> </section> <section id="CD014967-sec-0042"> <h4 class="title">Comparison of one ASM versus another</h4> <p>We included 18 trials (1342 infants) in our analysis. See <a href="./references#CD014967-sec-0279" title="">Characteristics of included studies</a>. </p> <section id="CD014967-sec-0043"> <h5 class="title">Phenobarbital versus levetiracetam as first‐line ASM</h5> <p>Nine studies (<a href="./references#CD014967-bbs2-0001" title="AkeelNE , SulimanHA , Al-ShokaryAH , IbrahimAO , KamalNM , AbdelgalilAA , et al. A comparative study of levetiracetam and phenobarbital for neonatal seizures as a first line treatment. Global Pediatric Health2022;9:2333794X221143572. [DOI: 10.1177/2333794X221143572] [PMID: 36578326]">Akeel 2022</a>; <a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>; <a href="./references#CD014967-bbs2-0004" title="GhaffarJ , RiazA , Uzair, VirkAO , BhattiA . Comparative efficacy of intravenous levetiracetam vs phenobarbitone in neonatal seizures. Medical Forum2020;31(7):25-8. [WEBSITE: medforum.pk/article/6-comparative-efficacy-of-intravenous-levetiracetam-vs-phenobarbitone-in-neonatal-seizures]">Ghaffar 2020</a>; <a href="./references#CD014967-bbs2-0005" title="GowdaVK , RomanaA , ShivannaNH , BenakappaN , BenakappaA . Levetiracetam versus phenobarbitone in neonatal seizures — a randomized controlled trial. Indian Pediatrics2019;56(8):643-6. [PMID: 31477643]">Gowda 2019</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>; <a href="./references#CD014967-bbs2-0010" title="PerveenS , SinghA , UpadhyayA , SinghN , ChauhanR . A randomized controlled trial on comparison of phenobarbitone and levetiracetam for the treatment of neonatal seizures: pilot study. International Journal of Research in Medical Sciences2016;4(6):2073-8. [DOI: 10.18203/2320-6012.ijrms20161763] [URL: msjonline.org/index.php/ijrms/article/view/865/836]">Perveen 2016</a>; <a href="./references#CD014967-bbs2-0011" title="PrakashA , RichaR , SahniGS . Neonatal seizures – levetiracetam versus phenobarbital. Indian Journal of Child Health2019;6(11):605-8. [DOI: 10.32677/IJCH.2019.v06.i11.008]">Prakash 2019</a>; <a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>; <a href="./references#CD014967-bbs2-0017" title="SusnerwalaS , JoshiA , DeshmukhL , LondheA . Levetiracetam or phenobarbitone as a first-line anticonvulsant in asphyxiated term newborns? An open-label, single-center, randomized, controlled, pragmatic trial. Hospital Pediatrics2022;12(7):647-52. [DOI: 10.1542/hpeds.2021-006415] [PMID: 35673948]">Susnerwala 2022</a>), compared phenobarbital versus levetiracetam as first‐line ASM. All nine studies had included term and late preterm neonates. While <a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a> utilised EEG to confirm seizures, the other eight studies used clinical diagnosis of seizures (<a href="./references#CD014967-bbs2-0001" title="AkeelNE , SulimanHA , Al-ShokaryAH , IbrahimAO , KamalNM , AbdelgalilAA , et al. A comparative study of levetiracetam and phenobarbital for neonatal seizures as a first line treatment. Global Pediatric Health2022;9:2333794X221143572. [DOI: 10.1177/2333794X221143572] [PMID: 36578326]">Akeel 2022</a>; <a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>; <a href="./references#CD014967-bbs2-0004" title="GhaffarJ , RiazA , Uzair, VirkAO , BhattiA . Comparative efficacy of intravenous levetiracetam vs phenobarbitone in neonatal seizures. Medical Forum2020;31(7):25-8. [WEBSITE: medforum.pk/article/6-comparative-efficacy-of-intravenous-levetiracetam-vs-phenobarbitone-in-neonatal-seizures]">Ghaffar 2020</a>; <a href="./references#CD014967-bbs2-0005" title="GowdaVK , RomanaA , ShivannaNH , BenakappaN , BenakappaA . Levetiracetam versus phenobarbitone in neonatal seizures — a randomized controlled trial. Indian Pediatrics2019;56(8):643-6. [PMID: 31477643]">Gowda 2019</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>; <a href="./references#CD014967-bbs2-0010" title="PerveenS , SinghA , UpadhyayA , SinghN , ChauhanR . A randomized controlled trial on comparison of phenobarbitone and levetiracetam for the treatment of neonatal seizures: pilot study. International Journal of Research in Medical Sciences2016;4(6):2073-8. [DOI: 10.18203/2320-6012.ijrms20161763] [URL: msjonline.org/index.php/ijrms/article/view/865/836]">Perveen 2016</a>; <a href="./references#CD014967-bbs2-0011" title="PrakashA , RichaR , SahniGS . Neonatal seizures – levetiracetam versus phenobarbital. Indian Journal of Child Health2019;6(11):605-8. [DOI: 10.32677/IJCH.2019.v06.i11.008]">Prakash 2019</a>; <a href="./references#CD014967-bbs2-0017" title="SusnerwalaS , JoshiA , DeshmukhL , LondheA . Levetiracetam or phenobarbitone as a first-line anticonvulsant in asphyxiated term newborns? An open-label, single-center, randomized, controlled, pragmatic trial. Hospital Pediatrics2022;12(7):647-52. [DOI: 10.1542/hpeds.2021-006415] [PMID: 35673948]">Susnerwala 2022</a>). The aetiology of seizures included all causes except hypoglycaemia and hypocalcaemia in six studies (<a href="./references#CD014967-bbs2-0001" title="AkeelNE , SulimanHA , Al-ShokaryAH , IbrahimAO , KamalNM , AbdelgalilAA , et al. A comparative study of levetiracetam and phenobarbital for neonatal seizures as a first line treatment. Global Pediatric Health2022;9:2333794X221143572. [DOI: 10.1177/2333794X221143572] [PMID: 36578326]">Akeel 2022</a>; <a href="./references#CD014967-bbs2-0004" title="GhaffarJ , RiazA , Uzair, VirkAO , BhattiA . Comparative efficacy of intravenous levetiracetam vs phenobarbitone in neonatal seizures. Medical Forum2020;31(7):25-8. [WEBSITE: medforum.pk/article/6-comparative-efficacy-of-intravenous-levetiracetam-vs-phenobarbitone-in-neonatal-seizures]">Ghaffar 2020</a>; <a href="./references#CD014967-bbs2-0005" title="GowdaVK , RomanaA , ShivannaNH , BenakappaN , BenakappaA . Levetiracetam versus phenobarbitone in neonatal seizures — a randomized controlled trial. Indian Pediatrics2019;56(8):643-6. [PMID: 31477643]">Gowda 2019</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>; <a href="./references#CD014967-bbs2-0011" title="PrakashA , RichaR , SahniGS . Neonatal seizures – levetiracetam versus phenobarbital. Indian Journal of Child Health2019;6(11):605-8. [DOI: 10.32677/IJCH.2019.v06.i11.008]">Prakash 2019</a>; <a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>); while <a href="./references#CD014967-bbs2-0010" title="PerveenS , SinghA , UpadhyayA , SinghN , ChauhanR . A randomized controlled trial on comparison of phenobarbitone and levetiracetam for the treatment of neonatal seizures: pilot study. International Journal of Research in Medical Sciences2016;4(6):2073-8. [DOI: 10.18203/2320-6012.ijrms20161763] [URL: msjonline.org/index.php/ijrms/article/view/865/836]">Perveen 2016</a> included seizures due to any aetiology. The aetiologies were HIE, intracranial haemorrhage and meningitis in <a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>. <a href="./references#CD014967-bbs2-0017" title="SusnerwalaS , JoshiA , DeshmukhL , LondheA . Levetiracetam or phenobarbitone as a first-line anticonvulsant in asphyxiated term newborns? An open-label, single-center, randomized, controlled, pragmatic trial. Hospital Pediatrics2022;12(7):647-52. [DOI: 10.1542/hpeds.2021-006415] [PMID: 35673948]">Susnerwala 2022</a> included seizures due to HIE alone. Seizure control was defined variably as seizure‐free for 24 hours in <a href="./references#CD014967-bbs2-0001" title="AkeelNE , SulimanHA , Al-ShokaryAH , IbrahimAO , KamalNM , AbdelgalilAA , et al. A comparative study of levetiracetam and phenobarbital for neonatal seizures as a first line treatment. Global Pediatric Health2022;9:2333794X221143572. [DOI: 10.1177/2333794X221143572] [PMID: 36578326]">Akeel 2022</a>; <a href="./references#CD014967-bbs2-0004" title="GhaffarJ , RiazA , Uzair, VirkAO , BhattiA . Comparative efficacy of intravenous levetiracetam vs phenobarbitone in neonatal seizures. Medical Forum2020;31(7):25-8. [WEBSITE: medforum.pk/article/6-comparative-efficacy-of-intravenous-levetiracetam-vs-phenobarbitone-in-neonatal-seizures]">Ghaffar 2020</a>; <a href="./references#CD014967-bbs2-0005" title="GowdaVK , RomanaA , ShivannaNH , BenakappaN , BenakappaA . Levetiracetam versus phenobarbitone in neonatal seizures — a randomized controlled trial. Indian Pediatrics2019;56(8):643-6. [PMID: 31477643]">Gowda 2019</a>, <a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a> and <a href="./references#CD014967-bbs2-0017" title="SusnerwalaS , JoshiA , DeshmukhL , LondheA . Levetiracetam or phenobarbitone as a first-line anticonvulsant in asphyxiated term newborns? An open-label, single-center, randomized, controlled, pragmatic trial. Hospital Pediatrics2022;12(7):647-52. [DOI: 10.1542/hpeds.2021-006415] [PMID: 35673948]">Susnerwala 2022</a>; 48 hours in <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>; five days in <a href="./references#CD014967-bbs2-0011" title="PrakashA , RichaR , SahniGS . Neonatal seizures – levetiracetam versus phenobarbital. Indian Journal of Child Health2019;6(11):605-8. [DOI: 10.32677/IJCH.2019.v06.i11.008]">Prakash 2019</a> and one week in <a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>. All nine studies have continued maintenance doses of ASM after achieving seizure control. </p> <p>While <a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a> excluded infants who required an additional ASM for seizure control, the other studies have included infants requiring further ASMs. In <a href="./references#CD014967-bbs2-0004" title="GhaffarJ , RiazA , Uzair, VirkAO , BhattiA . Comparative efficacy of intravenous levetiracetam vs phenobarbitone in neonatal seizures. Medical Forum2020;31(7):25-8. [WEBSITE: medforum.pk/article/6-comparative-efficacy-of-intravenous-levetiracetam-vs-phenobarbitone-in-neonatal-seizures]">Ghaffar 2020</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>; <a href="./references#CD014967-bbs2-0010" title="PerveenS , SinghA , UpadhyayA , SinghN , ChauhanR . A randomized controlled trial on comparison of phenobarbitone and levetiracetam for the treatment of neonatal seizures: pilot study. International Journal of Research in Medical Sciences2016;4(6):2073-8. [DOI: 10.18203/2320-6012.ijrms20161763] [URL: msjonline.org/index.php/ijrms/article/view/865/836]">Perveen 2016</a> and <a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>, second and third‐line ASMs were chosen as per the NICU protocol or at the discretion of the treating neonatologist. <a href="./references#CD014967-bbs2-0001" title="AkeelNE , SulimanHA , Al-ShokaryAH , IbrahimAO , KamalNM , AbdelgalilAA , et al. A comparative study of levetiracetam and phenobarbital for neonatal seizures as a first line treatment. Global Pediatric Health2022;9:2333794X221143572. [DOI: 10.1177/2333794X221143572] [PMID: 36578326]">Akeel 2022</a>; <a href="./references#CD014967-bbs2-0005" title="GowdaVK , RomanaA , ShivannaNH , BenakappaN , BenakappaA . Levetiracetam versus phenobarbitone in neonatal seizures — a randomized controlled trial. Indian Pediatrics2019;56(8):643-6. [PMID: 31477643]">Gowda 2019</a>; <a href="./references#CD014967-bbs2-0011" title="PrakashA , RichaR , SahniGS . Neonatal seizures – levetiracetam versus phenobarbital. Indian Journal of Child Health2019;6(11):605-8. [DOI: 10.32677/IJCH.2019.v06.i11.008]">Prakash 2019</a> and <a href="./references#CD014967-bbs2-0017" title="SusnerwalaS , JoshiA , DeshmukhL , LondheA . Levetiracetam or phenobarbitone as a first-line anticonvulsant in asphyxiated term newborns? An open-label, single-center, randomized, controlled, pragmatic trial. Hospital Pediatrics2022;12(7):647-52. [DOI: 10.1542/hpeds.2021-006415] [PMID: 35673948]">Susnerwala 2022</a> are add‐on trials (strictly speaking, not cross‐over trials as phenobarbital has a long half‐life and there was no washout phase), where phenobarbital was used as the second‐line drug in the levetiracetam group and vice versa. For the outcomes on efficacy, i.e. 'seizure control after single dose ASM' and 'seizure control after maximum dose ASM', we considered only the monotherapy effect, that is, seizure control after the first‐line drug that was randomised. However, for all the other outcomes during further hospital stay, after discharge and for long‐term outcomes at 18 to 24 months, we analysed as per the randomisation, and we did not exclude infants who had received other drugs as second‐ or third‐ line ASMs. Further, we did not analyse cross‐over trials separately, because no study included washout periods due to ethical considerations (See <a href="#CD014967-sec-0277">Differences between protocol and review</a>). Further, since we have only three or four drugs that can be used for neonatal seizures, we were of the view that all trials were essentially like cross‐over trials, as the authors would have used the comparator drug as a second‐ or third‐line ASM in the intervention group, and vice versa. </p> <p>The dose of phenobarbital and levetiracetam also varied across the studies. While <a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>; <a href="./references#CD014967-bbs2-0010" title="PerveenS , SinghA , UpadhyayA , SinghN , ChauhanR . A randomized controlled trial on comparison of phenobarbitone and levetiracetam for the treatment of neonatal seizures: pilot study. International Journal of Research in Medical Sciences2016;4(6):2073-8. [DOI: 10.18203/2320-6012.ijrms20161763] [URL: msjonline.org/index.php/ijrms/article/view/865/836]">Perveen 2016</a> and <a href="./references#CD014967-bbs2-0017" title="SusnerwalaS , JoshiA , DeshmukhL , LondheA . Levetiracetam or phenobarbitone as a first-line anticonvulsant in asphyxiated term newborns? An open-label, single-center, randomized, controlled, pragmatic trial. Hospital Pediatrics2022;12(7):647-52. [DOI: 10.1542/hpeds.2021-006415] [PMID: 35673948]">Susnerwala 2022</a> used 20 mg/kg of phenobarbital, <a href="./references#CD014967-bbs2-0001" title="AkeelNE , SulimanHA , Al-ShokaryAH , IbrahimAO , KamalNM , AbdelgalilAA , et al. A comparative study of levetiracetam and phenobarbital for neonatal seizures as a first line treatment. Global Pediatric Health2022;9:2333794X221143572. [DOI: 10.1177/2333794X221143572] [PMID: 36578326]">Akeel 2022</a> and <a href="./references#CD014967-bbs2-0005" title="GowdaVK , RomanaA , ShivannaNH , BenakappaN , BenakappaA . Levetiracetam versus phenobarbitone in neonatal seizures — a randomized controlled trial. Indian Pediatrics2019;56(8):643-6. [PMID: 31477643]">Gowda 2019</a> used 30 mg/kg (20 mg/kg followed by 10 mg/kg); and <a href="./references#CD014967-bbs2-0004" title="GhaffarJ , RiazA , Uzair, VirkAO , BhattiA . Comparative efficacy of intravenous levetiracetam vs phenobarbitone in neonatal seizures. Medical Forum2020;31(7):25-8. [WEBSITE: medforum.pk/article/6-comparative-efficacy-of-intravenous-levetiracetam-vs-phenobarbitone-in-neonatal-seizures]">Ghaffar 2020</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>; <a href="./references#CD014967-bbs2-0011" title="PrakashA , RichaR , SahniGS . Neonatal seizures – levetiracetam versus phenobarbital. Indian Journal of Child Health2019;6(11):605-8. [DOI: 10.32677/IJCH.2019.v06.i11.008]">Prakash 2019</a> and <a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a> used 40 mg/kg (20 mg/kg followed by 2 doses of 10 mg/kg each). The maintenance dose used was 5 mg/kg/day in all studies. In the levetiracetam group, <a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a> and <a href="./references#CD014967-bbs2-0017" title="SusnerwalaS , JoshiA , DeshmukhL , LondheA . Levetiracetam or phenobarbitone as a first-line anticonvulsant in asphyxiated term newborns? An open-label, single-center, randomized, controlled, pragmatic trial. Hospital Pediatrics2022;12(7):647-52. [DOI: 10.1542/hpeds.2021-006415] [PMID: 35673948]">Susnerwala 2022</a> used only a single loading dose of 20 mg/kg; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a> and <a href="./references#CD014967-bbs2-0010" title="PerveenS , SinghA , UpadhyayA , SinghN , ChauhanR . A randomized controlled trial on comparison of phenobarbitone and levetiracetam for the treatment of neonatal seizures: pilot study. International Journal of Research in Medical Sciences2016;4(6):2073-8. [DOI: 10.18203/2320-6012.ijrms20161763] [URL: msjonline.org/index.php/ijrms/article/view/865/836]">Perveen 2016</a> used a single loading dose of 50 mg/kg and 60 mg/kg respectively; <a href="./references#CD014967-bbs2-0011" title="PrakashA , RichaR , SahniGS . Neonatal seizures – levetiracetam versus phenobarbital. Indian Journal of Child Health2019;6(11):605-8. [DOI: 10.32677/IJCH.2019.v06.i11.008]">Prakash 2019</a> used an initial loading dose of 10 mg/kg and maximal loading dose of 15 mg/kg; <a href="./references#CD014967-bbs2-0001" title="AkeelNE , SulimanHA , Al-ShokaryAH , IbrahimAO , KamalNM , AbdelgalilAA , et al. A comparative study of levetiracetam and phenobarbital for neonatal seizures as a first line treatment. Global Pediatric Health2022;9:2333794X221143572. [DOI: 10.1177/2333794X221143572] [PMID: 36578326]">Akeel 2022</a> used an initial loading dose of 20 mg/kg and maximal loading dose of 30 mg//kg; <a href="./references#CD014967-bbs2-0004" title="GhaffarJ , RiazA , Uzair, VirkAO , BhattiA . Comparative efficacy of intravenous levetiracetam vs phenobarbitone in neonatal seizures. Medical Forum2020;31(7):25-8. [WEBSITE: medforum.pk/article/6-comparative-efficacy-of-intravenous-levetiracetam-vs-phenobarbitone-in-neonatal-seizures]">Ghaffar 2020</a> used an initial loading dose of 30 mg/kg and maximal loading dose of 40 mg/kg, <a href="./references#CD014967-bbs2-0005" title="GowdaVK , RomanaA , ShivannaNH , BenakappaN , BenakappaA . Levetiracetam versus phenobarbitone in neonatal seizures — a randomized controlled trial. Indian Pediatrics2019;56(8):643-6. [PMID: 31477643]">Gowda 2019</a> used an initial loading dose of 20 mg/kg and maximal loading dose of 40 mg/kg, and <a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a> used an initial loading dose of 40 mg/kg and maximal loading dose of 60 mg/kg. </p> </section> <section id="CD014967-sec-0044"> <h5 class="title">Phenobarbital versus phenytoin as first‐line ASM</h5> <p>Three studies (<a href="./references#CD014967-bbs2-0008" title="PainterMJ , ScherMS , SteinAD , ArmattiS , WangZ , GardinerJC , et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine1999;341(7):485-9. [DOI: 10.1056/NEJM199908123410704] [PMID: 10441604]ScherMS , AlvinJ , GausL , MinnighB , PainterMJ . Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology2003;28(4):277-80. [DOI: 10.1016/s0887-8994(02)00621-5] [PMID: 12849880]">Painter 1999</a>; <a href="./references#CD014967-bbs2-0009" title="PathakG , UpadhyayA , PathakU , ChawlaD , GoelSP . Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial. Indian Pediatrics2013;50(8):753-7. [DOI: 10.1007/s13312-013-0218-6] [PMID: 23502660]">Pathak 2013</a>; <a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>), compared phenobarbital versus phenytoin as first‐line ASM. All three studies included term and late preterm neonates. While <a href="./references#CD014967-bbs2-0008" title="PainterMJ , ScherMS , SteinAD , ArmattiS , WangZ , GardinerJC , et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine1999;341(7):485-9. [DOI: 10.1056/NEJM199908123410704] [PMID: 10441604]ScherMS , AlvinJ , GausL , MinnighB , PainterMJ . Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology2003;28(4):277-80. [DOI: 10.1016/s0887-8994(02)00621-5] [PMID: 12849880]">Painter 1999</a> utilised EEG to confirm seizures, the two other studies (<a href="./references#CD014967-bbs2-0009" title="PathakG , UpadhyayA , PathakU , ChawlaD , GoelSP . Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial. Indian Pediatrics2013;50(8):753-7. [DOI: 10.1007/s13312-013-0218-6] [PMID: 23502660]">Pathak 2013</a>; <a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>), used clinical diagnosis of seizures. The aetiology of seizures included all causes except hypoglycaemia and hypocalcaemia in two studies (<a href="./references#CD014967-bbs2-0009" title="PathakG , UpadhyayA , PathakU , ChawlaD , GoelSP . Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial. Indian Pediatrics2013;50(8):753-7. [DOI: 10.1007/s13312-013-0218-6] [PMID: 23502660]">Pathak 2013</a>; <a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>), while <a href="./references#CD014967-bbs2-0008" title="PainterMJ , ScherMS , SteinAD , ArmattiS , WangZ , GardinerJC , et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine1999;341(7):485-9. [DOI: 10.1056/NEJM199908123410704] [PMID: 10441604]ScherMS , AlvinJ , GausL , MinnighB , PainterMJ . Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology2003;28(4):277-80. [DOI: 10.1016/s0887-8994(02)00621-5] [PMID: 12849880]">Painter 1999</a> included seizures due to all causes. Seizure control was defined as stopping of seizures within 2.5 minutes of the loading dose in two studies (<a href="./references#CD014967-bbs2-0008" title="PainterMJ , ScherMS , SteinAD , ArmattiS , WangZ , GardinerJC , et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine1999;341(7):485-9. [DOI: 10.1056/NEJM199908123410704] [PMID: 10441604]ScherMS , AlvinJ , GausL , MinnighB , PainterMJ . Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology2003;28(4):277-80. [DOI: 10.1016/s0887-8994(02)00621-5] [PMID: 12849880]">Painter 1999</a>; <a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>), while it was defined as seizure control soon after the loading dose in <a href="./references#CD014967-bbs2-0009" title="PathakG , UpadhyayA , PathakU , ChawlaD , GoelSP . Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial. Indian Pediatrics2013;50(8):753-7. [DOI: 10.1007/s13312-013-0218-6] [PMID: 23502660]">Pathak 2013</a>. One study (<a href="./references#CD014967-bbs2-0008" title="PainterMJ , ScherMS , SteinAD , ArmattiS , WangZ , GardinerJC , et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine1999;341(7):485-9. [DOI: 10.1056/NEJM199908123410704] [PMID: 10441604]ScherMS , AlvinJ , GausL , MinnighB , PainterMJ . Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology2003;28(4):277-80. [DOI: 10.1016/s0887-8994(02)00621-5] [PMID: 12849880]">Painter 1999</a>), gave maintenance doses after the loading dose, while the other two studies (<a href="./references#CD014967-bbs2-0009" title="PathakG , UpadhyayA , PathakU , ChawlaD , GoelSP . Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial. Indian Pediatrics2013;50(8):753-7. [DOI: 10.1007/s13312-013-0218-6] [PMID: 23502660]">Pathak 2013</a>; <a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>), did not give maintenance doses of ASM. </p> <p>Two studies (<a href="./references#CD014967-bbs2-0008" title="PainterMJ , ScherMS , SteinAD , ArmattiS , WangZ , GardinerJC , et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine1999;341(7):485-9. [DOI: 10.1056/NEJM199908123410704] [PMID: 10441604]ScherMS , AlvinJ , GausL , MinnighB , PainterMJ . Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology2003;28(4):277-80. [DOI: 10.1016/s0887-8994(02)00621-5] [PMID: 12849880]">Painter 1999</a>; <a href="./references#CD014967-bbs2-0009" title="PathakG , UpadhyayA , PathakU , ChawlaD , GoelSP . Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial. Indian Pediatrics2013;50(8):753-7. [DOI: 10.1007/s13312-013-0218-6] [PMID: 23502660]">Pathak 2013</a>), were cross‐over trials where phenytoin was used as the second‐line ASM in the phenobarbital group and vice versa. In <a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>, the choice of further ASMs was at the clinician's discretion. Both phenobarbital and phenytoin were used at a dose of 20 mg/kg for loading in <a href="./references#CD014967-bbs2-0009" title="PathakG , UpadhyayA , PathakU , ChawlaD , GoelSP . Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial. Indian Pediatrics2013;50(8):753-7. [DOI: 10.1007/s13312-013-0218-6] [PMID: 23502660]">Pathak 2013</a> and <a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>, while <a href="./references#CD014967-bbs2-0008" title="PainterMJ , ScherMS , SteinAD , ArmattiS , WangZ , GardinerJC , et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine1999;341(7):485-9. [DOI: 10.1056/NEJM199908123410704] [PMID: 10441604]ScherMS , AlvinJ , GausL , MinnighB , PainterMJ . Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology2003;28(4):277-80. [DOI: 10.1016/s0887-8994(02)00621-5] [PMID: 12849880]">Painter 1999</a> used the dose of ASM required to achieve a serum concentration of 2.5 mcg/mL. </p> </section> <section id="CD014967-sec-0045"> <h5 class="title">Phenobarbital and phenytoin versus lorazepam as first‐line ASM</h5> <p>One study (<a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>), compared phenobarbital and phenytoin versus lorazepam as first‐line ASM. The study included term and late preterm neonates, and used only clinical diagnosis of seizures. The aetiology of seizures included all causes except hypoglycaemia and hypocalcaemia. Seizure control was defined as stopping seizures within 2.5 minutes of the loading dose. The choice of further ASMs was at the clinician's discretion. Phenobarbital and phenytoin were used at a dose of 20 mg/kg, while lorazepam was used at a dose of 0.05 mg/kg for loading in the study. The study authors did not administer maintenance doses after the loading dose. </p> </section> <section id="CD014967-sec-0046"> <h5 class="title">Phenobarbital + bumetanide versus phenobarbital alone as first‐line ASM</h5> <p>One study (<a href="./references#CD014967-bbs2-0015" title="SoulJS , BerginAM , StoppC , HayesB , SinghA , FortunoCR , et al, Boston Bumetanide Trial Group. A pilot randomized, controlled, double‐blind trial of bumetanide to treat neonatal seizures. Annals of Neurology2021;89(2):327-40. [DOI: 10.1002/ana.25959] [PMID: 33201535]">Soul 2021</a>), compared phenobarbital + bumetanide versus phenobarbital alone. The study included neonates born at ≥ 33 weeks' gestation who had EEG‐confirmed seizures. The aetiology of seizures included all causes except hypoglycaemia, hypocalcaemia, and inborn errors of metabolism. Neonates who had seizures despite 20 to &lt; 40 mg/kg of phenobarbital were randomised to phenobarbital alone (5 to 10 mg/kg) or phenobarbital (5 to 10 mg/kg) and bumetanide (0.1 to 0.3 mg/kg). The choice of further ASMs was as per the unit protocol. The study primarily aimed to evaluate the pharmacokinetics and pharmacodynamics of bumetanide. Seizure control was a post hoc outcome. </p> </section> <section id="CD014967-sec-0047"> <h5 class="title">Lidocaine versus benzodiazepines as second‐line ASM</h5> <p>One study (<a href="./references#CD014967-bbs2-0002" title="BoylanGB , RennieJM , ChorleyG , PresslerRM , FoxGF , FarrerK , et al. Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study. Neurology2004;62(3):486-8. [DOI: 10.1212/01.wnl.0000106944.59990.e6] [PMID: 14872039]">Boylan 2004</a>), compared lidocaine versus benzodiazepines (midazolam or clonazepam) as second‐line ASM. The study included both term and preterm neonates who had EEG‐confirmed seizures. The aetiology of seizures included HIE, intracranial haemorrhage and meningitis. First‐line ASM was phenobarbital, given at 40 mg/kg maximal loading dose. Seizure control was defined as reduction in seizure burden by 80% in 12 hours. Lidocaine was given at a dose of 4 mg/kg over 20 minutes, followed by 2 mg/kg/h, and increased to 4 mg/kg/h if seizure control was not achieved. Midazolam was administered at a dose of 60 µg/kg loading followed by 150 µg/kg/h, and increased up to 300 µg/kg/h after 12 hours if seizure control was not achieved. </p> </section> </section> <section id="CD014967-sec-0048"> <h4 class="title">Maintenance therapy with ASM versus no maintenance therapy after achieving seizure control </h4> <p>Two trials and 373 infants (<a href="./references#CD014967-bbs2-0006" title="JindalA , AnguranaSK , SutharR , KumarP , SundaramV . Effect of early withdrawal of phenobarbitone on the recurrence of neonatal seizures: an open-label randomized controlled trial. Epilepsy &amp; Behavior2021;117:107875. [DOI: 10.1016/j.yebeh.2021.107875] [PMID: 33706247]">Jindal 2021</a>; <a href="./references#CD014967-bbs2-0012" title="SaxenaP , SinghA , UpadhyayA , GuptaP , SharmaS , VishnubatlaS . Effect of withholding phenobarbitone maintenance in neonatal seizures: a randomized controlled trial. Indian Pediatrics2016;53(12):1069-73. [PMID: 27889710]">Saxena 2016</a>), were included in the comparison of short‐term maintenance therapy with ASM versus no maintenance therapy for neonatal seizures during hospital stay. Both trials included neonates born at ≥ 34 weeks' gestation and had only clinically‐diagnosed seizures. The aetiologies of seizures were perinatal asphyxia, meningitis and intracranial haemorrhage in both trials, while <a href="./references#CD014967-bbs2-0012" title="SaxenaP , SinghA , UpadhyayA , GuptaP , SharmaS , VishnubatlaS . Effect of withholding phenobarbitone maintenance in neonatal seizures: a randomized controlled trial. Indian Pediatrics2016;53(12):1069-73. [PMID: 27889710]">Saxena 2016</a> also included seizures due to metabolic causes. Both trials included only those neonates who achieved seizure control after a single loading dose of 20 mg/kg of phenobarbital. Infants who required further doses of phenobarbital or other ASMs to achieve seizure control were excluded. The time of randomisation was 12 hours seizure‐free after 20 mg//kg phenobarbital in both trials. The duration of maintenance therapy with phenobarbital was five days in one trial (<a href="./references#CD014967-bbs2-0012" title="SaxenaP , SinghA , UpadhyayA , GuptaP , SharmaS , VishnubatlaS . Effect of withholding phenobarbitone maintenance in neonatal seizures: a randomized controlled trial. Indian Pediatrics2016;53(12):1069-73. [PMID: 27889710]">Saxena 2016</a>), while it was until hospital discharge in the other trial (<a href="./references#CD014967-bbs2-0006" title="JindalA , AnguranaSK , SutharR , KumarP , SundaramV . Effect of early withdrawal of phenobarbitone on the recurrence of neonatal seizures: an open-label randomized controlled trial. Epilepsy &amp; Behavior2021;117:107875. [DOI: 10.1016/j.yebeh.2021.107875] [PMID: 33706247]">Jindal 2021</a>). </p> </section> <section id="CD014967-sec-0049"> <h4 class="title">Treatment of both clinical and electrographic seizures versus treatment of clinical seizures alone in neonates </h4> <p>Two trials and 68 infants (<a href="./references#CD014967-bbs2-0016" title="SrinivasakumarP , ZempelJ , TrivediS , WallendorfM , RaoR , SmithB , et al. Treating EEG seizures in hypoxic ischemic encephalopathy: a randomized controlled trial. Pediatrics2015;136(5):e1302-9. [DOI: 10.1542/peds.2014-3777] [PMID: 26482675]">Srinivasakumar 2015</a>; <a href="./references#CD014967-bbs2-0018" title="Van RooijLG , ToetMC , Van HuffelenAC , GroenendaalF , LaanW , ZecicA , et al. Effect of treatment of subclinical neonatal seizures detected with aEEG: randomized, controlled trial. Pediatrics2010;125(2):e358-e66. [DOI: 10.1542/peds.2009-0136] [PMID: 20100767]">Van Rooji 2010</a>), were included in the comparison of any ASM treatment versus no treatment for only‐electrographic seizures. Both trials were performed on neonates born at ≥ 35 weeks' gestation and both included only neonates with HIE. The ASMs used were phenobarbital, phenytoin and midazolam in <a href="./references#CD014967-bbs2-0016" title="SrinivasakumarP , ZempelJ , TrivediS , WallendorfM , RaoR , SmithB , et al. Treating EEG seizures in hypoxic ischemic encephalopathy: a randomized controlled trial. Pediatrics2015;136(5):e1302-9. [DOI: 10.1542/peds.2014-3777] [PMID: 26482675]">Srinivasakumar 2015</a>, while <a href="./references#CD014967-bbs2-0018" title="Van RooijLG , ToetMC , Van HuffelenAC , GroenendaalF , LaanW , ZecicA , et al. Effect of treatment of subclinical neonatal seizures detected with aEEG: randomized, controlled trial. Pediatrics2010;125(2):e358-e66. [DOI: 10.1542/peds.2009-0136] [PMID: 20100767]">Van Rooji 2010</a> used phenobarbital, midazolam, lignocaine and clonazepam. The time of randomisation was before the onset of electrographic seizures in <a href="./references#CD014967-bbs2-0016" title="SrinivasakumarP , ZempelJ , TrivediS , WallendorfM , RaoR , SmithB , et al. Treating EEG seizures in hypoxic ischemic encephalopathy: a randomized controlled trial. Pediatrics2015;136(5):e1302-9. [DOI: 10.1542/peds.2014-3777] [PMID: 26482675]">Srinivasakumar 2015</a>, though the outcomes were reported only for those neonates who had electrographic seizures. The time of randomisation was after the onset of electrographic seizures in the <a href="./references#CD014967-bbs2-0018" title="Van RooijLG , ToetMC , Van HuffelenAC , GroenendaalF , LaanW , ZecicA , et al. Effect of treatment of subclinical neonatal seizures detected with aEEG: randomized, controlled trial. Pediatrics2010;125(2):e358-e66. [DOI: 10.1542/peds.2009-0136] [PMID: 20100767]">Van Rooji 2010</a> study. While <a href="./references#CD014967-bbs2-0016" title="SrinivasakumarP , ZempelJ , TrivediS , WallendorfM , RaoR , SmithB , et al. Treating EEG seizures in hypoxic ischemic encephalopathy: a randomized controlled trial. Pediatrics2015;136(5):e1302-9. [DOI: 10.1542/peds.2014-3777] [PMID: 26482675]">Srinivasakumar 2015</a> used continuous video EEG to diagnose seizures, <a href="./references#CD014967-bbs2-0018" title="Van RooijLG , ToetMC , Van HuffelenAC , GroenendaalF , LaanW , ZecicA , et al. Effect of treatment of subclinical neonatal seizures detected with aEEG: randomized, controlled trial. Pediatrics2010;125(2):e358-e66. [DOI: 10.1542/peds.2009-0136] [PMID: 20100767]">Van Rooji 2010</a> used aEEG. </p> </section> <section id="CD014967-sec-0050"> <h4 class="title">Excluded studies</h4> <p>We excluded 30 studies for the reasons described below. See <a href="./references#CD014967-sec-0280" title="">Characteristics of excluded studies</a>. </p> </section> <section id="CD014967-sec-0051"> <h4 class="title">Studies without a comparator</h4> <p>Several studies described the effect of a single ASM without a comparator and therefore had to be excluded. Retrospective case series examined the effect of levetiracetam as first‐line ASM (<a href="./references#CD014967-bbs2-0019" title="AbendNS , Gutierrez-ColinaAM , MonkHM , DlugosDJ , ClancyRR . Levetiracetam for treatment of neonatal seizures. Journal of Child Neurology2011;26(4):465-70. [DOI: 10.1177/0883073810384263] [PMID: 21233461]">Abend 2011</a>; <a href="./references#CD014967-bbs2-0027" title="HanJY , MoonCJ , YounYA , SungIK , LeeIG . Efficacy of levetiracetam for neonatal seizures in preterm infants. BMC Pediatrics2018;18(1):131. [DOI: 10.1186/s12887-018-1103-1] [PMID: 29636029]">Han 2018</a>; <a href="./references#CD014967-bbs2-0033" title="KanmazS , Altun Köroğlu Ö, TerekD , SerinHM , SimsekE , Dokurel Cetin İ, et al. Efficacy of levetiracetam as first-line therapy for neonatal clinical seizures and neurodevelopmental outcome at 12 months of age. Acta Neurologica Belgica2021;121(6):1495-503. [DOI: 10.1007/s13760-020-01366-7] [PMID: 32424740]">Kanmaz 2021</a>), sodium valproate (<a href="./references#CD014967-bbs2-0025" title="GalP , OlesKS , GilmanJT , WeaverR . Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures. Neurology1988;38(3):467-71. [DOI: 10.1212/wnl.38.3.467] [PMID: 3126410]">Gal 1988</a>), or lidocaine (<a href="./references#CD014967-bbs2-0024" title="FaviéLM , HuitemaAD , vanden BroekMP , RademakerCM , deHaanTR , vanStraatenHL , et al, PharmaCool study group*. Lidocaine as treatment for neonatal seizures: Evaluation of previously developed population pharmacokinetic models and dosing regimen. British Journal of Clinical Pharmacology2020;86(1):75-84. [DOI: 10.1111/bcp.14136] [PMID: 31663153]">Favié 2020</a>; <a href="./references#CD014967-bbs2-0047" title="WeekeLC , ToetMC , vanRooijLG , GroenendaalF , BoylanGB , PresslerRM , et al. Lidocaine response rate in aEEG-confirmed neonatal seizures: retrospective study of 413 full-term and preterm infants. Epilepsia2016;57(2):233-42. [DOI: 10.1111/epi.13286] [PMID: 6719344]">Weeke 2016</a>). Uncontrolled cohort studies examined the effect of levetiracetam as first‐line medication (<a href="./references#CD014967-bbs2-0042" title="SedighiM , AsadiF , MoradianN , VakiliaminiM , MoradianM . Efficacy and safety of levetiracetam in the management of seizures in neonates. Neurosciences2016;21(3):232-5. [DOI: 10.17712/nsj.2016.3.20150726] [PMID: 27356654]">Sedighi 2016</a>; <a href="./references#CD014967-bbs2-0039" title="RamantaniG , IkonomidouC , WalterB , RatingD , DingerJ . Levetiracetam: safety and efficacy in neonatal seizures. European Journal of Paediatric Neurology2011;15(1):1-7. [DOI: 10.1016/j.ejpn.2010.10.003] [PMID: 21094062]">Ramantani 2011</a>), or lidocaine (<a href="./references#CD014967-bbs2-0028" title="Hellström-WestasL , WestgrenU , RosénI , SvenningsenNW . Lidocaine for treatment of severe seizures in newborn infants.: I. Clinical effects and cerebral electrical activity monitoring. Acta Paediatrica1988;77(1):79-84. [DOI: 10.1111/j.1651-2227.1988.tb10602.x] [PMID: 3369308]">Hellström‐Westas 1988</a>). One study describing clinical, neuroimaging, and electrographic predictors of phenobarbital failure in newborns with hypoxic ischaemic encephalopathy and seizures also had to be excluded (<a href="./references#CD014967-bbs2-0023" title="DwivediD , LinN , VenkatesanC , Kline-FathB , HollandK , SchapiroM . Clinical, neuroimaging, and electrographic predictors of phenobarbital failure in newborns with hypoxic ischemic encephalopathy and seizures. Journal of Child Neurology2019;34(8):458-63. [DOI: 10.1177/0883073819838171] [PMID: 30966848]">Dwivedi 2019</a>). Another study examined the effect of phenobarbital on EEG (<a href="./references#CD014967-bbs2-0035" title="LowE , StevensonNJ , MathiesonSR , LivingstoneV , RyanAC , RennieJM , et al. Short-term effects of phenobarbitone on electrographic seizures in neonates. Neonatology2016;110(1):40-6. [DOI: 10.1159/000443782] [PMID: 27027306]">Low 2016</a>), without a comparator. </p> </section> <section id="CD014967-sec-0052"> <h4 class="title">Comparison of one ASM versus another</h4> <section id="CD014967-sec-0053"> <h5 class="title">Phenobarbital versus levetiracetam as first‐line ASM</h5> <p>The efficacy of phenobarbital versus levetiracetam was retrospectively compared by six studies, all of which had to be excluded because of the retrospective design (<a href="./references#CD014967-bbs2-0034" title="LiuBK , JiangL , LiXJ , HongSQ , ChenW , HuY . Efficacy and safety of levetiracetam in the off-label treatment of neonatal seizures. International Journal of Neuroscience2020;130(4):336-42. [DOI: 10.1080/00207454.2019.1687469] [PMID: 31665950]">Liu 2020</a>; <a href="./references#CD014967-bbs2-0036" title="MaitreNL , SmolinskyC , SlaughterJC , StarkAR . Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures. Journal of Perinatology2013;33(11):841-6. [DOI: 10.1038/jp.2013.116] [PMID: 24051577]">Maitre 2013</a>; <a href="./references#CD014967-bbs2-0040" title="RaoLM , HussainSA , ZakiT , ChoA , ChanlawT , GargM , et al. A comparison of levetiracetam and phenobarbital for the treatment of neonatal seizures associated with hypoxic–ischemic encephalopathy. Epilepsy &amp; Behavior2018;88:212-7. [DOI: 10.1016/j.yebeh.2018.09.015] [PMID: 30296665]">Rao 2018</a>; <a href="./references#CD014967-bbs2-0044" title="ThibaultC , NaimMY , AbendNS , LichtDJ , GaynorJW , XiaoR , et al. A retrospective comparison of phenobarbital and levetiracetam for the treatment of seizures following cardiac surgery in neonates. Epilepsia2020;61(4):627-35. [DOI: 10.1111/epi.16469] [PMID: 32162678]">Thibault 2020</a>; <a href="./references#CD014967-bbs2-0045" title="VerwoerdC , LimjocoJ , RajamanickamV , KnoxA . Efficacy of levetiracetam and phenobarbital as first-line treatment for neonatal seizures. Journal of Child Neurology2022;37(5):401-9. [DOI: 10.1177/08830738221086107] [PMID: 35311411]">Verwoerd 2022</a>; <a href="./references#CD014967-bbs2-0046" title="WagnerCB , KreimerAM , CarrilloNP , AutryE , SchadlerA , CookAM , et al. Levetiracetam compared to phenobarbital as a frst line therapy for neonatal seizures: an unexpected influence of benzodiazepines on seizure response. Journal of Pediatric Pharmacology and Therapeutics2021;26(2):144-50. [DOI: 10.5863/1551-6776-26.2.144] [PMID: 33603577]">Wagner 2021</a>). The authors of one study specifically addressed neurodevelopmental outcomes (<a href="./references#CD014967-bbs2-0036" title="MaitreNL , SmolinskyC , SlaughterJC , StarkAR . Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures. Journal of Perinatology2013;33(11):841-6. [DOI: 10.1038/jp.2013.116] [PMID: 24051577]">Maitre 2013</a>); another study focused on newborns undergoing cardiac surgery (<a href="./references#CD014967-bbs2-0044" title="ThibaultC , NaimMY , AbendNS , LichtDJ , GaynorJW , XiaoR , et al. A retrospective comparison of phenobarbital and levetiracetam for the treatment of seizures following cardiac surgery in neonates. Epilepsia2020;61(4):627-35. [DOI: 10.1111/epi.16469] [PMID: 32162678]">Thibault 2020</a>). One cross‐sectional study examined neurodevelopment of newborns with seizures following treatment with phenobarbital versus levetiracetam and also had to be excluded because of lack of randomisation (<a href="./references#CD014967-bbs2-0020" title="AricanP , Olgac DundarN , Mete AtaseverN , Akkaya InalM , GencpinarP , CavusogluD , et al. Comparison of the neurocognitive outcomes in term infants treated with levetiracetam and phenobarbital monotherapy for neonatal clinical seizures. Seizure2020;80:71-4. [DOI: 10.1016/j.seizure.2020.06.006] [PMID: 32540641]">Arican 2020</a>). </p> </section> <section id="CD014967-sec-0054"> <h5 class="title">Phenobarbital versus other medications as first‐line ASM</h5> <p>One RCT comparing the effects of phenobarbital, phenytoin, clonazepam, and sodium valproate was excluded because data were only published as a conference abstract (<a href="./references#CD014967-bbs2-0041" title="RochefortMJ , WilkinsonAR . The safety and efficacy of alternative anticonvulsant regimes to control newborn seizures. Early Human Development1989;19(3):218. [EMBASE: 10.1016/0378-3782(89)90090-X]WilkinsonAR , RochefortMJ . Phenytoin reduces frequency and duration of neonatal seizures in the newborn: a randomised trial of four anticonvulsants. Pediatric Research1989;26:522. [DOI: 10.1203/00006450-198911000-00138]">Rochefort 1989</a>). </p> </section> <section id="CD014967-sec-0055"> <h5 class="title">Second and third‐line ASM</h5> <p>One uncontrolled cohort study compared the effects of phenytoin in newborns with clinical seizures not controlled by phenobarbital as second‐line ASM (<a href="./references#CD014967-bbs2-0031" title="JawadekarYM , ShahKN , KshirsagarNA , JoshiMV , PohujaniSM . A study of phenobarbital and dilantin in neonatal seizures. Indian Journal of Pediatrics1992;59(6):729-34. [DOI: 10.1007/BF02859409] [PMID: 1340862]">Jawadekar 1992</a>). This study also addressed the pharmacokinetics of phenobarbital in newborns. Another cohort study examined the effect of midazolam as third‐line ASM, without a comparator (<a href="./references#CD014967-bbs2-0021" title="Castro CondeJR , Hernández BorgesAA , Doménech MartínezE , González CampoC , Perera SolerR . Midazolam in neonatal seizures with no response to phenobarbital. Neurology2005;64(5):876-9. [DOI: 10.1212/01.WNL.0000152891.58694.71] [PMID: 15753426]">Castro Conde 2005</a>). Retrospective studies addressed possible effects of lidocaine or midazolam on newborns with seizures not controlled by phenobarbital (<a href="./references#CD014967-bbs2-0043" title="ShanyE , BenzaqenO , WatembergN . Comparison of continuous drip of midazolam or lidocaine in the treatment of intractable neonatal seizures. Journal of Child Neurology2007;22(3):255-9. [DOI: 10.1177/0883073807299858] [PMID: 17621493]">Shany 2007</a>). Pharmacokinetics and effects of bumetanide in newborns with EEG‐confirmed seizures not responding to a loading dose of phenobarbital was examined in one study (<a href="./references#CD014967-bbs2-0038" title="PresslerRM , BoylanGB , MarlowN , BlennowM , ChironC , CrossJH , et al, NEonatal seizure treatment with Medication Off-patent (NEMO) consortium. Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial. Lancet Neurology2015;14(5):469-77. [DOI: 10.1016/S1474-4422(14)70303-5] [PMID: 25765333]">Pressler 2015</a>). A retrospective study examined the effect of lorazepam as third‐line ASM (<a href="./references#CD014967-bbs2-0022" title="DeshmukhA , WittertW , SchnitzlerE , MangurtenHH . Lorazepam in the treatment of refractory neonatal seizures. A pilot study. American Journal of Diseases of Children1986;140(10):1042-2. [DOI: 10.1001/archpedi.1986.02140240088032] [PMID: 3752014]">Deshmukh 1986</a>). The efficacy and safety of midazolam versus levetiracetam as third‐line ASM was investigated in one non‐randomised study, with no confirmation of seizures by EEG (<a href="./references#CD014967-bbs2-0032" title="JayswalD , RoyUK , GhoshT , MandalP . Effectiveness and adverse drug reactions of levetiracetam and midazolam in refractory neonatal seizure: a cross‑sectional comparative study. Journal of Education and Health Promotion2021;10:118. [DOI: 10.4103/jehp.jehp_937_20] [PMID: 34084865]">Jayswal 2021</a>). An uncontrolled cohort study examined the efficacy of oral levetiracetam as third‐line ASM in neonates with clinical seizures not responding to phenobarbital and phenytoin (<a href="./references#CD014967-bbs2-0037" title="MollamohammadiM , AmirhoseiniZS , SaadatiA , PirzadehZ , Hassandvand Amouzadeh M. Oral levetiracetam as add-on therapy in refractory neonatal seizures. Iranian Journal of Child Neurology2018;12(4):103-10. [PMID: 30279713h]">Mollamohammadi 2018</a>). </p> </section> </section> <section id="CD014967-sec-0056"> <h4 class="title">Maintenance therapy with ASM versus no maintenance therapy after achieving seizure control </h4> <p>Safety of early discontinuation of ASM after acute symptomatic neonatal seizures was retrospectively assessed in one study (<a href="./references#CD014967-bbs2-0026" title="GlassHC , SoulJS , ChangT , WusthoffCJ , ChuCJ , MasseySL , et al. Safety of early discontinuation of antiseizure medication after acute aymptomatic neonatal seizures. JAMA Neurology2021;78(7):817-25. [DOI: 10.1001/jamaneurol.2021.1437] [PMID: 34028496]">Glass 2021</a>). The study found no difference in neurodevelopment or epilepsy at age 24 months amongst children whose ASM was discontinued versus maintained at hospital discharge after resolution of acute symptomatic neonatal seizures. The study was excluded because of its retrospective nature. </p> </section> <section id="CD014967-sec-0057"> <h4 class="title">Treatment of both clinical and electrographic seizures versus treatment of clinical seizures alone in neonates </h4> <p>A RCT examining neurodevelopment following treatment of electrographic‐only seizures versus clinical seizures (<a href="./references#CD014967-bbs2-0030" title="HuntRW , LileyHG , WaghD , SchembriR , LeeKJ , ShearmanAD , et al, Newborn Electrographic Seizure Trial Investigators. Effect of treatment of clinical seizures vs electrographic seizures in full-term and near-term neonates: a randomized clinical trial. JAMA Network Open2021;4(12):e2139604. [DOI: 10.1001/jamanetworkopen.2021.39604] [PMID: 34919132]">Hunt 2021</a>) was excluded because seizure detection was based on aEEG alone and assessment of seizure burden was only initiated over 24 hours after birth. Thus, the study design impedes reaching conclusive results regarding the question examined. </p> </section> <section id="CD014967-sec-0058"> <h4 class="title">Studies awaiting classification</h4> <p>There are two studies awaiting classification (<a href="./references#CD014967-bbs2-0049" title="GyandeepG , BehuraSS , SahuSK , PandaSK . Comparison between phenobarbitone and levetiracetam as the initial anticonvulsant in preterm neonatal seizures - a pilot randomized control trial in developing country setup. European Journal of Pediatrics 2023 May;182(5):2133-8. [DOI: 10.1007/s00431-023-04864-x] [PMID: 36823477]">Gyandeep 2023</a>; <a href="./references#CD014967-bbs2-0050" title=" MohammadiM , KadivarM , SangsariR , MirniaK , Saeedi M, AdhamiP . Comparing the efficacy and safety of levetiracetam versus phenytoin for treating the acute phase of neonatal seizures. Iranian Journal of Child Neurology2023;17(1):65-71. [DOI: 10.22037/ijcn.v17i1.36008] [PMID: 36721831]">Mohammadi 2023</a>). They are awaiting classification for the following reason: we need additional data from the study authors to classify the studies and include in the appropriate meta‐analyses. </p> <p>For further details, see <a href="./references#CD014967-sec-0281" title="">Characteristics of studies awaiting classification</a>. </p> </section> <section id="CD014967-sec-0059"> <h4 class="title">Ongoing studies</h4> <p>There are 23 ongoing studies (<a href="./references#CD014967-bbs2-0051" title="ACTRN12622000470796. Efficacy and safety levetiracetam versus phenytoin for neonatal seizures. A randomized controlled trial [Efficacy and safety of levetricetam versus phenytoin for neonatal seizures: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12622000470796 (first received 25 March 2022). [CENTRAL: CN-02408074] ">ACTRN12622000470796</a>; <a href="./references#CD014967-bbs2-0052" title="CTRI/2013/01/003310. Comparison of levetiracetam with phenobarbitone in neonatal seizure. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2013/01/003310 (first received 21 January 2013). [CENTRAL: CN-01807519] ">CTRI/2013/01/003310</a>; <a href="./references#CD014967-bbs2-0053" title="CTRI/2013/04/003585. Levetiracetam for management of seizures in newborn. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2013/04/003585 (first received 26 April 2013). [CENTRAL: CN-01860078] ">CTRI/2013/04/003585</a>; <a href="./references#CD014967-bbs2-0054" title="CTRI/2014/06/004659. Does Levetiracetam reduce death/ control fits better than phenobarbitone in neonates. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2014/06/004659 (first received 9 June 2014). [CENTRAL: CN-01807076] ">CTRI/2014/06/004659</a>; <a href="./references#CD014967-bbs2-0055" title="CTRI/2015/06/005849. To see if levetiracetam, a new seizure control medication is better over older medication phenobarbitone for immediate neonatal seizure control. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2015/06/005849 (first received 3 June 2015). [CENTRAL: CN-01884226] ">CTRI/2015/06/005849</a>; <a href="./references#CD014967-bbs2-0056" title="CTRI/2016/10/007412. A clinical study to compare levetiracetam and phenobarbitone in newborns with birth asphyxia. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2016/10/007412 (first received 27 October 2016). [CENTRAL: CN-01819521] ">CTRI/2016/10/007412</a>; <a href="./references#CD014967-bbs2-0057" title="CTRI/2018/04/013161. Levetiracetam used as first line anti epileptic versus phenobarbitone in neonatal convulsions. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2018/04/013161 (first received 11 April 2018). [CENTRAL: CN-01903226] ">CTRI/2018/04/013161</a>; <a href="./references#CD014967-bbs2-0058" title="CTRI/2020/03/023961. Levetiracetam versus phenobarbitone for treatment of neonatal seizure. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/03/023961 (first received 13 March 2020). [CENTRAL: CN-02167335] ">CTRI/2020/03/023961</a>; <a href="./references#CD014967-bbs2-0059" title="CTRI/2021/02/031290. Comparision between phenobarbitone and levetiracetam as the intial anti convulsant in treating preterm neonatal seizures. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2021/02/031290 (first received 15 February 2021). [CENTRAL: CN-02239413] ">CTRI/2021/02/031290</a>; <a href="./references#CD014967-bbs2-0060" title="CTRI/2022/09/045658. To compare the effect of two anticonvulsant drugs levetiracetam and phenobarbitone in neonates with seizures [Efficacy of levetiracetam vs phenobarbitone in neonatal seizures: a randomized controlled trial ]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2022/09/045658 (first received 19 September 2022). [CENTRAL: CN-02473289] ">CTRI/2022/09/045658</a>; <a href="./references#CD014967-bbs2-0061" title="CTRI/2023/02/049794. Study comparing efficacy of two drugs as first line drug in late preterm and term babies with neonatal seizure [Phenobarbitone versus levetiracetam as 1st line therapy for neonatal seizures- a randomized control trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2023/02/049794 (first received 16 February 2023). [CENTRAL: CN-02529443] ">CTRI/2023/02/049794</a>; <a href="./references#CD014967-bbs2-0062" title="IRCT2014070318334N1. Study of levetiracetam effect in reduction of seizure frecuency in neonats with seizure. irct.ir/trial/16656 (first received 26 August 2014). ">IRCT2014070318334N1</a>; <a href="./references#CD014967-bbs2-0063" title="IRCT20160523028008N23. The effect of levetiracetam and phenobarbital on the control of neonatal seizures [Comparison of efficacy and safety of levetiracetam and phenobarbital in controlling neonatal seizures]. trialsearch.who.int/Trial2.aspx?TrialID=IRCT20160523028008N23 (first received 13 June 2022). [CENTRAL: CN-02429576] ">IRCT20160523028008N23</a>; <a href="./references#CD014967-bbs2-0064" title="IRCT20190526043717N1. Comparison of intravenous levetiracetam and phenobarbital in neonatal seizures. trialsearch.who.int/Trial2.aspx?TrialID=IRCT20190526043717N1 (first received 31 May 2019). [CENTRAL: CN-01975695] ">IRCT20190526043717N1</a>; <a href="./references#CD014967-bbs2-0065" title="IRCT20200115046137N1. The effect of phenobarbital, topiramate, and levothiracetam on neonatal seizures. trialsearch.who.int/Trial2.aspx?TrialID=IRCT20200115046137N1 (first received 5 August 2020). [CENTRAL: CN-02187707] ">IRCT20200115046137N1</a>; <a href="./references#CD014967-bbs2-0066" title="IRCT20200131046317N3. Comparison of the effects of phenobarbital and levetiracetam on neonatal seizure after discharge. trialsearch.who.int/Trial2.aspx?TrialID=IRCT20200131046317N3 (first received 25 August 2021). [CENTRAL: CN-02329536] ">IRCT20200131046317N3</a>; <a href="./references#CD014967-bbs2-0067" title="IRCT20200528047589N1. Comparison of effects of phenobarbital and levetiracetam in neonatal seizure control. trialsearch.who.int/Trial2.aspx?TrialID=IRCT20200528047589N1 (first received 8 September 2020). [CENTRAL: CN-02187848] ">IRCT20200528047589N1</a>; <a href="./references#CD014967-bbs2-0068" title="IRCT20220619055221N1. Efficacy of levetiracetam compared to intravenous phenytoin in treatment of acute phase of neonatal seizure. irct.ir/trial/64286 (first received 09 November 2022). ">IRCT20220619055221N1</a>; <a href="./references#CD014967-bbs2-0069" title="NCT01089504. Prophylactic phenobarbital after neonatal seizures. clinicaltrials.gov/ct2/show/NCT01089504 (first received 18 March 2010). [CENTRAL: CN-01528653] ">NCT01089504</a>; <a href="./references#CD014967-bbs2-0070" title="NCT02550028. Levetiracetam treatment of neonatal seizures. clinicaltrials.gov/ct2/show/NCT02550028 (first received 15 September 2015). [CENTRAL: CN-01580562] ">NCT02550028</a>; <a href="./references#CD014967-bbs2-0071" title="NCT03107507. Efficacy of levetiracetam in control of neonatal seizures guided by an EEG. clinicaltrials.gov/ct2/show/NCT03107507 (first received 11 April 2017). [CENTRAL: CN-01597110] ">NCT03107507</a>; <a href="./references#CD014967-bbs2-0072" title="NCT04320940. Efficacy and safety of intravenous phenobarbital in neonatal seizures. clinicaltrials.gov/ct2/show/NCT04320940 (first received 25 March 2020). [CENTRAL: CN-02089336] ">NCT04320940</a>; <a href="./references#CD014967-bbs2-0073" title="NCT05291455. Lacosamide in neonatal status epilepticus. clinicaltrials.gov/ct2/show/NCT05291455 (first received 22 March 2022). [CENTRAL: CN-02385527] ">NCT05291455</a>). </p> <p>For further details, see <a href="./references#CD014967-sec-0282" title="">Characteristics of ongoing studies</a>. </p> </section> </section> <section id="CD014967-sec-0060"> <h3 class="title">Risk of bias in included studies</h3> <p>Amongst the 18 trials included in the review, the <b>randomisation process</b> domain had a low risk of bias for 12 trials (<a href="./references#CD014967-bbs2-0001" title="AkeelNE , SulimanHA , Al-ShokaryAH , IbrahimAO , KamalNM , AbdelgalilAA , et al. A comparative study of levetiracetam and phenobarbital for neonatal seizures as a first line treatment. Global Pediatric Health2022;9:2333794X221143572. [DOI: 10.1177/2333794X221143572] [PMID: 36578326]">Akeel 2022</a>; <a href="./references#CD014967-bbs2-0005" title="GowdaVK , RomanaA , ShivannaNH , BenakappaN , BenakappaA . Levetiracetam versus phenobarbitone in neonatal seizures — a randomized controlled trial. Indian Pediatrics2019;56(8):643-6. [PMID: 31477643]">Gowda 2019</a>; <a href="./references#CD014967-bbs2-0006" title="JindalA , AnguranaSK , SutharR , KumarP , SundaramV . Effect of early withdrawal of phenobarbitone on the recurrence of neonatal seizures: an open-label randomized controlled trial. Epilepsy &amp; Behavior2021;117:107875. [DOI: 10.1016/j.yebeh.2021.107875] [PMID: 33706247]">Jindal 2021</a>; <a href="./references#CD014967-bbs2-0009" title="PathakG , UpadhyayA , PathakU , ChawlaD , GoelSP . Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial. Indian Pediatrics2013;50(8):753-7. [DOI: 10.1007/s13312-013-0218-6] [PMID: 23502660]">Pathak 2013</a>; <a href="./references#CD014967-bbs2-0010" title="PerveenS , SinghA , UpadhyayA , SinghN , ChauhanR . A randomized controlled trial on comparison of phenobarbitone and levetiracetam for the treatment of neonatal seizures: pilot study. International Journal of Research in Medical Sciences2016;4(6):2073-8. [DOI: 10.18203/2320-6012.ijrms20161763] [URL: msjonline.org/index.php/ijrms/article/view/865/836]">Perveen 2016</a>; <a href="./references#CD014967-bbs2-0011" title="PrakashA , RichaR , SahniGS . Neonatal seizures – levetiracetam versus phenobarbital. Indian Journal of Child Health2019;6(11):605-8. [DOI: 10.32677/IJCH.2019.v06.i11.008]">Prakash 2019</a>; <a href="./references#CD014967-bbs2-0012" title="SaxenaP , SinghA , UpadhyayA , GuptaP , SharmaS , VishnubatlaS . Effect of withholding phenobarbitone maintenance in neonatal seizures: a randomized controlled trial. Indian Pediatrics2016;53(12):1069-73. [PMID: 27889710]">Saxena 2016</a>; <a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>; <a href="./references#CD014967-bbs2-0015" title="SoulJS , BerginAM , StoppC , HayesB , SinghA , FortunoCR , et al, Boston Bumetanide Trial Group. A pilot randomized, controlled, double‐blind trial of bumetanide to treat neonatal seizures. Annals of Neurology2021;89(2):327-40. [DOI: 10.1002/ana.25959] [PMID: 33201535]">Soul 2021</a>; <a href="./references#CD014967-bbs2-0016" title="SrinivasakumarP , ZempelJ , TrivediS , WallendorfM , RaoR , SmithB , et al. Treating EEG seizures in hypoxic ischemic encephalopathy: a randomized controlled trial. Pediatrics2015;136(5):e1302-9. [DOI: 10.1542/peds.2014-3777] [PMID: 26482675]">Srinivasakumar 2015</a>; <a href="./references#CD014967-bbs2-0017" title="SusnerwalaS , JoshiA , DeshmukhL , LondheA . Levetiracetam or phenobarbitone as a first-line anticonvulsant in asphyxiated term newborns? An open-label, single-center, randomized, controlled, pragmatic trial. Hospital Pediatrics2022;12(7):647-52. [DOI: 10.1542/hpeds.2021-006415] [PMID: 35673948]">Susnerwala 2022</a>; <a href="./references#CD014967-bbs2-0018" title="Van RooijLG , ToetMC , Van HuffelenAC , GroenendaalF , LaanW , ZecicA , et al. Effect of treatment of subclinical neonatal seizures detected with aEEG: randomized, controlled trial. Pediatrics2010;125(2):e358-e66. [DOI: 10.1542/peds.2009-0136] [PMID: 20100767]">Van Rooji 2010</a>). The domain had some concerns for four trials (<a href="./references#CD014967-bbs2-0002" title="BoylanGB , RennieJM , ChorleyG , PresslerRM , FoxGF , FarrerK , et al. Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study. Neurology2004;62(3):486-8. [DOI: 10.1212/01.wnl.0000106944.59990.e6] [PMID: 14872039]">Boylan 2004</a>; <a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>; <a href="./references#CD014967-bbs2-0004" title="GhaffarJ , RiazA , Uzair, VirkAO , BhattiA . Comparative efficacy of intravenous levetiracetam vs phenobarbitone in neonatal seizures. Medical Forum2020;31(7):25-8. [WEBSITE: medforum.pk/article/6-comparative-efficacy-of-intravenous-levetiracetam-vs-phenobarbitone-in-neonatal-seizures]">Ghaffar 2020</a>), as there was no information on allocation concealment, but baseline characteristics did not show any difference between the two groups. The domain had high risk for two trials (<a href="./references#CD014967-bbs2-0008" title="PainterMJ , ScherMS , SteinAD , ArmattiS , WangZ , GardinerJC , et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine1999;341(7):485-9. [DOI: 10.1056/NEJM199908123410704] [PMID: 10441604]ScherMS , AlvinJ , GausL , MinnighB , PainterMJ . Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology2003;28(4):277-80. [DOI: 10.1016/s0887-8994(02)00621-5] [PMID: 12849880]">Painter 1999</a>; <a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>), as there was no information on allocation concealment and baseline characteristics suggested a mismatch between the two groups despite randomisation. </p> <p>The domain '<b>deviation from intended interventions</b>' had a low risk of bias for all 18 trials, as one was a triple‐masked trial (<a href="./references#CD014967-bbs2-0015" title="SoulJS , BerginAM , StoppC , HayesB , SinghA , FortunoCR , et al, Boston Bumetanide Trial Group. A pilot randomized, controlled, double‐blind trial of bumetanide to treat neonatal seizures. Annals of Neurology2021;89(2):327-40. [DOI: 10.1002/ana.25959] [PMID: 33201535]">Soul 2021</a>) and, in the other 14 trials, although the personnel were aware of the intervention allocation, there seemed to be no deviations that arose outside the trial context. Also, all the patients were analysed as randomised in these trials. </p> <p>The domain '<b>missing outcome data</b>' also had a low risk of bias for all the trials, as the outcome data were reasonably complete for all randomised patients in 15 trials (<a href="./references#CD014967-bbs2-0001" title="AkeelNE , SulimanHA , Al-ShokaryAH , IbrahimAO , KamalNM , AbdelgalilAA , et al. A comparative study of levetiracetam and phenobarbital for neonatal seizures as a first line treatment. Global Pediatric Health2022;9:2333794X221143572. [DOI: 10.1177/2333794X221143572] [PMID: 36578326]">Akeel 2022</a>; <a href="./references#CD014967-bbs2-0002" title="BoylanGB , RennieJM , ChorleyG , PresslerRM , FoxGF , FarrerK , et al. Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study. Neurology2004;62(3):486-8. [DOI: 10.1212/01.wnl.0000106944.59990.e6] [PMID: 14872039]">Boylan 2004</a>; <a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>; <a href="./references#CD014967-bbs2-0004" title="GhaffarJ , RiazA , Uzair, VirkAO , BhattiA . Comparative efficacy of intravenous levetiracetam vs phenobarbitone in neonatal seizures. Medical Forum2020;31(7):25-8. [WEBSITE: medforum.pk/article/6-comparative-efficacy-of-intravenous-levetiracetam-vs-phenobarbitone-in-neonatal-seizures]">Ghaffar 2020</a>; <a href="./references#CD014967-bbs2-0005" title="GowdaVK , RomanaA , ShivannaNH , BenakappaN , BenakappaA . Levetiracetam versus phenobarbitone in neonatal seizures — a randomized controlled trial. Indian Pediatrics2019;56(8):643-6. [PMID: 31477643]">Gowda 2019</a>; <a href="./references#CD014967-bbs2-0006" title="JindalA , AnguranaSK , SutharR , KumarP , SundaramV . Effect of early withdrawal of phenobarbitone on the recurrence of neonatal seizures: an open-label randomized controlled trial. Epilepsy &amp; Behavior2021;117:107875. [DOI: 10.1016/j.yebeh.2021.107875] [PMID: 33706247]">Jindal 2021</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>; <a href="./references#CD014967-bbs2-0008" title="PainterMJ , ScherMS , SteinAD , ArmattiS , WangZ , GardinerJC , et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine1999;341(7):485-9. [DOI: 10.1056/NEJM199908123410704] [PMID: 10441604]ScherMS , AlvinJ , GausL , MinnighB , PainterMJ . Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology2003;28(4):277-80. [DOI: 10.1016/s0887-8994(02)00621-5] [PMID: 12849880]">Painter 1999</a>; <a href="./references#CD014967-bbs2-0009" title="PathakG , UpadhyayA , PathakU , ChawlaD , GoelSP . Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial. Indian Pediatrics2013;50(8):753-7. [DOI: 10.1007/s13312-013-0218-6] [PMID: 23502660]">Pathak 2013</a>; <a href="./references#CD014967-bbs2-0010" title="PerveenS , SinghA , UpadhyayA , SinghN , ChauhanR . A randomized controlled trial on comparison of phenobarbitone and levetiracetam for the treatment of neonatal seizures: pilot study. International Journal of Research in Medical Sciences2016;4(6):2073-8. [DOI: 10.18203/2320-6012.ijrms20161763] [URL: msjonline.org/index.php/ijrms/article/view/865/836]">Perveen 2016</a>; <a href="./references#CD014967-bbs2-0011" title="PrakashA , RichaR , SahniGS . Neonatal seizures – levetiracetam versus phenobarbital. Indian Journal of Child Health2019;6(11):605-8. [DOI: 10.32677/IJCH.2019.v06.i11.008]">Prakash 2019</a>; <a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>; <a href="./references#CD014967-bbs2-0015" title="SoulJS , BerginAM , StoppC , HayesB , SinghA , FortunoCR , et al, Boston Bumetanide Trial Group. A pilot randomized, controlled, double‐blind trial of bumetanide to treat neonatal seizures. Annals of Neurology2021;89(2):327-40. [DOI: 10.1002/ana.25959] [PMID: 33201535]">Soul 2021</a>; <a href="./references#CD014967-bbs2-0016" title="SrinivasakumarP , ZempelJ , TrivediS , WallendorfM , RaoR , SmithB , et al. Treating EEG seizures in hypoxic ischemic encephalopathy: a randomized controlled trial. Pediatrics2015;136(5):e1302-9. [DOI: 10.1542/peds.2014-3777] [PMID: 26482675]">Srinivasakumar 2015</a>; <a href="./references#CD014967-bbs2-0017" title="SusnerwalaS , JoshiA , DeshmukhL , LondheA . Levetiracetam or phenobarbitone as a first-line anticonvulsant in asphyxiated term newborns? An open-label, single-center, randomized, controlled, pragmatic trial. Hospital Pediatrics2022;12(7):647-52. [DOI: 10.1542/hpeds.2021-006415] [PMID: 35673948]">Susnerwala 2022</a>). In <a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>, although there were missing data, analysis methods that corrected for bias, such as sensitivity analyses showing that results were little changed under a range of plausible assumptions about the relationship between the missing value in the outcome and its true value, were performed. In <a href="./references#CD014967-bbs2-0018" title="Van RooijLG , ToetMC , Van HuffelenAC , GroenendaalF , LaanW , ZecicA , et al. Effect of treatment of subclinical neonatal seizures detected with aEEG: randomized, controlled trial. Pediatrics2010;125(2):e358-e66. [DOI: 10.1542/peds.2009-0136] [PMID: 20100767]">Van Rooji 2010</a>, although nine out of 42 patients randomised were excluded, the reasons for the same were stated, and they did not differ substantially between the groups, thus indicating that the results might not be biassed. In <a href="./references#CD014967-bbs2-0012" title="SaxenaP , SinghA , UpadhyayA , GuptaP , SharmaS , VishnubatlaS . Effect of withholding phenobarbitone maintenance in neonatal seizures: a randomized controlled trial. Indian Pediatrics2016;53(12):1069-73. [PMID: 27889710]">Saxena 2016</a>, data were reasonably complete for all the included patients until hospital discharge. Though many of the enrolled participants were lost to follow‐up, it was balanced between the two groups. Hence, it seemed that the result was not biassed as reasons for the loss to follow‐up did not differ significantly between the groups. </p> <p>For the domain '<b>measurement of outcome</b>', objective outcomes were scored 'low risk' for all 18 trials. However, for subjective outcomes, only <a href="./references#CD014967-bbs2-0015" title="SoulJS , BerginAM , StoppC , HayesB , SinghA , FortunoCR , et al, Boston Bumetanide Trial Group. A pilot randomized, controlled, double‐blind trial of bumetanide to treat neonatal seizures. Annals of Neurology2021;89(2):327-40. [DOI: 10.1002/ana.25959] [PMID: 33201535]">Soul 2021</a> had a low risk of bias as it was a triple‐masked trial. Other trials were scored 'some concerns' for subjective outcomes, as the assessors were aware of the intervention and there was a likelihood of assessment being influenced by the knowledge of the allocation group. For outcomes related to seizure assessment such as seizure control after a single loading dose of ASM, seizure control after maximal loading dose of ASM, and recurrence of seizures before hospital discharge, trials that used EEG/aEEG to diagnose seizures were scored low risk (<a href="./references#CD014967-bbs2-0002" title="BoylanGB , RennieJM , ChorleyG , PresslerRM , FoxGF , FarrerK , et al. Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study. Neurology2004;62(3):486-8. [DOI: 10.1212/01.wnl.0000106944.59990.e6] [PMID: 14872039]">Boylan 2004</a>; <a href="./references#CD014967-bbs2-0008" title="PainterMJ , ScherMS , SteinAD , ArmattiS , WangZ , GardinerJC , et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine1999;341(7):485-9. [DOI: 10.1056/NEJM199908123410704] [PMID: 10441604]ScherMS , AlvinJ , GausL , MinnighB , PainterMJ . Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology2003;28(4):277-80. [DOI: 10.1016/s0887-8994(02)00621-5] [PMID: 12849880]">Painter 1999</a>; <a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>; <a href="./references#CD014967-bbs2-0016" title="SrinivasakumarP , ZempelJ , TrivediS , WallendorfM , RaoR , SmithB , et al. Treating EEG seizures in hypoxic ischemic encephalopathy: a randomized controlled trial. Pediatrics2015;136(5):e1302-9. [DOI: 10.1542/peds.2014-3777] [PMID: 26482675]">Srinivasakumar 2015</a>; <a href="./references#CD014967-bbs2-0018" title="Van RooijLG , ToetMC , Van HuffelenAC , GroenendaalF , LaanW , ZecicA , et al. Effect of treatment of subclinical neonatal seizures detected with aEEG: randomized, controlled trial. Pediatrics2010;125(2):e358-e66. [DOI: 10.1542/peds.2009-0136] [PMID: 20100767]">Van Rooji 2010</a>). Amongst the trials that used clinical diagnosis of seizures, seven trials (<a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>; <a href="./references#CD014967-bbs2-0004" title="GhaffarJ , RiazA , Uzair, VirkAO , BhattiA . Comparative efficacy of intravenous levetiracetam vs phenobarbitone in neonatal seizures. Medical Forum2020;31(7):25-8. [WEBSITE: medforum.pk/article/6-comparative-efficacy-of-intravenous-levetiracetam-vs-phenobarbitone-in-neonatal-seizures]">Ghaffar 2020</a>; <a href="./references#CD014967-bbs2-0005" title="GowdaVK , RomanaA , ShivannaNH , BenakappaN , BenakappaA . Levetiracetam versus phenobarbitone in neonatal seizures — a randomized controlled trial. Indian Pediatrics2019;56(8):643-6. [PMID: 31477643]">Gowda 2019</a>; <a href="./references#CD014967-bbs2-0006" title="JindalA , AnguranaSK , SutharR , KumarP , SundaramV . Effect of early withdrawal of phenobarbitone on the recurrence of neonatal seizures: an open-label randomized controlled trial. Epilepsy &amp; Behavior2021;117:107875. [DOI: 10.1016/j.yebeh.2021.107875] [PMID: 33706247]">Jindal 2021</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>; <a href="./references#CD014967-bbs2-0010" title="PerveenS , SinghA , UpadhyayA , SinghN , ChauhanR . A randomized controlled trial on comparison of phenobarbitone and levetiracetam for the treatment of neonatal seizures: pilot study. International Journal of Research in Medical Sciences2016;4(6):2073-8. [DOI: 10.18203/2320-6012.ijrms20161763] [URL: msjonline.org/index.php/ijrms/article/view/865/836]">Perveen 2016</a>; <a href="./references#CD014967-bbs2-0012" title="SaxenaP , SinghA , UpadhyayA , GuptaP , SharmaS , VishnubatlaS . Effect of withholding phenobarbitone maintenance in neonatal seizures: a randomized controlled trial. Indian Pediatrics2016;53(12):1069-73. [PMID: 27889710]">Saxena 2016</a>), were scored high risk, as there was no clear definition for different seizure types, how it was differentiated from non‐epileptic events and how it was assessed and by whom. Five trials (<a href="./references#CD014967-bbs2-0001" title="AkeelNE , SulimanHA , Al-ShokaryAH , IbrahimAO , KamalNM , AbdelgalilAA , et al. A comparative study of levetiracetam and phenobarbital for neonatal seizures as a first line treatment. Global Pediatric Health2022;9:2333794X221143572. [DOI: 10.1177/2333794X221143572] [PMID: 36578326]">Akeel 2022</a>; <a href="./references#CD014967-bbs2-0009" title="PathakG , UpadhyayA , PathakU , ChawlaD , GoelSP . Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial. Indian Pediatrics2013;50(8):753-7. [DOI: 10.1007/s13312-013-0218-6] [PMID: 23502660]">Pathak 2013</a>; <a href="./references#CD014967-bbs2-0011" title="PrakashA , RichaR , SahniGS . Neonatal seizures – levetiracetam versus phenobarbital. Indian Journal of Child Health2019;6(11):605-8. [DOI: 10.32677/IJCH.2019.v06.i11.008]">Prakash 2019</a>; <a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>; <a href="./references#CD014967-bbs2-0017" title="SusnerwalaS , JoshiA , DeshmukhL , LondheA . Levetiracetam or phenobarbitone as a first-line anticonvulsant in asphyxiated term newborns? An open-label, single-center, randomized, controlled, pragmatic trial. Hospital Pediatrics2022;12(7):647-52. [DOI: 10.1542/hpeds.2021-006415] [PMID: 35673948]">Susnerwala 2022</a>), that have specified the details of the seizure definition used and who diagnosed the seizures, were scored 'some concerns'. </p> <p>For the domain '<b>selection of reported results</b>', 11 trials (<a href="./references#CD014967-bbs2-0005" title="GowdaVK , RomanaA , ShivannaNH , BenakappaN , BenakappaA . Levetiracetam versus phenobarbitone in neonatal seizures — a randomized controlled trial. Indian Pediatrics2019;56(8):643-6. [PMID: 31477643]">Gowda 2019</a>; <a href="./references#CD014967-bbs2-0006" title="JindalA , AnguranaSK , SutharR , KumarP , SundaramV . Effect of early withdrawal of phenobarbitone on the recurrence of neonatal seizures: an open-label randomized controlled trial. Epilepsy &amp; Behavior2021;117:107875. [DOI: 10.1016/j.yebeh.2021.107875] [PMID: 33706247]">Jindal 2021</a>; <a href="./references#CD014967-bbs2-0009" title="PathakG , UpadhyayA , PathakU , ChawlaD , GoelSP . Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial. Indian Pediatrics2013;50(8):753-7. [DOI: 10.1007/s13312-013-0218-6] [PMID: 23502660]">Pathak 2013</a>; <a href="./references#CD014967-bbs2-0010" title="PerveenS , SinghA , UpadhyayA , SinghN , ChauhanR . A randomized controlled trial on comparison of phenobarbitone and levetiracetam for the treatment of neonatal seizures: pilot study. International Journal of Research in Medical Sciences2016;4(6):2073-8. [DOI: 10.18203/2320-6012.ijrms20161763] [URL: msjonline.org/index.php/ijrms/article/view/865/836]">Perveen 2016</a>; <a href="./references#CD014967-bbs2-0012" title="SaxenaP , SinghA , UpadhyayA , GuptaP , SharmaS , VishnubatlaS . Effect of withholding phenobarbitone maintenance in neonatal seizures: a randomized controlled trial. Indian Pediatrics2016;53(12):1069-73. [PMID: 27889710]">Saxena 2016</a>; <a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>; <a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>; <a href="./references#CD014967-bbs2-0016" title="SrinivasakumarP , ZempelJ , TrivediS , WallendorfM , RaoR , SmithB , et al. Treating EEG seizures in hypoxic ischemic encephalopathy: a randomized controlled trial. Pediatrics2015;136(5):e1302-9. [DOI: 10.1542/peds.2014-3777] [PMID: 26482675]">Srinivasakumar 2015</a>; <a href="./references#CD014967-bbs2-0017" title="SusnerwalaS , JoshiA , DeshmukhL , LondheA . Levetiracetam or phenobarbitone as a first-line anticonvulsant in asphyxiated term newborns? An open-label, single-center, randomized, controlled, pragmatic trial. Hospital Pediatrics2022;12(7):647-52. [DOI: 10.1542/hpeds.2021-006415] [PMID: 35673948]">Susnerwala 2022</a>; <a href="./references#CD014967-bbs2-0018" title="Van RooijLG , ToetMC , Van HuffelenAC , GroenendaalF , LaanW , ZecicA , et al. Effect of treatment of subclinical neonatal seizures detected with aEEG: randomized, controlled trial. Pediatrics2010;125(2):e358-e66. [DOI: 10.1542/peds.2009-0136] [PMID: 20100767]">Van Rooji 2010</a>), had a low risk of bias as these trials were analysed as per <i>a priori</i> registered protocol, while seven trials (<a href="./references#CD014967-bbs2-0001" title="AkeelNE , SulimanHA , Al-ShokaryAH , IbrahimAO , KamalNM , AbdelgalilAA , et al. A comparative study of levetiracetam and phenobarbital for neonatal seizures as a first line treatment. Global Pediatric Health2022;9:2333794X221143572. [DOI: 10.1177/2333794X221143572] [PMID: 36578326]">Akeel 2022</a>; <a href="./references#CD014967-bbs2-0002" title="BoylanGB , RennieJM , ChorleyG , PresslerRM , FoxGF , FarrerK , et al. Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study. Neurology2004;62(3):486-8. [DOI: 10.1212/01.wnl.0000106944.59990.e6] [PMID: 14872039]">Boylan 2004</a>; <a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>; <a href="./references#CD014967-bbs2-0004" title="GhaffarJ , RiazA , Uzair, VirkAO , BhattiA . Comparative efficacy of intravenous levetiracetam vs phenobarbitone in neonatal seizures. Medical Forum2020;31(7):25-8. [WEBSITE: medforum.pk/article/6-comparative-efficacy-of-intravenous-levetiracetam-vs-phenobarbitone-in-neonatal-seizures]">Ghaffar 2020</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>; <a href="./references#CD014967-bbs2-0008" title="PainterMJ , ScherMS , SteinAD , ArmattiS , WangZ , GardinerJC , et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine1999;341(7):485-9. [DOI: 10.1056/NEJM199908123410704] [PMID: 10441604]ScherMS , AlvinJ , GausL , MinnighB , PainterMJ . Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology2003;28(4):277-80. [DOI: 10.1016/s0887-8994(02)00621-5] [PMID: 12849880]">Painter 1999</a>; <a href="./references#CD014967-bbs2-0011" title="PrakashA , RichaR , SahniGS . Neonatal seizures – levetiracetam versus phenobarbital. Indian Journal of Child Health2019;6(11):605-8. [DOI: 10.32677/IJCH.2019.v06.i11.008]">Prakash 2019</a>), had some concerns as the trial protocols were not available for assessment. </p> <p>The overall risk of bias of the included trials was as follows: one trial had a low risk of overall bias for all the outcomes (<a href="./references#CD014967-bbs2-0015" title="SoulJS , BerginAM , StoppC , HayesB , SinghA , FortunoCR , et al, Boston Bumetanide Trial Group. A pilot randomized, controlled, double‐blind trial of bumetanide to treat neonatal seizures. Annals of Neurology2021;89(2):327-40. [DOI: 10.1002/ana.25959] [PMID: 33201535]">Soul 2021</a>). 12 trials had a low risk for objective outcomes and some concerns or high risk for subjective outcomes (<a href="./references#CD014967-bbs2-0001" title="AkeelNE , SulimanHA , Al-ShokaryAH , IbrahimAO , KamalNM , AbdelgalilAA , et al. A comparative study of levetiracetam and phenobarbital for neonatal seizures as a first line treatment. Global Pediatric Health2022;9:2333794X221143572. [DOI: 10.1177/2333794X221143572] [PMID: 36578326]">Akeel 2022</a>; <a href="./references#CD014967-bbs2-0005" title="GowdaVK , RomanaA , ShivannaNH , BenakappaN , BenakappaA . Levetiracetam versus phenobarbitone in neonatal seizures — a randomized controlled trial. Indian Pediatrics2019;56(8):643-6. [PMID: 31477643]">Gowda 2019</a>; <a href="./references#CD014967-bbs2-0006" title="JindalA , AnguranaSK , SutharR , KumarP , SundaramV . Effect of early withdrawal of phenobarbitone on the recurrence of neonatal seizures: an open-label randomized controlled trial. Epilepsy &amp; Behavior2021;117:107875. [DOI: 10.1016/j.yebeh.2021.107875] [PMID: 33706247]">Jindal 2021</a>; <a href="./references#CD014967-bbs2-0009" title="PathakG , UpadhyayA , PathakU , ChawlaD , GoelSP . Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial. Indian Pediatrics2013;50(8):753-7. [DOI: 10.1007/s13312-013-0218-6] [PMID: 23502660]">Pathak 2013</a>; <a href="./references#CD014967-bbs2-0010" title="PerveenS , SinghA , UpadhyayA , SinghN , ChauhanR . A randomized controlled trial on comparison of phenobarbitone and levetiracetam for the treatment of neonatal seizures: pilot study. International Journal of Research in Medical Sciences2016;4(6):2073-8. [DOI: 10.18203/2320-6012.ijrms20161763] [URL: msjonline.org/index.php/ijrms/article/view/865/836]">Perveen 2016</a>; <a href="./references#CD014967-bbs2-0011" title="PrakashA , RichaR , SahniGS . Neonatal seizures – levetiracetam versus phenobarbital. Indian Journal of Child Health2019;6(11):605-8. [DOI: 10.32677/IJCH.2019.v06.i11.008]">Prakash 2019</a>; <a href="./references#CD014967-bbs2-0012" title="SaxenaP , SinghA , UpadhyayA , GuptaP , SharmaS , VishnubatlaS . Effect of withholding phenobarbitone maintenance in neonatal seizures: a randomized controlled trial. Indian Pediatrics2016;53(12):1069-73. [PMID: 27889710]">Saxena 2016</a>; <a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>; <a href="./references#CD014967-bbs2-0016" title="SrinivasakumarP , ZempelJ , TrivediS , WallendorfM , RaoR , SmithB , et al. Treating EEG seizures in hypoxic ischemic encephalopathy: a randomized controlled trial. Pediatrics2015;136(5):e1302-9. [DOI: 10.1542/peds.2014-3777] [PMID: 26482675]">Srinivasakumar 2015</a>; <a href="./references#CD014967-bbs2-0017" title="SusnerwalaS , JoshiA , DeshmukhL , LondheA . Levetiracetam or phenobarbitone as a first-line anticonvulsant in asphyxiated term newborns? An open-label, single-center, randomized, controlled, pragmatic trial. Hospital Pediatrics2022;12(7):647-52. [DOI: 10.1542/hpeds.2021-006415] [PMID: 35673948]">Susnerwala 2022</a>; <a href="./references#CD014967-bbs2-0018" title="Van RooijLG , ToetMC , Van HuffelenAC , GroenendaalF , LaanW , ZecicA , et al. Effect of treatment of subclinical neonatal seizures detected with aEEG: randomized, controlled trial. Pediatrics2010;125(2):e358-e66. [DOI: 10.1542/peds.2009-0136] [PMID: 20100767]">Van Rooji 2010</a>). Five trials had a high risk of overall bias for all the outcomes (<a href="./references#CD014967-bbs2-0002" title="BoylanGB , RennieJM , ChorleyG , PresslerRM , FoxGF , FarrerK , et al. Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study. Neurology2004;62(3):486-8. [DOI: 10.1212/01.wnl.0000106944.59990.e6] [PMID: 14872039]">Boylan 2004</a>; <a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>; <a href="./references#CD014967-bbs2-0008" title="PainterMJ , ScherMS , SteinAD , ArmattiS , WangZ , GardinerJC , et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine1999;341(7):485-9. [DOI: 10.1056/NEJM199908123410704] [PMID: 10441604]ScherMS , AlvinJ , GausL , MinnighB , PainterMJ . Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology2003;28(4):277-80. [DOI: 10.1016/s0887-8994(02)00621-5] [PMID: 12849880]">Painter 1999</a>; <a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>). </p> </section> <section id="CD014967-sec-0061"> <h3 class="title" id="CD014967-sec-0061">Effects of interventions</h3> <p>See: <a href="./full#CD014967-tbl-0001"><b>Summary of findings 1</b> Summary of findings table ‐ Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures</a>; <a href="./full#CD014967-tbl-0002"><b>Summary of findings 2</b> Summary of findings table ‐ Phenobarbital versus levetiracetam as first‐line ASM for clinically diagnosed neonatal seizures</a>; <a href="./full#CD014967-tbl-0003"><b>Summary of findings 3</b> Summary of findings table ‐ Phenobarbital versus phenytoin as first‐line ASM for EEG‐confirmed neonatal seizures</a>; <a href="./full#CD014967-tbl-0004"><b>Summary of findings 4</b> Summary of findings table ‐ Phenobarbital versus phenytoin as first‐line ASM for clinically diagnosed neonatal seizures</a>; <a href="./full#CD014967-tbl-0005"><b>Summary of findings 5</b> Summary of findings table ‐ Phenobarbital versus Lorazepam as first‐line ASM for clinically diagnosed neonatal seizures</a>; <a href="./full#CD014967-tbl-0006"><b>Summary of findings 6</b> Summary of findings table ‐ Phenytoin versus lorazepam as first‐line ASM for clinically diagnosed neonatal seizures</a>; <a href="./full#CD014967-tbl-0007"><b>Summary of findings 7</b> Summary of findings table ‐ Phenobarbital + bumetanide versus phenobarbital alone for EEG‐confirmed neonatal seizures</a>; <a href="./full#CD014967-tbl-0008"><b>Summary of findings 8</b> Summary of findings table ‐ Lignocaine versus benzodiazepines as second‐line ASM for EEG‐confirmed neonatal seizures</a>; <a href="./full#CD014967-tbl-0009"><b>Summary of findings 9</b> Summary of findings table ‐ Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures</a>; <a href="./full#CD014967-tbl-0010"><b>Summary of findings 10</b> Summary of findings table ‐ Treatment of clinical and electrographic seizures versus treatment of clinical seizures alone in neonates</a> </p> <section id="CD014967-sec-0062"> <h4 class="title">Comparison 1: Comparison of one ASM versus another</h4> <section id="CD014967-sec-0063"> <h5 class="title">Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures</h5> <p>Please see <a href="./full#CD014967-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD014967-sec-0064"> <h6 class="title">Primary outcomes</h6> <section id="CD014967-sec-0065"> <p><b>Proportion of infants who achieve seizure control after first loading dose of ASM</b></p> <p>As the dosage regimen of ASM was variable across the studies, we defined the first loading dose of ASM as 20 mg/kg for phenobarbital and 20 to 40 mg/kg for levetiracetam. We defined (post hoc) a time limit of 24 to 48 hours from the time of ASM administration to evaluate seizure control. </p> <p>Data from one trial (<a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>) showed that phenobarbital probably results in better seizure control after the first loading dose of ASM compared to levetiracetam in EEG‐confirmed neonatal seizures (RR 2.32, 95% CI 1.63 to 3.30; 106 participants; moderate‐certainty evidence; <a href="./references#CD014967-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD014967-sec-0066"> <p><b>Proportion of infants who achieve seizure control after maximal loading dose of ASM</b></p> <p>The maximum loading dose of ASM was defined as 30 to 40 mg/kg for phenobarbital and 40 to 60 mg/kg for levetiracetam. </p> <p>Data from one trial (<a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>), showed that phenobarbital probably results in better seizure control after the first loading dose of ASM compared to levetiracetam in EEG‐confirmed neonatal seizures (RR 2.83, 95% CI 1.78 to 4.50; 83 participants; moderate‐certainty evidence; <a href="./references#CD014967-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD014967-sec-0067"> <p><b>Mortality or neurodevelopmental disability at 18 to 24 months' corrected age</b></p> <p>The trial did not report this outcome (<a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>). </p> </section> </section> <section id="CD014967-sec-0068"> <h6 class="title">Secondary outcomes</h6> <section id="CD014967-sec-0069"> <p><b>Mortality before hospital discharge</b></p> <p>Based on the data from one trial (<a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>), we are uncertain about the effect of using phenobarbital versus levetiracetam as first‐line ASM on all‐cause mortality before hospital discharge (RR 0.30, 95% CI 0.04 to 2.52; 106 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD014967-sec-0070"> <p><b>Neurodevelopmental disability at 18 to 24 months' corrected age</b></p> <p>This outcome was not reported in the included study.</p> </section> <section id="CD014967-sec-0071"> <p><b>Proportion of infants who develop cognitive impairment at two years or more</b></p> <p>This outcome was not reported in the included study.</p> </section> <section id="CD014967-sec-0072"> <p><b>Seizure burden (seizure hours per infant, or minutes per hour of monitoring) during hospitalisation</b></p> <p>This outcome was not reported in the included study.</p> </section> <section id="CD014967-sec-0073"> <p><b>Proportion of infants with one or more of the adverse effects related to ASM(s) during hospitalisation</b></p> <p><i>Requirement of mechanical ventilation</i> </p> <p>This outcome was reported in the one included trial (<a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>). We are uncertain about the effect of using phenobarbital versus levetiracetam as first‐line ASM for the requirement of mechanical ventilation (RR 1.21, 95% CI 0.76 to 1.91; 106 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0007" title="">Analysis 1.4</a>). </p> <p><i>Proportion of infants who develop sedation or drowsiness</i> </p> <p>Based on data from the included trial (<a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>), we are uncertain about the effect of using phenobarbital versus levetiracetam as first‐line ASM on the proportion of infants who develop sedation or drowsiness (RR 1.74, 95% CI 0.68 to 4.44; 106 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0008" title="">Analysis 1.5</a>). </p> <p><i>Arrhythmias causing circulatory disturbance</i> </p> <p>This outcome was not reported in the included study.</p> <p><i>Bradycardia</i> </p> <p><a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a> did not find a difference in the incidence of bradycardia between the two groups (RR 0.76, 95% CI 0.31 to 1.87; 106 participants; <a href="./references#CD014967-fig-0009" title="">Analysis 1.6</a>). </p> <p><i>Hypotension requiring volume or inotropic support</i> </p> <p>The one included trial (<a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>) did not find a difference in hypotension between the phenobarbital and levetiracetam groups (RR 3.56, 95% CI 0.97 to 12.99; 106 participants; <a href="./references#CD014967-fig-0010" title="">Analysis 1.7</a>). </p> <p><i>Shock requiring volume or inotropes</i> </p> <p>The one included trial (<a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>) did not find a difference in the incidence of shock between the two groups (RR 1.98, 99% CI 0.76 to 5.15; 106 participants; <a href="./references#CD014967-fig-0011" title="">Analysis 1.8</a>). </p> <p><i>Hepatotoxicity resulting in discontinuation of therapy</i> </p> <p>This outcome was not reported in the included study.</p> <p><i>Acute kidney injury (of any stage)</i> </p> <p>This outcome was not reported in the included study.</p> </section> <section id="CD014967-sec-0074"> <p><b>Proportion of infants with an abnormal background pattern in EEG during ASM treatment</b></p> <p>This outcome was not reported in the included study.</p> </section> <section id="CD014967-sec-0075"> <p><b>Proportion of infants with an abnormal background pattern in EEG after ASM treatment</b></p> <p>This outcome was not reported in the included study.</p> </section> <section id="CD014967-sec-0076"> <p><b>Duration of hospital stay (days)</b></p> <p>This outcome was not reported in the included study.</p> </section> <section id="CD014967-sec-0077"> <p><b>Recurrence of seizures before hospital discharge</b></p> <p>The one included trial (<a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>) did not find a difference in recurrence of seizures during hospital stay between the phenobarbital and levetiracetam groups (RR 1.33, 95% CI 0.52 to 3.40; 106 participants; <a href="./references#CD014967-fig-0012" title="">Analysis 1.9</a>). </p> </section> <section id="CD014967-sec-0078"> <p><b>Proportion of infants with persistent seizures or requiring ASM(s) at discharge (or both)</b></p> <p>This outcome was not reported in the included study.</p> </section> <section id="CD014967-sec-0079"> <p><b>Proportion of infants discharged on gavage feeds</b></p> <p>This outcome was not reported in the included study.</p> </section> <section id="CD014967-sec-0080"> <p><b>Proportion of infants with abnormal neurological examination at discharge</b></p> <p>This outcome was not reported in the included study.</p> </section> <section id="CD014967-sec-0081"> <p><b>Proportion of infants who develop epilepsy post‐discharge</b></p> <p>Based on data from one trial (<a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>) we are uncertain about the effect of using phenobarbital versus levetiracetam as first‐line ASM on the proportion of infants who develop epilepsy post‐discharge (RR 0.92, 95% CI 0.48 to 1.76; 45 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0013" title="">Analysis 1.10</a>). </p> </section> </section> </section> <section id="CD014967-sec-0082"> <h5 class="title">Phenobarbital versus levetiracetam as first‐line ASM for clinically diagnosed neonatal seizures </h5> <p>Please see <a href="./full#CD014967-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD014967-sec-0083"> <h6 class="title">Primary outcomes</h6> <section id="CD014967-sec-0084"> <p><b>Proportion of infants who achieve seizure control after the first loading dose of ASM</b></p> <p>Three trials (<a href="./references#CD014967-bbs2-0001" title="AkeelNE , SulimanHA , Al-ShokaryAH , IbrahimAO , KamalNM , AbdelgalilAA , et al. A comparative study of levetiracetam and phenobarbital for neonatal seizures as a first line treatment. Global Pediatric Health2022;9:2333794X221143572. [DOI: 10.1177/2333794X221143572] [PMID: 36578326]">Akeel 2022</a>; <a href="./references#CD014967-bbs2-0005" title="GowdaVK , RomanaA , ShivannaNH , BenakappaN , BenakappaA . Levetiracetam versus phenobarbitone in neonatal seizures — a randomized controlled trial. Indian Pediatrics2019;56(8):643-6. [PMID: 31477643]">Gowda 2019</a>; <a href="./references#CD014967-bbs2-0017" title="SusnerwalaS , JoshiA , DeshmukhL , LondheA . Levetiracetam or phenobarbitone as a first-line anticonvulsant in asphyxiated term newborns? An open-label, single-center, randomized, controlled, pragmatic trial. Hospital Pediatrics2022;12(7):647-52. [DOI: 10.1542/hpeds.2021-006415] [PMID: 35673948]">Susnerwala 2022</a>), have reported the outcome of seizure control until 24 to 48 hours after the first loading dose of ASM. We are uncertain about the effect of using phenobarbital versus levetiracetam as first‐line ASM on achieving seizure control after the first loading dose in clinically‐diagnosed seizures (RR 0.69, 95% CI 0.55 to 0.86; 286 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0014" title="">Analysis 2.1</a>). </p> </section> <section id="CD014967-sec-0085"> <p><b>Proportion of infants who achieve seizure control after the maximal loading dose of ASM</b></p> <p>Three trials (<a href="./references#CD014967-bbs2-0004" title="GhaffarJ , RiazA , Uzair, VirkAO , BhattiA . Comparative efficacy of intravenous levetiracetam vs phenobarbitone in neonatal seizures. Medical Forum2020;31(7):25-8. [WEBSITE: medforum.pk/article/6-comparative-efficacy-of-intravenous-levetiracetam-vs-phenobarbitone-in-neonatal-seizures]">Ghaffar 2020</a>; <a href="./references#CD014967-bbs2-0005" title="GowdaVK , RomanaA , ShivannaNH , BenakappaN , BenakappaA . Levetiracetam versus phenobarbitone in neonatal seizures — a randomized controlled trial. Indian Pediatrics2019;56(8):643-6. [PMID: 31477643]">Gowda 2019</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>) reported this outcome. We are uncertain about the effect of using phenobarbital versus levetiracetam as first‐line ASM on achieving seizure control after maximal loading dose of ASM in clinically‐diagnosed seizures (RR 0.58, 95% CI 0.47 to 0.72; 260 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0015" title="">Analysis 2.2</a>). </p> </section> <section id="CD014967-sec-0086"> <p><b>Mortality or neurodevelopmental disability at 18 to 24 months' corrected age</b></p> <p>This outcome was not reported in the eight included trials (<a href="./references#CD014967-bbs2-0001" title="AkeelNE , SulimanHA , Al-ShokaryAH , IbrahimAO , KamalNM , AbdelgalilAA , et al. A comparative study of levetiracetam and phenobarbital for neonatal seizures as a first line treatment. Global Pediatric Health2022;9:2333794X221143572. [DOI: 10.1177/2333794X221143572] [PMID: 36578326]">Akeel 2022</a>; <a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>; <a href="./references#CD014967-bbs2-0004" title="GhaffarJ , RiazA , Uzair, VirkAO , BhattiA . Comparative efficacy of intravenous levetiracetam vs phenobarbitone in neonatal seizures. Medical Forum2020;31(7):25-8. [WEBSITE: medforum.pk/article/6-comparative-efficacy-of-intravenous-levetiracetam-vs-phenobarbitone-in-neonatal-seizures]">Ghaffar 2020</a>; <a href="./references#CD014967-bbs2-0005" title="GowdaVK , RomanaA , ShivannaNH , BenakappaN , BenakappaA . Levetiracetam versus phenobarbitone in neonatal seizures — a randomized controlled trial. Indian Pediatrics2019;56(8):643-6. [PMID: 31477643]">Gowda 2019</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>; <a href="./references#CD014967-bbs2-0010" title="PerveenS , SinghA , UpadhyayA , SinghN , ChauhanR . A randomized controlled trial on comparison of phenobarbitone and levetiracetam for the treatment of neonatal seizures: pilot study. International Journal of Research in Medical Sciences2016;4(6):2073-8. [DOI: 10.18203/2320-6012.ijrms20161763] [URL: msjonline.org/index.php/ijrms/article/view/865/836]">Perveen 2016</a>; <a href="./references#CD014967-bbs2-0011" title="PrakashA , RichaR , SahniGS . Neonatal seizures – levetiracetam versus phenobarbital. Indian Journal of Child Health2019;6(11):605-8. [DOI: 10.32677/IJCH.2019.v06.i11.008]">Prakash 2019</a>; <a href="./references#CD014967-bbs2-0017" title="SusnerwalaS , JoshiA , DeshmukhL , LondheA . Levetiracetam or phenobarbitone as a first-line anticonvulsant in asphyxiated term newborns? An open-label, single-center, randomized, controlled, pragmatic trial. Hospital Pediatrics2022;12(7):647-52. [DOI: 10.1542/hpeds.2021-006415] [PMID: 35673948]">Susnerwala 2022</a>). </p> </section> </section> <section id="CD014967-sec-0087"> <h6 class="title">Secondary outcomes</h6> <section id="CD014967-sec-0088"> <p><b>Mortality before hospital discharge</b></p> <p>Six trials (<a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>; <a href="./references#CD014967-bbs2-0004" title="GhaffarJ , RiazA , Uzair, VirkAO , BhattiA . Comparative efficacy of intravenous levetiracetam vs phenobarbitone in neonatal seizures. Medical Forum2020;31(7):25-8. [WEBSITE: medforum.pk/article/6-comparative-efficacy-of-intravenous-levetiracetam-vs-phenobarbitone-in-neonatal-seizures]">Ghaffar 2020</a>; <a href="./references#CD014967-bbs2-0005" title="GowdaVK , RomanaA , ShivannaNH , BenakappaN , BenakappaA . Levetiracetam versus phenobarbitone in neonatal seizures — a randomized controlled trial. Indian Pediatrics2019;56(8):643-6. [PMID: 31477643]">Gowda 2019</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>; <a href="./references#CD014967-bbs2-0011" title="PrakashA , RichaR , SahniGS . Neonatal seizures – levetiracetam versus phenobarbital. Indian Journal of Child Health2019;6(11):605-8. [DOI: 10.32677/IJCH.2019.v06.i11.008]">Prakash 2019</a>; <a href="./references#CD014967-bbs2-0017" title="SusnerwalaS , JoshiA , DeshmukhL , LondheA . Levetiracetam or phenobarbitone as a first-line anticonvulsant in asphyxiated term newborns? An open-label, single-center, randomized, controlled, pragmatic trial. Hospital Pediatrics2022;12(7):647-52. [DOI: 10.1542/hpeds.2021-006415] [PMID: 35673948]">Susnerwala 2022</a>) reported this outcome. Use of phenobarbital versus levetiracetam as first‐line ASM may have little or no effect on all‐cause mortality before hospital discharge (RR 1.41, 95% CI 0.82 to 2.43; 452 participants; low‐certainty evidence; <a href="./references#CD014967-fig-0016" title="">Analysis 2.3</a>). </p> </section> <section id="CD014967-sec-0089"> <p><b>Neurodevelopmental disability at 18 to 24 months' corrected age</b></p> <p>This outcome was not reported in the eight included trials.</p> </section> <section id="CD014967-sec-0090"> <p><b>Proportion of infants who develop cognitive impairment at two years or more</b></p> <p>This outcome was not reported in the eight included trials.</p> </section> <section id="CD014967-sec-0091"> <p><b>Seizure burden (seizure hours per infant, or minutes per hour of monitoring) during hospitalisation</b></p> <p>This outcome was not reported in the eight included trials.</p> </section> <section id="CD014967-sec-0092"> <p><b>Proportion of infants with one or more of the adverse effects related to ASM(s) during hospitalisation</b></p> <p><i>Requirement for mechanical ventilation</i> </p> <p>The requirement for mechanical ventilation in trial participants was reported in five trials (<a href="./references#CD014967-bbs2-0001" title="AkeelNE , SulimanHA , Al-ShokaryAH , IbrahimAO , KamalNM , AbdelgalilAA , et al. A comparative study of levetiracetam and phenobarbital for neonatal seizures as a first line treatment. Global Pediatric Health2022;9:2333794X221143572. [DOI: 10.1177/2333794X221143572] [PMID: 36578326]">Akeel 2022</a>; <a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>; <a href="./references#CD014967-bbs2-0004" title="GhaffarJ , RiazA , Uzair, VirkAO , BhattiA . Comparative efficacy of intravenous levetiracetam vs phenobarbitone in neonatal seizures. Medical Forum2020;31(7):25-8. [WEBSITE: medforum.pk/article/6-comparative-efficacy-of-intravenous-levetiracetam-vs-phenobarbitone-in-neonatal-seizures]">Ghaffar 2020</a>; <a href="./references#CD014967-bbs2-0005" title="GowdaVK , RomanaA , ShivannaNH , BenakappaN , BenakappaA . Levetiracetam versus phenobarbitone in neonatal seizures — a randomized controlled trial. Indian Pediatrics2019;56(8):643-6. [PMID: 31477643]">Gowda 2019</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>). We are uncertain about the effect of using phenobarbital versus levetiracetam as first‐line ASM on the need for mechanical ventilation (RR 2.20, 95% CI 0.50 to 9.68; 394 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0017" title="">Analysis 2.4</a>). </p> <p><i>Proportion of infants who develop sedation or drowsiness</i> </p> <p>Meta‐analysis of two trials (<a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>; <a href="./references#CD014967-bbs2-0011" title="PrakashA , RichaR , SahniGS . Neonatal seizures – levetiracetam versus phenobarbital. Indian Journal of Child Health2019;6(11):605-8. [DOI: 10.32677/IJCH.2019.v06.i11.008]">Prakash 2019</a>) showed no difference in sedation/drowsiness between the two groups (RR 1.88, 95% CI 0.66 to 5.37; 180 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0018" title="">Analysis 2.5</a>). </p> <p><i>Arrhythmias causing circulatory disturbance</i> </p> <p>This outcome was not reported in the eight included trials.</p> <p><i>Bradycardia</i> </p> <p>Meta‐analysis of four trials (<a href="./references#CD014967-bbs2-0001" title="AkeelNE , SulimanHA , Al-ShokaryAH , IbrahimAO , KamalNM , AbdelgalilAA , et al. A comparative study of levetiracetam and phenobarbital for neonatal seizures as a first line treatment. Global Pediatric Health2022;9:2333794X221143572. [DOI: 10.1177/2333794X221143572] [PMID: 36578326]">Akeel 2022</a>; <a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>; <a href="./references#CD014967-bbs2-0005" title="GowdaVK , RomanaA , ShivannaNH , BenakappaN , BenakappaA . Levetiracetam versus phenobarbitone in neonatal seizures — a randomized controlled trial. Indian Pediatrics2019;56(8):643-6. [PMID: 31477643]">Gowda 2019</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>) showed no difference in the incidence of bradycardia between phenobarbital and levetiracetam groups (RR 6.00, 95% CI 0.74 to 48.97; 334 participants; <a href="./references#CD014967-fig-0019" title="">Analysis 2.6</a>). </p> <p><i>Hypotension requiring volume or inotropic support</i> </p> <p>Two trials (<a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>) reported this outcome. None of the infants in either study had hypotension requiring volume or inotropic support (<a href="./references#CD014967-fig-0020" title="">Analysis 2.7</a>). </p> <p><i>Shock requiring volume or inotropes</i> </p> <p>Meta‐analysis of three trials (<a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>; <a href="./references#CD014967-bbs2-0010" title="PerveenS , SinghA , UpadhyayA , SinghN , ChauhanR . A randomized controlled trial on comparison of phenobarbitone and levetiracetam for the treatment of neonatal seizures: pilot study. International Journal of Research in Medical Sciences2016;4(6):2073-8. [DOI: 10.18203/2320-6012.ijrms20161763] [URL: msjonline.org/index.php/ijrms/article/view/865/836]">Perveen 2016</a>) showed no difference in the risk of shock between phenobarbital and levetiracetam groups (RR 0.67, 99% CI 0.30 to 1.51; 190 participants; <a href="./references#CD014967-fig-0021" title="">Analysis 2.8</a>). </p> <p><i>Hepatotoxicity resulting in discontinuation of therapy</i> </p> <p>This outcome was not reported in the eight included trials.</p> <p><i>Acute kidney injury (of any stage)</i> </p> <p>This outcome was not reported in the eight included trials.</p> </section> <section id="CD014967-sec-0093"> <p><b>Proportion of infants with an abnormal background pattern in EEG during ASM treatment</b></p> <p>One trial (<a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>), did not find a difference in the proportion of infants with an abnormal background pattern in EEG during ASM treatment between phenobarbital and levetiracetam groups (RR 1.00, 95% CI 0.88 to 1.13; 30 participants; <a href="./references#CD014967-fig-0022" title="">Analysis 2.9</a>). </p> </section> <section id="CD014967-sec-0094"> <p><b>Proportion of infants with an abnormal background pattern in EEG after stopping ASM treatment</b></p> <p>One trial (<a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>), did not find a difference in the proportion of infants with an abnormal background pattern in EEG after the ASM treatment between phenobarbital and levetiracetam groups (RR 0.63, 95% CI 0.26 to 1.47; 30 participants; <a href="./references#CD014967-fig-0023" title="">Analysis 2.10</a>). </p> </section> <section id="CD014967-sec-0095"> <p><b>Duration of hospital stay (days)</b></p> <p>Meta‐analysis of two trials (<a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>; <a href="./references#CD014967-bbs2-0010" title="PerveenS , SinghA , UpadhyayA , SinghN , ChauhanR . A randomized controlled trial on comparison of phenobarbitone and levetiracetam for the treatment of neonatal seizures: pilot study. International Journal of Research in Medical Sciences2016;4(6):2073-8. [DOI: 10.18203/2320-6012.ijrms20161763] [URL: msjonline.org/index.php/ijrms/article/view/865/836]">Perveen 2016</a>) showed an increase in the duration of hospital stay in the phenobarbital group compared to the levetiracetam group (MD 2.36 days, 95% CI 0.54 to 4.18; 90 participants; <a href="./references#CD014967-fig-0024" title="">Analysis 2.11</a>). </p> </section> <section id="CD014967-sec-0096"> <p><b>Recurrence of seizures before hospital discharge</b></p> <p>Meta‐analysis of two trials (<a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>) showed no difference in recurrence of seizures during hospital stay between phenobarbital and levetiracetam groups (RR 1.67, 95% CI 0.42 to 6.60; 130 participants; <a href="./references#CD014967-fig-0025" title="">Analysis 2.12</a>). </p> </section> <section id="CD014967-sec-0097"> <p><b>Proportion of infants with persistent seizures or requiring ASM(s) at discharge (or both)</b></p> <p>One trial (<a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>) did not find a difference in the proportion of infants with persistent seizures or requiring ASM at discharge (RR 0.50, 95% CI 0.05 to 4.94; 30 participants; <a href="./references#CD014967-fig-0026" title="">Analysis 2.13</a>). </p> </section> <section id="CD014967-sec-0098"> <p><b>Proportion of infants discharged on gavage feeds</b></p> <p>Two trials (<a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>) reported this outcome. None of the babies in either group was discharged on gavage feeds (<a href="./references#CD014967-fig-0027" title="">Analysis 2.14</a>). </p> </section> <section id="CD014967-sec-0099"> <p><b>Proportion of infants with an abnormal neurological examination at discharge</b></p> <p>Meta‐analysis of four trials (<a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>; <a href="./references#CD014967-bbs2-0010" title="PerveenS , SinghA , UpadhyayA , SinghN , ChauhanR . A randomized controlled trial on comparison of phenobarbitone and levetiracetam for the treatment of neonatal seizures: pilot study. International Journal of Research in Medical Sciences2016;4(6):2073-8. [DOI: 10.18203/2320-6012.ijrms20161763] [URL: msjonline.org/index.php/ijrms/article/view/865/836]">Perveen 2016</a>; <a href="./references#CD014967-bbs2-0017" title="SusnerwalaS , JoshiA , DeshmukhL , LondheA . Levetiracetam or phenobarbitone as a first-line anticonvulsant in asphyxiated term newborns? An open-label, single-center, randomized, controlled, pragmatic trial. Hospital Pediatrics2022;12(7):647-52. [DOI: 10.1542/hpeds.2021-006415] [PMID: 35673948]">Susnerwala 2022</a>), showed no difference in the proportion of infants with an abnormal neurological examination at discharge between phenobarbital and levetiracetam groups (RR 0.80, 95% CI 0.51 to 1.24; 272 participants; <a href="./references#CD014967-fig-0028" title="">Analysis 2.15</a>). </p> </section> <section id="CD014967-sec-0100"> <p><b>Proportion of infants who develop epilepsy post‐discharge</b></p> <p>One trial (<a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>) has reported this outcome. We are uncertain about the effect of using phenobarbital versus levetiracetam as first‐line ASM on achieving seizure control after the first loading dose in clinically‐diagnosed seizures (RR 0.50, 95% CI 0.05 to 4.9; 30 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0029" title="">Analysis 2.16</a>). </p> </section> </section> </section> <section id="CD014967-sec-0101"> <h5 class="title">Phenobarbital versus phenytoin as first‐line ASM for EEG‐confirmed neonatal seizures</h5> <p>Please see <a href="./full#CD014967-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD014967-sec-0102"> <h6 class="title">Primary outcomes</h6> <section id="CD014967-sec-0103"> <p><b>Proportion of infants who achieve seizure control after first loading dose of ASM</b></p> <p>The one included trial did not report this outcome (<a href="./references#CD014967-bbs2-0008" title="PainterMJ , ScherMS , SteinAD , ArmattiS , WangZ , GardinerJC , et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine1999;341(7):485-9. [DOI: 10.1056/NEJM199908123410704] [PMID: 10441604]ScherMS , AlvinJ , GausL , MinnighB , PainterMJ . Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology2003;28(4):277-80. [DOI: 10.1016/s0887-8994(02)00621-5] [PMID: 12849880]">Painter 1999</a>). </p> </section> <section id="CD014967-sec-0104"> <p><b>Proportion of infants who achieve seizure control after the maximal loading dose of ASM</b></p> <p>One trial (<a href="./references#CD014967-bbs2-0008" title="PainterMJ , ScherMS , SteinAD , ArmattiS , WangZ , GardinerJC , et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine1999;341(7):485-9. [DOI: 10.1056/NEJM199908123410704] [PMID: 10441604]ScherMS , AlvinJ , GausL , MinnighB , PainterMJ . Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology2003;28(4):277-80. [DOI: 10.1016/s0887-8994(02)00621-5] [PMID: 12849880]">Painter 1999</a>) has reported this outcome. We are uncertain about the effect of using phenobarbital versus phenytoin as first‐line ASM on achieving seizure control after the maximal dose of ASM in EEG‐confirmed neonatal seizures (RR 0.97, 95% CI 0.54 to 1.72; 59 participants; very low‐certainty evidence). </p> </section> <section id="CD014967-sec-0105"> <p><b>Mortality or neurodevelopmental disability at 18 to 24 months' corrected age</b></p> <p>The one included trial did not report this outcome.</p> </section> </section> <section id="CD014967-sec-0106"> <h6 class="title">Secondary outcomes</h6> <section id="CD014967-sec-0107"> <p><b>Mortality before hospital discharge</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0108"> <p><b>Neurodevelopmental disability at 18 to 24 months' corrected age</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0109"> <p><b>Proportion of infants who develop cognitive impairment at two years or more</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0110"> <p><b>Seizure burden during hospitalisation</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0111"> <p><b>Proportion of infants with one or more of the adverse effects related to ASM(s) during hospitalisation</b></p> <p><i>Requirement for mechanical ventilation</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Proportion of infants who develop sedation or drowsiness</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Arrhythmias causing circulatory disturbance</i> </p> <p>The one included trial (<a href="./references#CD014967-bbs2-0008" title="PainterMJ , ScherMS , SteinAD , ArmattiS , WangZ , GardinerJC , et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine1999;341(7):485-9. [DOI: 10.1056/NEJM199908123410704] [PMID: 10441604]ScherMS , AlvinJ , GausL , MinnighB , PainterMJ . Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology2003;28(4):277-80. [DOI: 10.1016/s0887-8994(02)00621-5] [PMID: 12849880]">Painter 1999</a>) reported this outcome. None of the babies in either group developed any arrythmia in this trial (<a href="./references#CD014967-fig-0031" title="">Analysis 3.2</a>). </p> <p><i>Bradycardia</i> </p> <p>The one included trial (<a href="./references#CD014967-bbs2-0008" title="PainterMJ , ScherMS , SteinAD , ArmattiS , WangZ , GardinerJC , et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine1999;341(7):485-9. [DOI: 10.1056/NEJM199908123410704] [PMID: 10441604]ScherMS , AlvinJ , GausL , MinnighB , PainterMJ . Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology2003;28(4):277-80. [DOI: 10.1016/s0887-8994(02)00621-5] [PMID: 12849880]">Painter 1999</a>) reported this outcome. None of the babies in either group developed bradycardia in this trial (<a href="./references#CD014967-fig-0032" title="">Analysis 3.3</a>). </p> <p><i>Hypotension requiring volume or inotropic support</i> </p> <p>The one included trial (<a href="./references#CD014967-bbs2-0008" title="PainterMJ , ScherMS , SteinAD , ArmattiS , WangZ , GardinerJC , et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine1999;341(7):485-9. [DOI: 10.1056/NEJM199908123410704] [PMID: 10441604]ScherMS , AlvinJ , GausL , MinnighB , PainterMJ . Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology2003;28(4):277-80. [DOI: 10.1016/s0887-8994(02)00621-5] [PMID: 12849880]">Painter 1999</a>) reported this outcome. None of the babies in either group developed hypotension in this trial (<a href="./references#CD014967-fig-0033" title="">Analysis 3.4</a>). </p> <p><i>Shock requiring volume or inotropes</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Hepatotoxicity resulting in discontinuation of therapy</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Acute kidney injury (of any stage)</i> </p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0112"> <p><b>Proportion of infants with an abnormal background pattern in EEG during ASM treatment</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0113"> <p><b>Proportion of infants with an abnormal background pattern in EEG after stopping the ASM</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0114"> <p><b>Duration of hospital stay (days)</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0115"> <p><b>Proportion of infants with persistent seizures or requiring ASM(s) at discharge (or both)</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0116"> <p><b>Proportion of infants discharged on gavage feeds</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0117"> <p><b>Proportion of infants with abnormal neurological examination at discharge</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0118"> <p><b>Proportion of infants who develop epilepsy post‐discharge</b></p> <p>The one included trial did not report this outcome.</p> </section> </section> </section> <section id="CD014967-sec-0119"> <h5 class="title">Phenobarbital versus phenytoin as first‐line ASM for clinically diagnosed neonatal seizures </h5> <p>Please see <a href="./full#CD014967-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD014967-sec-0120"> <h6 class="title">Primary outcomes</h6> <section id="CD014967-sec-0121"> <p><b>Proportion of infants who achieve seizure control after the first loading dose of ASM</b></p> <p>Both included trials (<a href="./references#CD014967-bbs2-0009" title="PathakG , UpadhyayA , PathakU , ChawlaD , GoelSP . Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial. Indian Pediatrics2013;50(8):753-7. [DOI: 10.1007/s13312-013-0218-6] [PMID: 23502660]">Pathak 2013</a>; <a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>) reported this outcome. Using phenobarbital may result in better seizure control after the first loading dose of ASM when compared to phenytoin in clinically diagnosed seizures (RR 1.92, 95% CI 1.40 to 2.64; 179 participants; low‐certainty evidence; <a href="./references#CD014967-fig-0034" title="">Analysis 4.1</a>). </p> </section> <section id="CD014967-sec-0122"> <p><b>Proportion of infants who achieve seizure control after the maximal loading dose of ASM</b></p> <p>Neither of the two included trials reported this outcome.</p> </section> <section id="CD014967-sec-0123"> <p><b>Mortality or neurodevelopmental disability at 18 to 24 months' corrected age</b></p> <p>Neither of the two included studies reported this outcome.</p> </section> </section> <section id="CD014967-sec-0124"> <h6 class="title">Secondary outcomes</h6> <section id="CD014967-sec-0125"> <p><b>Mortality before hospital discharge</b></p> <p>Both included trials (<a href="./references#CD014967-bbs2-0009" title="PathakG , UpadhyayA , PathakU , ChawlaD , GoelSP . Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial. Indian Pediatrics2013;50(8):753-7. [DOI: 10.1007/s13312-013-0218-6] [PMID: 23502660]">Pathak 2013</a>; <a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>) reported this outcome. We are uncertain about the effect of using phenobarbital versus phenytoin as first‐line ASM on all‐cause mortality before hospital discharge (RR 1.33, 95% CI 0.79 to 2.26; 179 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0035" title="">Analysis 4.2</a>). </p> </section> <section id="CD014967-sec-0126"> <p><b>Neurodevelopmental disability at 18 to 24 months' corrected age</b></p> <p>Neither of the two included studies reported this outcome.</p> </section> <section id="CD014967-sec-0127"> <p><b>Proportion of infants who develop cognitive impairment at two years or more</b></p> <p>Neither of the two included studies reported this outcome.</p> </section> <section id="CD014967-sec-0128"> <p><b>Seizure burden during hospitalisation</b></p> <p>Neither of the two included studies reported this outcome.</p> </section> <section id="CD014967-sec-0129"> <p><b>Proportion of infants with one or more of the adverse effects related to ASM(s) during hospitalisation</b></p> <p><i>Requirement for mechanical ventilation</i> </p> <p>One trial (<a href="./references#CD014967-bbs2-0009" title="PathakG , UpadhyayA , PathakU , ChawlaD , GoelSP . Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial. Indian Pediatrics2013;50(8):753-7. [DOI: 10.1007/s13312-013-0218-6] [PMID: 23502660]">Pathak 2013</a>) reported on the need for mechanical ventilation. We are uncertain about the effect of using phenobarbital versus phenytoin as first‐line ASM on the need for mechanical ventilation (RR 7.13, 95% CI 0.38 to 134.78; 109 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0036" title="">Analysis 4.3</a>). </p> <p><i>Proportion of infants with sedation or drowsiness</i> </p> <p>Based on data from one trial (<a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>), we are uncertain about the effect of using phenobarbital versus phenytoin as first‐line ASM on the risk of sedation or drowsiness (RR 23.00, 95% CI 1.41 to 375.77; 70 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0037" title="">Analysis 4.4</a>). </p> <p><i>Arrhythmias causing circulatory disturbance</i> </p> <p>Neither of the two included studies reported this outcome.</p> <p><i>Bradycardia</i> </p> <p>One trial (<a href="./references#CD014967-bbs2-0009" title="PathakG , UpadhyayA , PathakU , ChawlaD , GoelSP . Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial. Indian Pediatrics2013;50(8):753-7. [DOI: 10.1007/s13312-013-0218-6] [PMID: 23502660]">Pathak 2013</a>), did not find a difference in the proportion of infants with bradycardia between the groups (RR 0.20, 95% CI 0.01 to 4.15; <a href="./references#CD014967-fig-0038" title="">Analysis 4.5</a>). </p> <p><i>Hypotension requiring volume or inotropic support</i> </p> <p>Neither of the two included studies reported this outcome.</p> <p><i>Shock requiring volume or inotropes</i> </p> <p>Neither of the two included studies reported this outcome.</p> <p><i>Hepatotoxicity resulting in discontinuation of therapy</i> </p> <p>Neither of the two included studies reported this outcome.</p> <p><i>Acute kidney injury (of any stage)</i> </p> <p>Neither of the two included studies reported this outcome.</p> </section> <section id="CD014967-sec-0130"> <p><b>Proportion of infants with an abnormal background pattern in EEG during ASM treatment</b></p> <p>Neither of the two included studies reported this outcome.</p> </section> <section id="CD014967-sec-0131"> <p><b>Proportion of infants with an abnormal background pattern in EEG after stopping ASM</b></p> <p>Neither of the two included studies reported this outcome.</p> </section> <section id="CD014967-sec-0132"> <p><b>Duration of hospital stay (days)</b></p> <p>Neither of the two included studies reported this outcome.</p> </section> <section id="CD014967-sec-0133"> <p><b>Proportion of infants with persistent seizures or requiring ASM(s) at discharge (or both)</b></p> <p>One trial (<a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>) did not find a difference in the proportion of infants with persistent seizures or requiring ASM at discharge between the phenobarbital and phenytoin groups (RR 0.67, 95% CI 0.21 to 2.16; 70 participants; <a href="./references#CD014967-fig-0039" title="">Analysis 4.6</a>). </p> </section> <section id="CD014967-sec-0134"> <p><b>Proportion of infants discharged on gavage feeds</b></p> <p>Neither of the two included studies reported this outcome.</p> </section> <section id="CD014967-sec-0135"> <p><b>Proportion of infants with an abnormal neurological examination at discharge</b></p> <p>Neither of the two included studies reported this outcome.</p> </section> <section id="CD014967-sec-0136"> <p><b>Proportion of infants who develop epilepsy post‐discharge</b></p> <p>Neither of the two included studies reported this outcome.</p> </section> </section> </section> <section id="CD014967-sec-0137"> <h5 class="title">Phenobarbital versus lorazepam as first‐line ASM for clinically diagnosed neonatal seizures </h5> <p>Please see <a href="./full#CD014967-tbl-0005">summary of findings Table 5</a>. </p> <section id="CD014967-sec-0138"> <h6 class="title">Primary outcomes</h6> <section id="CD014967-sec-0139"> <p><b>Proportion of infants who achieve seizure control after the first loading dose of ASM</b></p> <p>The one included trial (<a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>) reported this outcome. We are uncertain about the effect of phenobarbital compared to lorazepam on seizure control after the first loading dose of ASM (RR 0.71, 95% CI 0.53 to 0.94; 71 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0040" title="">Analysis 5.1</a>). </p> </section> <section id="CD014967-sec-0140"> <p><b>Proportion of infants who achieve seizure control after the maximal loading dose of ASM</b></p> <p>The one included trial did not report this outcome (<a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>). </p> </section> <section id="CD014967-sec-0141"> <p><b>Mortality or neurodevelopmental disability at 18 to 24 months' corrected age</b></p> <p>The one included trial did not report this outcome.</p> </section> </section> <section id="CD014967-sec-0142"> <h6 class="title">Secondary outcomes</h6> <section id="CD014967-sec-0143"> <p><b>Mortality before hospital discharge</b></p> <p>The one included trial (<a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>) reported this outcome. We are uncertain about the effect of phenobarbital compared to lorazepam on mortality before discharge (RR 1.76, 95% CI 0.79 to 3.95; 71 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0041" title="">Analysis 5.2</a>). </p> </section> <section id="CD014967-sec-0144"> <p><b>Neurodevelopmental disability at 18 to 24 months' corrected age</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0145"> <p><b>Proportion of infants who develop cognitive impairment at two years or more</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0146"> <p><b>Seizure burden during hospitalisation</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0147"> <p><b>Proportion of infants with one or more of the adverse effects related to ASM(s) during hospitalisation</b></p> <p><i>Requirement for mechanical ventilation</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Proportion of infants who develop sedation or drowsiness</i> </p> <p>The one included trial (<a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>) reported this outcome. We are uncertain about the effect of phenobarbital compared to lorazepam on sedation or drowsiness (RR 5.66, 95% CI 1.35 to 23.71; 71 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0042" title="">Analysis 5.3</a>). </p> <p><i>Arrhythmias causing circulatory disturbance</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Bradycardia</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Hypotension requiring volume or inotropic support</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Shock requiring volume or inotropes</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Hepatotoxicity resulting in discontinuation of therapy</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Acute kidney injury (of any stage)</i> </p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0148"> <p><b>Proportion of infants with an abnormal background pattern in EEG during ASM treatment</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0149"> <p><b>Proportion of infants with an abnormal background pattern in EEG after stopping ASM</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0150"> <p><b>Duration of hospital stay (days)</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0151"> <p><b>Proportion of infants with persistent seizures or requiring ASM(s) at discharge</b></p> <p>The one included trial (<a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>) did not find a difference in the proportion of infants with persistent seizures or requiring ASM at discharge between the phenobarbital and lorazepam groups (RR 9.25, 95% CI 0.52 to 165.69; 71 participants; <a href="./references#CD014967-fig-0043" title="">Analysis 5.4</a>). </p> </section> <section id="CD014967-sec-0152"> <p><b>Proportion of infants discharged on gavage feeds</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0153"> <p><b>Proportion of infants with an abnormal neurological examination at discharge</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0154"> <p><b>Proportion of infants who develop epilepsy post‐discharge</b></p> <p>The one included trial did not report this outcome.</p> </section> </section> </section> <section id="CD014967-sec-0155"> <h5 class="title">Phenytoin versus lorazepam as first‐line ASM for clinically diagnosed neonatal seizures</h5> <p>Please see <a href="./full#CD014967-tbl-0006">summary of findings Table 6</a>. </p> <section id="CD014967-sec-0156"> <h6 class="title">Primary outcomes</h6> <section id="CD014967-sec-0157"> <p><b>Proportion of infants who achieve seizure control after the first loading dose of ASM</b></p> <p>The one included trial (<a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>) reported this outcome. We are uncertain about the effect of phenytoin compared to lorazepam on seizure control after the first loading dose of ASM (RR 0.77, 95% CI 0.60 to 0.99; 71 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0044" title="">Analysis 6.1</a>). </p> </section> <section id="CD014967-sec-0158"> <p><b>Proportion of infants who achieve seizure control after the maximal loading dose of ASM</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0159"> <p><b>Mortality or neurodevelopmental disability at 18 to 24 months' corrected age</b></p> <p>The one included trial did not report this outcome.</p> </section> </section> <section id="CD014967-sec-0160"> <h6 class="title">Secondary outcomes</h6> <section id="CD014967-sec-0161"> <p><b>Mortality before hospital discharge</b></p> <p>The one included trial (<a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>) reported this outcome. We are uncertain about the effect of phenytoin compared to lorazepam on mortality before discharge (RR 0.44, 95% CI 0.12 to 1.57; 71 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0045" title="">Analysis 6.2</a>). </p> </section> <section id="CD014967-sec-0162"> <p><b>Neurodevelopmental disability at 18 to 24 months' corrected age</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0163"> <p><b>Proportion of infants who develop cognitive impairment at two years or more</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0164"> <p><b>Seizure burden during hospitalisation</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0165"> <p><b>Proportion of infants with one or more of the adverse effects related to ASM(s) during hospitalisation</b></p> <p><i>Requirement for mechanical ventilation</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Proportion of infants who develop sedation or drowsiness</i> </p> <p>The one included trial (<a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>) reported this outcome. We are uncertain about the effect of phenobarbital compared to lorazepam on sedation or drowsiness (RR 0.21, 95% CI 0.01 to 4.13; 71 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0046" title="">Analysis 6.3</a>). </p> <p><i>Arrhythmias causing circulatory disturbance</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Bradycardia</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Hypotension requiring volume or inotropic support</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Shock requiring volume or inotropes</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Hepatotoxicity resulting in discontinuation of therapy</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Acute kidney injury (of any stage)</i> </p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0166"> <p><b>Proportion of infants with an abnormal background pattern in EEG during ASM treatment</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0167"> <p><b>Proportion of infants with an abnormal background pattern in EEG after stopping the ASM</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0168"> <p><b>Duration of hospital stay (days)</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0169"> <p><b>Proportion of infants with persistent seizures or requiring ASM(s) at discharge</b></p> <p>The one included trial (<a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>) did not find a difference in the proportion of infants with persistent seizures or requiring ASM at discharge between the phenytoin and lorazepam groups (RR 13.36, 95% CI 0.78 to 228.6; 71 participants; <a href="./references#CD014967-fig-0047" title="">Analysis 6.4</a>). </p> </section> <section id="CD014967-sec-0170"> <p><b>Proportion of infants discharged on gavage feeds</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0171"> <p><b>Proportion of infants with an abnormal neurological examination at discharge</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0172"> <p><b>Proportion of infants who develop epilepsy post‐discharge</b></p> <p>The one included trial did not report this outcome.</p> </section> </section> </section> <section id="CD014967-sec-0173"> <h5 class="title">Phenobarbital + bumetanide versus phenobarbital alone as first‐line ASM for EEG‐confirmed neonatal seizures </h5> <p>Please see <a href="./full#CD014967-tbl-0007">summary of findings Table 7</a>. </p> <section id="CD014967-sec-0174"> <h6 class="title">Primary outcomes</h6> <section id="CD014967-sec-0175"> <p><b>Proportion of infants who achieve seizure control after the first loading dose of ASM</b></p> <p>The one included trial (<a href="./references#CD014967-bbs2-0015" title="SoulJS , BerginAM , StoppC , HayesB , SinghA , FortunoCR , et al, Boston Bumetanide Trial Group. A pilot randomized, controlled, double‐blind trial of bumetanide to treat neonatal seizures. Annals of Neurology2021;89(2):327-40. [DOI: 10.1002/ana.25959] [PMID: 33201535]">Soul 2021</a>) reported this outcome. Phenobarbital + bumetanide when compared to phenobarbital alone may have little or no effect on seizure control after the first loading dose of ASM (RR 0.95, 95% CI 0.37 to 2.40; 43 participants; low‐certainty evidence; <a href="./references#CD014967-fig-0048" title="">Analysis 7.1</a>). </p> </section> <section id="CD014967-sec-0176"> <p><b>Proportion of infants who achieve seizure control after the maximal loading dose of ASM</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0177"> <p><b>Mortality or neurodevelopmental disability at 18 to 24 months' corrected age</b></p> <p>The one included trial did not report this outcome.</p> </section> </section> <section id="CD014967-sec-0178"> <h6 class="title">Secondary outcomes</h6> <section id="CD014967-sec-0179"> <p><b>Mortality before hospital discharge</b></p> <p>The one included trial (<a href="./references#CD014967-bbs2-0015" title="SoulJS , BerginAM , StoppC , HayesB , SinghA , FortunoCR , et al, Boston Bumetanide Trial Group. A pilot randomized, controlled, double‐blind trial of bumetanide to treat neonatal seizures. Annals of Neurology2021;89(2):327-40. [DOI: 10.1002/ana.25959] [PMID: 33201535]">Soul 2021</a>) reported this outcome. We are uncertain about the effect of phenobarbital + bumetanide when compared to phenobarbital alone on all‐cause mortality before hospital discharge (RR 0.20, 95% CI 0.02 to 1.74; 43 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0049" title="">Analysis 7.2</a>). </p> </section> <section id="CD014967-sec-0180"> <p><b>Neurodevelopmental disability at 18 to 24 months' corrected age</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0181"> <p><b>Proportion of infants who develop cognitive impairment at two years or more</b></p> <p>The one included trial (<a href="./references#CD014967-bbs2-0015" title="SoulJS , BerginAM , StoppC , HayesB , SinghA , FortunoCR , et al, Boston Bumetanide Trial Group. A pilot randomized, controlled, double‐blind trial of bumetanide to treat neonatal seizures. Annals of Neurology2021;89(2):327-40. [DOI: 10.1002/ana.25959] [PMID: 33201535]">Soul 2021</a>) reported cognitive impairment at 18 to 24 months. We are uncertain about the effect of phenobarbital + bumetanide when compared to phenobarbital alone on all‐cause mortality before hospital discharge (RR 0.53, 95% CI 0.13 to 2.15; 43 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0050" title="">Analysis 7.3</a>). </p> </section> <section id="CD014967-sec-0182"> <p><b>Seizure burden during hospitalisation</b></p> <p>The one included trial did not find a difference in seizure burden between the two groups (MD 1.90, 95% CI 0.52 to 3.28; 43 participants; <a href="./references#CD014967-fig-0051" title="">Analysis 7.4</a>). </p> </section> <section id="CD014967-sec-0183"> <p><b>Proportion of infants with one or more of the adverse effects related to ASM(s) during hospitalisation</b></p> <p><i>Requirement for mechanical ventilation</i> </p> <p>In the one included trial (<a href="./references#CD014967-bbs2-0015" title="SoulJS , BerginAM , StoppC , HayesB , SinghA , FortunoCR , et al, Boston Bumetanide Trial Group. A pilot randomized, controlled, double‐blind trial of bumetanide to treat neonatal seizures. Annals of Neurology2021;89(2):327-40. [DOI: 10.1002/ana.25959] [PMID: 33201535]">Soul 2021</a>), none of the babies in either group required mechanical ventilation (<a href="./references#CD014967-fig-0052" title="">Analysis 7.5</a>). </p> <p><i>Proportion of infants who develop sedation or drowsiness</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Arrhythmias causing circulatory disturbance</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Bradycardia</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Hypotension requiring volume or inotropic support</i> </p> <p>In the one included trial (<a href="./references#CD014967-bbs2-0015" title="SoulJS , BerginAM , StoppC , HayesB , SinghA , FortunoCR , et al, Boston Bumetanide Trial Group. A pilot randomized, controlled, double‐blind trial of bumetanide to treat neonatal seizures. Annals of Neurology2021;89(2):327-40. [DOI: 10.1002/ana.25959] [PMID: 33201535]">Soul 2021</a>), none of the babies in either group developed hypotension (<a href="./references#CD014967-fig-0053" title="">Analysis 7.6</a>). </p> <p><i>Shock requiring volume or inotropes</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Hepatotoxicity resulting in discontinuation of therapy</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Acute kidney injury (of any stage)</i> </p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0184"> <p><b>Proportion of infants with an abnormal background pattern in EEG during ASM treatment</b></p> <p>The one included trial (<a href="./references#CD014967-bbs2-0015" title="SoulJS , BerginAM , StoppC , HayesB , SinghA , FortunoCR , et al, Boston Bumetanide Trial Group. A pilot randomized, controlled, double‐blind trial of bumetanide to treat neonatal seizures. Annals of Neurology2021;89(2):327-40. [DOI: 10.1002/ana.25959] [PMID: 33201535]">Soul 2021</a>) found no difference in the proportion of infants with an abnormal background pattern in EEG during ASM treatment between phenobarbital + bumetanide and phenobarbital alone groups (RR 1.05, 95% CI 0.62 to 1.80; 43 participants; <a href="./references#CD014967-fig-0054" title="">Analysis 7.7</a>). </p> </section> <section id="CD014967-sec-0185"> <p><b>Proportion of infants with an abnormal background pattern in EEG after stopping ASM</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0186"> <p><b>Duration of hospital stay (days)</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0187"> <p><b>Proportion of infants with persistent seizures or requiring ASM(s) at discharge</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0188"> <p><b>Proportion of infants discharged on gavage feeds</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0189"> <p><b>Proportion of infants with an abnormal neurological examination at discharge</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0190"> <p><b>Proportion of infants who developed epilepsy post‐discharge</b></p> <p>The one included trial (<a href="./references#CD014967-bbs2-0015" title="SoulJS , BerginAM , StoppC , HayesB , SinghA , FortunoCR , et al, Boston Bumetanide Trial Group. A pilot randomized, controlled, double‐blind trial of bumetanide to treat neonatal seizures. Annals of Neurology2021;89(2):327-40. [DOI: 10.1002/ana.25959] [PMID: 33201535]">Soul 2021</a>) reported this outcome. We are uncertain about the effect of phenobarbital + bumetanide when compared to phenobarbital alone on the proportion of infants who developed epilepsy post‐discharge (RR 1.13, 95% CI 0.43 to 2.97; 39 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0055" title="">Analysis 7.8</a>). </p> </section> </section> </section> <section id="CD014967-sec-0191"> <h5 class="title">Lignocaine versus benzodiazepines as second‐line ASM for EEG‐confirmed neonatal seizures</h5> <p>Please see <a href="./full#CD014967-tbl-0008">summary of findings Table 8</a>. </p> <section id="CD014967-sec-0192"> <h6 class="title">Primary outcomes</h6> <section id="CD014967-sec-0193"> <p><b>Proportion of infants who achieve seizure control after the first loading dose of ASM</b></p> <p>The one included trial did not report this outcome (<a href="./references#CD014967-bbs2-0002" title="BoylanGB , RennieJM , ChorleyG , PresslerRM , FoxGF , FarrerK , et al. Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study. Neurology2004;62(3):486-8. [DOI: 10.1212/01.wnl.0000106944.59990.e6] [PMID: 14872039]">Boylan 2004</a>). </p> </section> <section id="CD014967-sec-0194"> <p><b>Proportion of infants who achieve seizure control after the maximal loading dose of ASM</b></p> <p>The one included trial (<a href="./references#CD014967-bbs2-0002" title="BoylanGB , RennieJM , ChorleyG , PresslerRM , FoxGF , FarrerK , et al. Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study. Neurology2004;62(3):486-8. [DOI: 10.1212/01.wnl.0000106944.59990.e6] [PMID: 14872039]">Boylan 2004</a>) reported this outcome. We are uncertain about the effect of lignocaine when compared to benzodiazepines as second‐line ASM on achieving seizure control after maximal loading dose of ASM (RR 8.17, 95% CI 0.52 to 128.42; 11 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0056" title="">Analysis 8.1</a>). </p> </section> <section id="CD014967-sec-0195"> <p><b>Mortality or neurodevelopmental disability at 12 months' corrected age</b></p> <p>The one included trial (<a href="./references#CD014967-bbs2-0002" title="BoylanGB , RennieJM , ChorleyG , PresslerRM , FoxGF , FarrerK , et al. Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study. Neurology2004;62(3):486-8. [DOI: 10.1212/01.wnl.0000106944.59990.e6] [PMID: 14872039]">Boylan 2004</a>) reported this outcome. We are uncertain about the effect of lignocaine when compared to benzodiazepines as second‐line ASM on mortality or neurodevelopmental disability at 18 to 24 months' corrected age (RR 1.00, 95% CI 0.71 to 1.41; 10 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0057" title="">Analysis 8.2</a>). </p> </section> </section> <section id="CD014967-sec-0196"> <h6 class="title">Secondary outcomes</h6> <section id="CD014967-sec-0197"> <p><b>Mortality before hospital discharge</b></p> <p>The one included trial (<a href="./references#CD014967-bbs2-0002" title="BoylanGB , RennieJM , ChorleyG , PresslerRM , FoxGF , FarrerK , et al. Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study. Neurology2004;62(3):486-8. [DOI: 10.1212/01.wnl.0000106944.59990.e6] [PMID: 14872039]">Boylan 2004</a>) reported this outcome. We are uncertain about the effect of lignocaine when compared to benzodiazepines as second‐line ASM on all‐cause mortality before discharge (RR 1.20, 95% CI 0.25 to 5.71; 11 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0058" title="">Analysis 8.3</a>). </p> </section> <section id="CD014967-sec-0198"> <p><b>Neurodevelopmental disability at 12 months' corrected age</b></p> <p>The one included trial (<a href="./references#CD014967-bbs2-0002" title="BoylanGB , RennieJM , ChorleyG , PresslerRM , FoxGF , FarrerK , et al. Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study. Neurology2004;62(3):486-8. [DOI: 10.1212/01.wnl.0000106944.59990.e6] [PMID: 14872039]">Boylan 2004</a>) reported this outcome. We are uncertain about the effect of lignocaine when compared to benzodiazepines as second‐line ASM on mortality or neurodevelopmental disability at 18 to 24 months' corrected age (RR 1.00, 95% CI 0.36 to 2.75; 10 participants; very low‐certainty evidence; <a href="./references#CD014967-fig-0059" title="">Analysis 8.4</a>). </p> </section> <section id="CD014967-sec-0199"> <p><b>Proportion of infants who develop cognitive impairment at two years or more</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0200"> <p><b>Seizure burden during hospitalisation</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0201"> <p><b>Proportion of infants with one or more of the adverse effects related to ASM(s) during hospitalisation</b></p> <p><i>Requirement of mechanical ventilation</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Proportion of infants who develop sedation or drowsiness</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Arrhythmias causing circulatory disturbance</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Bradycardia</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Hypotension requiring volume or inotropic support</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Shock requiring volume or inotropes</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Hepatotoxicity resulting in discontinuation of therapy</i> </p> <p>The one included trial did not report this outcome.</p> <p><i>Acute kidney injury (of any stage)</i> </p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0202"> <p><b>Proportion of infants with an abnormal background pattern in EEG during ASM treatment</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0203"> <p><b>Proportion of infants with an abnormal background pattern in EEG after stopping ASM</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0204"> <p><b>Duration of hospital stay (days)</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0205"> <p><b>Proportion of infants with persistent seizures or requiring ASM(s) at discharge</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0206"> <p><b>Proportion of infants discharged on gavage feeds</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0207"> <p><b>Proportion of infants with an abnormal neurological examination at discharge</b></p> <p>The one included trial did not report this outcome.</p> </section> <section id="CD014967-sec-0208"> <p><b>Proportion of infants who develop epilepsy post‐discharge</b></p> <p>The one included trial did not report this outcome.</p> </section> </section> </section> </section> <section id="CD014967-sec-0209"> <h4 class="title">Comparison 2: Maintenance therapy with ASM versus no maintenance therapy after achieving seizure control for clinically diagnosed neonatal seizures </h4> <p>Please see <a href="./full#CD014967-tbl-0009">summary of findings Table 9</a>. </p> <section id="CD014967-sec-0210"> <h5 class="title">Primary outcomes</h5> <section id="CD014967-sec-0211"> <h6 class="title">Proportion of infants who achieve seizure control after a single or maximal dose of the given ASM </h6> <p>These outcomes are not relevant to this comparison.</p> </section> <section id="CD014967-sec-0212"> <h6 class="title">Proportion of infants with repeat seizures before hospital discharge</h6> <p>The 'proportion of infants who achieve seizure control' was evaluated using the outcome 'proportion of infants who developed repeated seizures during hospitalisation'. Both included trials (<a href="./references#CD014967-bbs2-0006" title="JindalA , AnguranaSK , SutharR , KumarP , SundaramV . Effect of early withdrawal of phenobarbitone on the recurrence of neonatal seizures: an open-label randomized controlled trial. Epilepsy &amp; Behavior2021;117:107875. [DOI: 10.1016/j.yebeh.2021.107875] [PMID: 33706247]">Jindal 2021</a>; <a href="./references#CD014967-bbs2-0012" title="SaxenaP , SinghA , UpadhyayA , GuptaP , SharmaS , VishnubatlaS . Effect of withholding phenobarbitone maintenance in neonatal seizures: a randomized controlled trial. Indian Pediatrics2016;53(12):1069-73. [PMID: 27889710]">Saxena 2016</a>) reported this outcome. We are uncertain about the effect of maintenance therapy with ASM compared to no maintenance therapy after achieving seizure control on the incidence of recurrent seizures before hospital discharge (RR 0.76, 95% CI 0.56 to 1.01; 373 participants; very‐low certainty evidence; <a href="./references#CD014967-fig-0060" title="">Analysis 9.1</a>). </p> </section> <section id="CD014967-sec-0213"> <h6 class="title">Mortality or neurodevelopmental disability at 18 to 24 months' corrected age</h6> <p>Neither of the two included studies reported this outcome.</p> </section> </section> <section id="CD014967-sec-0214"> <h5 class="title">Secondary outcomes</h5> <section id="CD014967-sec-0215"> <h6 class="title">Mortality before hospital discharge</h6> <p>Both trials (<a href="./references#CD014967-bbs2-0006" title="JindalA , AnguranaSK , SutharR , KumarP , SundaramV . Effect of early withdrawal of phenobarbitone on the recurrence of neonatal seizures: an open-label randomized controlled trial. Epilepsy &amp; Behavior2021;117:107875. [DOI: 10.1016/j.yebeh.2021.107875] [PMID: 33706247]">Jindal 2021</a>; <a href="./references#CD014967-bbs2-0012" title="SaxenaP , SinghA , UpadhyayA , GuptaP , SharmaS , VishnubatlaS . Effect of withholding phenobarbitone maintenance in neonatal seizures: a randomized controlled trial. Indian Pediatrics2016;53(12):1069-73. [PMID: 27889710]">Saxena 2016</a>) reported this outcome. Maintenance therapy with ASM compared to no maintenance therapy may have little or no effect on all‐cause mortality before hospital discharge (RR 0.69, 95% CI 0.39 to 1.22; 373 participants; low‐certainty evidence; <a href="./references#CD014967-fig-0061" title="">Analysis 9.2</a>). </p> </section> <section id="CD014967-sec-0216"> <h6 class="title">Mortality at 18 to 24 months</h6> <p>One trial (<a href="./references#CD014967-bbs2-0012" title="SaxenaP , SinghA , UpadhyayA , GuptaP , SharmaS , VishnubatlaS . Effect of withholding phenobarbitone maintenance in neonatal seizures: a randomized controlled trial. Indian Pediatrics2016;53(12):1069-73. [PMID: 27889710]">Saxena 2016</a>) reported this outcome. Maintenance therapy with ASM compared to no maintenance therapy may have little or no effect on mortality at 18 to 24 months (RR 0.94, 95% CI 0.34 to 2.61; 111 participants; low‐certainty evidence; <a href="./references#CD014967-fig-0062" title="">Analysis 9.3</a>). </p> </section> <section id="CD014967-sec-0217"> <h6 class="title">Neurodevelopmental disability at 18 to 24 months' corrected age</h6> <p>One trial (<a href="./references#CD014967-bbs2-0012" title="SaxenaP , SinghA , UpadhyayA , GuptaP , SharmaS , VishnubatlaS . Effect of withholding phenobarbitone maintenance in neonatal seizures: a randomized controlled trial. Indian Pediatrics2016;53(12):1069-73. [PMID: 27889710]">Saxena 2016</a>) reported this outcome. Maintenance therapy with ASM compared to no maintenance therapy may have little or no effect on neurodevelopmental disability at 18 to 24 months (RR 0.89, 95% CI 0.13 to 6.12; 108 participants; low‐certainty evidence; <a href="./references#CD014967-fig-0063" title="">Analysis 9.4</a>). </p> </section> <section id="CD014967-sec-0218"> <h6 class="title">Proportion of infants who develop cognitive impairment at two years or more</h6> <p>Neither of the two included studies reported this outcome.</p> </section> <section id="CD014967-sec-0219"> <h6 class="title">Seizure burden during hospitalisation</h6> <p>Neither of the two included studies reported this outcome.</p> </section> <section id="CD014967-sec-0220"> <h6 class="title">Proportion of infants with one or more of the adverse effects related to ASM(s) during hospitalisation </h6> <p><i>Requirement for mechanical ventilation</i> </p> <p>Data from one trial (<a href="./references#CD014967-bbs2-0006" title="JindalA , AnguranaSK , SutharR , KumarP , SundaramV . Effect of early withdrawal of phenobarbitone on the recurrence of neonatal seizures: an open-label randomized controlled trial. Epilepsy &amp; Behavior2021;117:107875. [DOI: 10.1016/j.yebeh.2021.107875] [PMID: 33706247]">Jindal 2021</a>) showed no difference in the requirement of mechanical ventilation between the two groups (RR 0.83, 95% CI 0.63 to 1.10; 221 participants; <a href="./references#CD014967-fig-0064" title="">Analysis 9.5</a>). </p> <p><i>Proportion of infants with sedation or drowsiness</i> </p> <p>Neither of the two trials reported this outcome.</p> <p><i>Arrhythmias causing circulatory disturbance</i> </p> <p>Neither of the two included studies reported this outcome.</p> <p><i>Bradycardia</i> </p> <p>Neither of the two included studies reported this outcome.</p> <p><i>Hypotension requiring volume or inotropic support</i> </p> <p>Neither of the two included studies reported this outcome.</p> <p><i>Shock requiring volume or inotropes</i> </p> <p>Meta‐analysis of data from both trials (<a href="./references#CD014967-bbs2-0006" title="JindalA , AnguranaSK , SutharR , KumarP , SundaramV . Effect of early withdrawal of phenobarbitone on the recurrence of neonatal seizures: an open-label randomized controlled trial. Epilepsy &amp; Behavior2021;117:107875. [DOI: 10.1016/j.yebeh.2021.107875] [PMID: 33706247]">Jindal 2021</a>; <a href="./references#CD014967-bbs2-0012" title="SaxenaP , SinghA , UpadhyayA , GuptaP , SharmaS , VishnubatlaS . Effect of withholding phenobarbitone maintenance in neonatal seizures: a randomized controlled trial. Indian Pediatrics2016;53(12):1069-73. [PMID: 27889710]">Saxena 2016</a>) did not show a difference in the need for inotropes between the two groups (RR 0.84, 95% CI 0.67 to 1.07; 373 participants; <a href="./references#CD014967-fig-0065" title="">Analysis 9.6</a>). </p> <p><i>Hepatotoxicity resulting in discontinuation of therapy</i> </p> <p>Neither of the two included studies reported this outcome.</p> <p><i>Acute kidney injury (of any stage)</i> </p> <p>Neither of the two included studies reported this outcome.</p> </section> <section id="CD014967-sec-0221"> <h6 class="title">Proportion of infants with an abnormal background pattern in EEG during ASM treatment</h6> <p>Neither of the two included studies reported this outcome.</p> </section> <section id="CD014967-sec-0222"> <h6 class="title">Proportion of infants with an abnormal background pattern in EEG after achieving seizure control </h6> <p>Data from one trial (<a href="./references#CD014967-bbs2-0012" title="SaxenaP , SinghA , UpadhyayA , GuptaP , SharmaS , VishnubatlaS . Effect of withholding phenobarbitone maintenance in neonatal seizures: a randomized controlled trial. Indian Pediatrics2016;53(12):1069-73. [PMID: 27889710]">Saxena 2016</a>) showed no difference in the proportion of infants with an abnormal background pattern in EEG after achieving seizure control between maintenance therapy with ASM and no maintenance therapy groups (RR 0.76, 95% CI 0.30 to 1.97; 118 participants; <a href="./references#CD014967-fig-0066" title="">Analysis 9.7</a>). </p> </section> <section id="CD014967-sec-0223"> <h6 class="title">Duration of hospital stay (days)</h6> <p>Meta‐analysis of data from both trials (<a href="./references#CD014967-bbs2-0006" title="JindalA , AnguranaSK , SutharR , KumarP , SundaramV . Effect of early withdrawal of phenobarbitone on the recurrence of neonatal seizures: an open-label randomized controlled trial. Epilepsy &amp; Behavior2021;117:107875. [DOI: 10.1016/j.yebeh.2021.107875] [PMID: 33706247]">Jindal 2021</a>; <a href="./references#CD014967-bbs2-0012" title="SaxenaP , SinghA , UpadhyayA , GuptaP , SharmaS , VishnubatlaS . Effect of withholding phenobarbitone maintenance in neonatal seizures: a randomized controlled trial. Indian Pediatrics2016;53(12):1069-73. [PMID: 27889710]">Saxena 2016</a>) did not show a difference in the duration of hospital stay between maintenance therapy with ASM and no maintenance therapy groups (MD 0.13, 95% CI ‐0.44 to 0.70; 373 participants; <a href="./references#CD014967-fig-0067" title="">Analysis 9.8</a>). </p> </section> <section id="CD014967-sec-0224"> <h6 class="title">Proportion of infants with persistent seizures or requiring ASM(s) at discharge</h6> <p>Data from one trial (<a href="./references#CD014967-bbs2-0006" title="JindalA , AnguranaSK , SutharR , KumarP , SundaramV . Effect of early withdrawal of phenobarbitone on the recurrence of neonatal seizures: an open-label randomized controlled trial. Epilepsy &amp; Behavior2021;117:107875. [DOI: 10.1016/j.yebeh.2021.107875] [PMID: 33706247]">Jindal 2021</a>), showed no difference in the proportion of infants with persistent seizures or requiring ASM(s) at discharge between the two groups (RR 1.33, 95% CI 0.98 to 1.80; 221 participants; <a href="./references#CD014967-fig-0068" title="">Analysis 9.9</a>). </p> </section> <section id="CD014967-sec-0225"> <h6 class="title">Proportion of infants discharged on gavage feeds</h6> <p>Neither of the two included studies reported this outcome.</p> </section> <section id="CD014967-sec-0226"> <h6 class="title">Proportion of infants with an abnormal neurological examination at discharge</h6> <p>Meta‐analysis of data from both trials (<a href="./references#CD014967-bbs2-0006" title="JindalA , AnguranaSK , SutharR , KumarP , SundaramV . Effect of early withdrawal of phenobarbitone on the recurrence of neonatal seizures: an open-label randomized controlled trial. Epilepsy &amp; Behavior2021;117:107875. [DOI: 10.1016/j.yebeh.2021.107875] [PMID: 33706247]">Jindal 2021</a>; <a href="./references#CD014967-bbs2-0012" title="SaxenaP , SinghA , UpadhyayA , GuptaP , SharmaS , VishnubatlaS . Effect of withholding phenobarbitone maintenance in neonatal seizures: a randomized controlled trial. Indian Pediatrics2016;53(12):1069-73. [PMID: 27889710]">Saxena 2016</a>) did not show a difference in the proportion of infants with an abnormal neurological examination at discharge between the two groups (RR 0.88, 95% CI 0.62 to 1.26; 373 participants; <a href="./references#CD014967-fig-0069" title="">Analysis 9.10</a>). </p> </section> <section id="CD014967-sec-0227"> <h6 class="title">Proportion of infants who develop epilepsy post‐discharge</h6> <p>One trial (<a href="./references#CD014967-bbs2-0012" title="SaxenaP , SinghA , UpadhyayA , GuptaP , SharmaS , VishnubatlaS . Effect of withholding phenobarbitone maintenance in neonatal seizures: a randomized controlled trial. Indian Pediatrics2016;53(12):1069-73. [PMID: 27889710]">Saxena 2016</a>) reported this outcome. Maintenance therapy with ASM compared to no maintenance therapy may have little or no effect on the proportion of infants who develop epilepsy post‐discharge (RR 3.18, 95% CI 0.69 to 14.72; 126 participants; low certainty evidence; <a href="./references#CD014967-fig-0070" title="">Analysis 9.11</a>). </p> </section> </section> </section> <section id="CD014967-sec-0228"> <h4 class="title">Comparison 3: Treatment of both clinical and electrographic seizures versus treatment of clinical seizures alone in neonates </h4> <p>Please see <a href="./full#CD014967-tbl-0010">summary of findings Table 10</a>. </p> <section id="CD014967-sec-0229"> <h5 class="title">Primary outcomes</h5> <section id="CD014967-sec-0230"> <h6 class="title">Proportion of infants who achieve seizure control after the first or maximal dose of the given ASM </h6> <p>This outcome is not relevant to this comparison.</p> </section> <section id="CD014967-sec-0231"> <h6 class="title">Seizure burden during hospitalisation</h6> <p>The 'proportion of infants who achieve seizure control' was evaluated using the outcome 'seizure burden'. (See <a href="#CD014967-sec-0277">Differences between protocol and review</a>). </p> <p>Both trials (<a href="./references#CD014967-bbs2-0016" title="SrinivasakumarP , ZempelJ , TrivediS , WallendorfM , RaoR , SmithB , et al. Treating EEG seizures in hypoxic ischemic encephalopathy: a randomized controlled trial. Pediatrics2015;136(5):e1302-9. [DOI: 10.1542/peds.2014-3777] [PMID: 26482675]">Srinivasakumar 2015</a>; <a href="./references#CD014967-bbs2-0018" title="Van RooijLG , ToetMC , Van HuffelenAC , GroenendaalF , LaanW , ZecicA , et al. Effect of treatment of subclinical neonatal seizures detected with aEEG: randomized, controlled trial. Pediatrics2010;125(2):e358-e66. [DOI: 10.1542/peds.2009-0136] [PMID: 20100767]">Van Rooji 2010</a>) reported this outcome. Treatment of both clinical and electrographic seizures when compared to treatment of clinical seizures alone may have little or no effect on all‐cause mortality before hospital discharge (MD ‐1871.16, 95% CI ‐4525.05 to 782.73; 68 participants; low‐certainty evidence; <a href="./references#CD014967-fig-0071" title="">Analysis 10.1</a>). </p> </section> <section id="CD014967-sec-0232"> <h6 class="title">Mortality or neurodevelopmental disability at 18 to 24 months' corrected age</h6> <p>Neither of the two trials (<a href="./references#CD014967-bbs2-0016" title="SrinivasakumarP , ZempelJ , TrivediS , WallendorfM , RaoR , SmithB , et al. Treating EEG seizures in hypoxic ischemic encephalopathy: a randomized controlled trial. Pediatrics2015;136(5):e1302-9. [DOI: 10.1542/peds.2014-3777] [PMID: 26482675]">Srinivasakumar 2015</a>; <a href="./references#CD014967-bbs2-0018" title="Van RooijLG , ToetMC , Van HuffelenAC , GroenendaalF , LaanW , ZecicA , et al. Effect of treatment of subclinical neonatal seizures detected with aEEG: randomized, controlled trial. Pediatrics2010;125(2):e358-e66. [DOI: 10.1542/peds.2009-0136] [PMID: 20100767]">Van Rooji 2010</a>) that compared ASM treatment for only‐electrographic seizures versus no ASM treatment reported this outcome. </p> </section> </section> <section id="CD014967-sec-0233"> <h5 class="title">Secondary outcomes</h5> <section id="CD014967-sec-0234"> <h6 class="title">Mortality before hospital discharge</h6> <p>Both trials (<a href="./references#CD014967-bbs2-0016" title="SrinivasakumarP , ZempelJ , TrivediS , WallendorfM , RaoR , SmithB , et al. Treating EEG seizures in hypoxic ischemic encephalopathy: a randomized controlled trial. Pediatrics2015;136(5):e1302-9. [DOI: 10.1542/peds.2014-3777] [PMID: 26482675]">Srinivasakumar 2015</a>; <a href="./references#CD014967-bbs2-0018" title="Van RooijLG , ToetMC , Van HuffelenAC , GroenendaalF , LaanW , ZecicA , et al. Effect of treatment of subclinical neonatal seizures detected with aEEG: randomized, controlled trial. Pediatrics2010;125(2):e358-e66. [DOI: 10.1542/peds.2009-0136] [PMID: 20100767]">Van Rooji 2010</a>) reported this outcome. Treatment of both clinical and electrographic seizures when compared to treatment of clinical seizures alone may have little or no effect on all‐cause mortality before hospital discharge (RR 0.59, 95% CI 0.28 to 1.27; 68 participants; low‐certainty evidence; <a href="./references#CD014967-fig-0072" title="">Analysis 10.2</a>). </p> </section> <section id="CD014967-sec-0235"> <h6 class="title">Neurodevelopmental disability at 18 to 24 months corrected age</h6> <p>Neither of the two trials reported this outcome.</p> </section> <section id="CD014967-sec-0236"> <h6 class="title">Proportion of infants who develop cognitive impairment at two years or more</h6> <p>Neither of the two trials reported this outcome.</p> </section> <section id="CD014967-sec-0237"> <h6 class="title">Proportion of infants with one or more of the adverse effects related to ASM(s) during hospitalisation </h6> <p><i>Requirement for mechanical ventilation</i> </p> <p>Neither of the two trials reported this outcome.</p> <p><i>Proportion of infants with sedation or drowsiness</i> </p> <p>Neither of the two trials reported this outcome.</p> <p><i>Arrhythmias causing circulatory disturbance</i> </p> <p>Neither of the two trials reported this outcome.</p> <p><i>Bradycardia</i> </p> <p>Neither of the two trials reported this outcome.</p> <p><i>Hypotension requiring volume or inotropic support</i> </p> <p>Neither of the two trials reported this outcome.</p> <p><i>Shock requiring volume or inotropes</i> </p> <p>Neither of the two trials reported this outcome.</p> <p><i>Hepatotoxicity resulting in discontinuation of therapy</i> </p> <p>Neither of the two trials reported this outcome.</p> <p><i>Acute kidney injury (of any stage)</i> </p> <p>Neither of the two trials reported this outcome.</p> </section> <section id="CD014967-sec-0238"> <h6 class="title">Proportion of infants with an abnormal background pattern in EEG during ASM treatment</h6> <p>Neither of the two trials reported this outcome.</p> </section> <section id="CD014967-sec-0239"> <h6 class="title">Proportion of infants with an abnormal background pattern in EEG after stopping the ASM </h6> <p>Neither of the two trials reported this outcome.</p> </section> <section id="CD014967-sec-0240"> <h6 class="title">Duration of hospital stay (days)</h6> <p>Neither of the two trials reported this outcome.</p> </section> <section id="CD014967-sec-0241"> <h6 class="title">Proportion of infants with persistent seizures or requiring ASM(s) at discharge</h6> <p>Neither of the two trials reported this outcome.</p> </section> <section id="CD014967-sec-0242"> <h6 class="title">Proportion of infants discharged on gavage feeds</h6> <p>Neither of the two trials reported this outcome.</p> </section> <section id="CD014967-sec-0243"> <h6 class="title">Proportion of infants with an abnormal neurological examination at discharge</h6> <p>Neither of the two trials reported this outcome.</p> </section> <section id="CD014967-sec-0244"> <h6 class="title">Proportion of infants who develop epilepsy post‐discharge</h6> <p>One trial (<a href="./references#CD014967-bbs2-0016" title="SrinivasakumarP , ZempelJ , TrivediS , WallendorfM , RaoR , SmithB , et al. Treating EEG seizures in hypoxic ischemic encephalopathy: a randomized controlled trial. Pediatrics2015;136(5):e1302-9. [DOI: 10.1542/peds.2014-3777] [PMID: 26482675]">Srinivasakumar 2015</a>) reported this outcome. Treatment of both clinical and electrographic seizures when compared to treatment of clinical seizures alone may have little or no effect on the proportion of infants who developed epilepsy post‐discharge between the two groups (RR 0.75, 95% CI 0.12 to 4.73; 35 participants; low‐certainty evidence; <a href="./references#CD014967-fig-0073" title="">Analysis 10.3</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD014967-sec-0245" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD014967-sec-0245"></div> <section id="CD014967-sec-0246"> <h3 class="title" id="CD014967-sec-0246">Summary of main results</h3> <p>We included a total of 18 trials (1342 infants) in this systematic review.</p> <p>We included 14 trials for the comparison of one ASM versus an alternative ASM for the treatment of neonatal seizures (<a href="./references#CD014967-bbs2-0001" title="AkeelNE , SulimanHA , Al-ShokaryAH , IbrahimAO , KamalNM , AbdelgalilAA , et al. A comparative study of levetiracetam and phenobarbital for neonatal seizures as a first line treatment. Global Pediatric Health2022;9:2333794X221143572. [DOI: 10.1177/2333794X221143572] [PMID: 36578326]">Akeel 2022</a>; <a href="./references#CD014967-bbs2-0002" title="BoylanGB , RennieJM , ChorleyG , PresslerRM , FoxGF , FarrerK , et al. Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study. Neurology2004;62(3):486-8. [DOI: 10.1212/01.wnl.0000106944.59990.e6] [PMID: 14872039]">Boylan 2004</a>; <a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>; <a href="./references#CD014967-bbs2-0004" title="GhaffarJ , RiazA , Uzair, VirkAO , BhattiA . Comparative efficacy of intravenous levetiracetam vs phenobarbitone in neonatal seizures. Medical Forum2020;31(7):25-8. [WEBSITE: medforum.pk/article/6-comparative-efficacy-of-intravenous-levetiracetam-vs-phenobarbitone-in-neonatal-seizures]">Ghaffar 2020</a>; <a href="./references#CD014967-bbs2-0005" title="GowdaVK , RomanaA , ShivannaNH , BenakappaN , BenakappaA . Levetiracetam versus phenobarbitone in neonatal seizures — a randomized controlled trial. Indian Pediatrics2019;56(8):643-6. [PMID: 31477643]">Gowda 2019</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>; <a href="./references#CD014967-bbs2-0008" title="PainterMJ , ScherMS , SteinAD , ArmattiS , WangZ , GardinerJC , et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine1999;341(7):485-9. [DOI: 10.1056/NEJM199908123410704] [PMID: 10441604]ScherMS , AlvinJ , GausL , MinnighB , PainterMJ . Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology2003;28(4):277-80. [DOI: 10.1016/s0887-8994(02)00621-5] [PMID: 12849880]">Painter 1999</a>; <a href="./references#CD014967-bbs2-0009" title="PathakG , UpadhyayA , PathakU , ChawlaD , GoelSP . Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial. Indian Pediatrics2013;50(8):753-7. [DOI: 10.1007/s13312-013-0218-6] [PMID: 23502660]">Pathak 2013</a>; <a href="./references#CD014967-bbs2-0010" title="PerveenS , SinghA , UpadhyayA , SinghN , ChauhanR . A randomized controlled trial on comparison of phenobarbitone and levetiracetam for the treatment of neonatal seizures: pilot study. International Journal of Research in Medical Sciences2016;4(6):2073-8. [DOI: 10.18203/2320-6012.ijrms20161763] [URL: msjonline.org/index.php/ijrms/article/view/865/836]">Perveen 2016</a>; <a href="./references#CD014967-bbs2-0011" title="PrakashA , RichaR , SahniGS . Neonatal seizures – levetiracetam versus phenobarbital. Indian Journal of Child Health2019;6(11):605-8. [DOI: 10.32677/IJCH.2019.v06.i11.008]">Prakash 2019</a>; <a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>; <a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>; <a href="./references#CD014967-bbs2-0015" title="SoulJS , BerginAM , StoppC , HayesB , SinghA , FortunoCR , et al, Boston Bumetanide Trial Group. A pilot randomized, controlled, double‐blind trial of bumetanide to treat neonatal seizures. Annals of Neurology2021;89(2):327-40. [DOI: 10.1002/ana.25959] [PMID: 33201535]">Soul 2021</a>; <a href="./references#CD014967-bbs2-0017" title="SusnerwalaS , JoshiA , DeshmukhL , LondheA . Levetiracetam or phenobarbitone as a first-line anticonvulsant in asphyxiated term newborns? An open-label, single-center, randomized, controlled, pragmatic trial. Hospital Pediatrics2022;12(7):647-52. [DOI: 10.1542/hpeds.2021-006415] [PMID: 35673948]">Susnerwala 2022</a>). Amongst these, nine trials (<a href="./references#CD014967-bbs2-0001" title="AkeelNE , SulimanHA , Al-ShokaryAH , IbrahimAO , KamalNM , AbdelgalilAA , et al. A comparative study of levetiracetam and phenobarbital for neonatal seizures as a first line treatment. Global Pediatric Health2022;9:2333794X221143572. [DOI: 10.1177/2333794X221143572] [PMID: 36578326]">Akeel 2022</a>; <a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>; <a href="./references#CD014967-bbs2-0004" title="GhaffarJ , RiazA , Uzair, VirkAO , BhattiA . Comparative efficacy of intravenous levetiracetam vs phenobarbitone in neonatal seizures. Medical Forum2020;31(7):25-8. [WEBSITE: medforum.pk/article/6-comparative-efficacy-of-intravenous-levetiracetam-vs-phenobarbitone-in-neonatal-seizures]">Ghaffar 2020</a>; <a href="./references#CD014967-bbs2-0005" title="GowdaVK , RomanaA , ShivannaNH , BenakappaN , BenakappaA . Levetiracetam versus phenobarbitone in neonatal seizures — a randomized controlled trial. Indian Pediatrics2019;56(8):643-6. [PMID: 31477643]">Gowda 2019</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>; <a href="./references#CD014967-bbs2-0010" title="PerveenS , SinghA , UpadhyayA , SinghN , ChauhanR . A randomized controlled trial on comparison of phenobarbitone and levetiracetam for the treatment of neonatal seizures: pilot study. International Journal of Research in Medical Sciences2016;4(6):2073-8. [DOI: 10.18203/2320-6012.ijrms20161763] [URL: msjonline.org/index.php/ijrms/article/view/865/836]">Perveen 2016</a>; <a href="./references#CD014967-bbs2-0011" title="PrakashA , RichaR , SahniGS . Neonatal seizures – levetiracetam versus phenobarbital. Indian Journal of Child Health2019;6(11):605-8. [DOI: 10.32677/IJCH.2019.v06.i11.008]">Prakash 2019</a>; <a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>; <a href="./references#CD014967-bbs2-0017" title="SusnerwalaS , JoshiA , DeshmukhL , LondheA . Levetiracetam or phenobarbitone as a first-line anticonvulsant in asphyxiated term newborns? An open-label, single-center, randomized, controlled, pragmatic trial. Hospital Pediatrics2022;12(7):647-52. [DOI: 10.1542/hpeds.2021-006415] [PMID: 35673948]">Susnerwala 2022</a>) compared phenobarbital versus levetiracetam as first‐line ASM; two trials (<a href="./references#CD014967-bbs2-0008" title="PainterMJ , ScherMS , SteinAD , ArmattiS , WangZ , GardinerJC , et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine1999;341(7):485-9. [DOI: 10.1056/NEJM199908123410704] [PMID: 10441604]ScherMS , AlvinJ , GausL , MinnighB , PainterMJ . Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology2003;28(4):277-80. [DOI: 10.1016/s0887-8994(02)00621-5] [PMID: 12849880]">Painter 1999</a>; <a href="./references#CD014967-bbs2-0009" title="PathakG , UpadhyayA , PathakU , ChawlaD , GoelSP . Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial. Indian Pediatrics2013;50(8):753-7. [DOI: 10.1007/s13312-013-0218-6] [PMID: 23502660]">Pathak 2013</a>) compared phenobarbital versus phenytoin as first‐line ASM; one three‐armed trial (<a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>) compared phenobarbital versus phenytoin versus lorazepam as first‐line ASM; one trial (<a href="./references#CD014967-bbs2-0015" title="SoulJS , BerginAM , StoppC , HayesB , SinghA , FortunoCR , et al, Boston Bumetanide Trial Group. A pilot randomized, controlled, double‐blind trial of bumetanide to treat neonatal seizures. Annals of Neurology2021;89(2):327-40. [DOI: 10.1002/ana.25959] [PMID: 33201535]">Soul 2021</a>) compared phenobarbital+bumetanide versus phenobarbital alone and one trial (<a href="./references#CD014967-bbs2-0002" title="BoylanGB , RennieJM , ChorleyG , PresslerRM , FoxGF , FarrerK , et al. Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study. Neurology2004;62(3):486-8. [DOI: 10.1212/01.wnl.0000106944.59990.e6] [PMID: 14872039]">Boylan 2004</a>), compared lignocaine versus benzodiazepines as second‐line ASM. </p> <p>One trial (<a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>) compared phenobarbital versus levetiracetam as first‐line ASM in EEG‐confirmed neonatal seizures. Phenobarbital is probably more effective than levetiracetam in achieving seizure control after the first loading dose (RR 2.32, 95% CI 1.63 to 3.30; 106 participants; moderate‐certainty evidence). Similarly, phenobarbital is probably more effective than levetiracetam in achieving seizure control after the maximal loading dose (RR 2.83, 95% CI 1.78 to 4.50; 106 participants; moderate‐certainty evidence). However, we are uncertain about the effect of phenobarbital when compared to levetiracetam on other outcomes such as mortality before hospital discharge (RR 0.30, 95% CI 0.04 to 2.52; 106 participants; very low‐certainty evidence); the requirement for mechanical ventilation (RR 1.21, 95% CI 0.76 to 1.91; 106 participants; very low‐certainty evidence); sedation or drowsiness (RR 1.74, 95% CI 0.68 to 4.44; 106 participants; very low‐certainty evidence); and proportion of infants with epilepsy post‐discharge (RR 0.92, 95% CI 0.48 to 1.76; 106 participants; very low‐certainty evidence). We did not find any data on the impact of phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed seizures on important long‐term outcomes such as mortality or neurodevelopmental disability at 18 to 24 months or on cognitive impairment at two years or more. </p> <p>Eight trials (<a href="./references#CD014967-bbs2-0001" title="AkeelNE , SulimanHA , Al-ShokaryAH , IbrahimAO , KamalNM , AbdelgalilAA , et al. A comparative study of levetiracetam and phenobarbital for neonatal seizures as a first line treatment. Global Pediatric Health2022;9:2333794X221143572. [DOI: 10.1177/2333794X221143572] [PMID: 36578326]">Akeel 2022</a>; <a href="./references#CD014967-bbs2-0003" title="FalsaperlaR , MauceriL , PavoneP , BarbagalloM , VitalitiG , RuggieriM , et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behavioural Neurology2019;2019:3683548. [DOI: 10.1155/2019/3683548] [PMID: 31281546]">Falsaperla 2019</a>; <a href="./references#CD014967-bbs2-0004" title="GhaffarJ , RiazA , Uzair, VirkAO , BhattiA . Comparative efficacy of intravenous levetiracetam vs phenobarbitone in neonatal seizures. Medical Forum2020;31(7):25-8. [WEBSITE: medforum.pk/article/6-comparative-efficacy-of-intravenous-levetiracetam-vs-phenobarbitone-in-neonatal-seizures]">Ghaffar 2020</a>; <a href="./references#CD014967-bbs2-0005" title="GowdaVK , RomanaA , ShivannaNH , BenakappaN , BenakappaA . Levetiracetam versus phenobarbitone in neonatal seizures — a randomized controlled trial. Indian Pediatrics2019;56(8):643-6. [PMID: 31477643]">Gowda 2019</a>; <a href="./references#CD014967-bbs2-0007" title="KhanMT , RahmanMM , BanerjeeM , UddinMZ , NaharN , AkhterM . Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. Journal of Dhaka Medical College2020;27(2):182-9. [DOI: 10.3329/jdmc.v27i2.45831] [URL: sciencegate.app/app/document/download#10.3329/jdmc.v27i2.45831]">Khan 2020</a>; <a href="./references#CD014967-bbs2-0010" title="PerveenS , SinghA , UpadhyayA , SinghN , ChauhanR . A randomized controlled trial on comparison of phenobarbitone and levetiracetam for the treatment of neonatal seizures: pilot study. International Journal of Research in Medical Sciences2016;4(6):2073-8. [DOI: 10.18203/2320-6012.ijrms20161763] [URL: msjonline.org/index.php/ijrms/article/view/865/836]">Perveen 2016</a>; <a href="./references#CD014967-bbs2-0011" title="PrakashA , RichaR , SahniGS . Neonatal seizures – levetiracetam versus phenobarbital. Indian Journal of Child Health2019;6(11):605-8. [DOI: 10.32677/IJCH.2019.v06.i11.008]">Prakash 2019</a>; <a href="./references#CD014967-bbs2-0017" title="SusnerwalaS , JoshiA , DeshmukhL , LondheA . Levetiracetam or phenobarbitone as a first-line anticonvulsant in asphyxiated term newborns? An open-label, single-center, randomized, controlled, pragmatic trial. Hospital Pediatrics2022;12(7):647-52. [DOI: 10.1542/hpeds.2021-006415] [PMID: 35673948]">Susnerwala 2022</a>) compared phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures. We are uncertain about the efficacy of phenobarbital versus levetiracetam in achieving seizure control after the first loading dose (RR 0.69, 95% CI 0.55 to 0.86; 286 participants; very low‐certainty evidence), and seizure control after the maximal loading dose (RR 0.58, 95% CI 0.47 to 0.72; 260 participants; very low‐certainty evidence). Use of phenobarbital versus levetiracetam as first‐line ASM may have little or no effect on all‐cause mortality before discharge (RR 1.41, 95% CI 0.82 to 2.43; 452 participants; low‐certainty evidence). We are also uncertain regarding the effect of phenobarbital versus levetiracetam as first‐line ASM on other important outcomes such as requirement for mechanical ventilation (RR 2.20, 95% CI 0.50 to 9.68; 394 participants; very low‐certainty evidence); sedation or drowsiness (RR 1.88, 95% CI 0.66 to 5.37; 180 participants; very low‐certainty evidence); and proportion of infants with epilepsy post‐discharge (RR 0.50, 95% CI 0.05 to 4.94; 30 participants; very low‐certainty evidence). There were no data on important long‐term outcomes such as mortality or neurodevelopmental disability at 18 to 24 months or on cognitive impairment at two years or more. </p> <p>One trial (<a href="./references#CD014967-bbs2-0008" title="PainterMJ , ScherMS , SteinAD , ArmattiS , WangZ , GardinerJC , et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine1999;341(7):485-9. [DOI: 10.1056/NEJM199908123410704] [PMID: 10441604]ScherMS , AlvinJ , GausL , MinnighB , PainterMJ . Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology2003;28(4):277-80. [DOI: 10.1016/s0887-8994(02)00621-5] [PMID: 12849880]">Painter 1999</a>) compared phenobarbital versus phenytoin as first‐line ASM in EEG‐confirmed neonatal seizures. We are uncertain about the effect of phenobarbital versus phenytoin on achieving seizure control after the maximal dose (RR 0.97, 95% CI 0.54 to 1.72; 59 participants; very low‐certainty evidence). We did not find any data on the impact of phenobarbital versus phenytoin as first‐line ASM for EEG‐confirmed seizures on seizure control after the maximal loading dose, mortality before hospital discharge, risk of various adverse effects due to ASM, proportion of infants who develop epilepsy post‐discharge and on important long‐term outcomes such as mortality or neurodevelopmental disability at 18 to 24 months or on cognitive impairment at two years or more. </p> <p>Two trials (<a href="./references#CD014967-bbs2-0009" title="PathakG , UpadhyayA , PathakU , ChawlaD , GoelSP . Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial. Indian Pediatrics2013;50(8):753-7. [DOI: 10.1007/s13312-013-0218-6] [PMID: 23502660]">Pathak 2013</a>; <a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>) compared phenobarbital versus phenytoin as first‐line ASM in clinically diagnosed neonatal seizures. Phenobarbital may be more effective than phenytoin in achieving seizure control after the first loading dose (RR 1.92, 95% CI 1.40 to 2.64; 179 participants; low‐certainty evidence). We are uncertain regarding the effect of phenobarbital when compared to phenytoin on other outcomes such as mortality before hospital discharge (RR 1.33, 95% CI 0.79 to 2.26; 179 participants; very low‐certainty evidence); requirement for mechanical ventilation (RR 7.13, 95% CI 0.38 to 134.78; 109 participants; very low‐certainty evidence); and sedation or drowsiness (RR 23.00, 95% CI 1.41 to 375.77; 70 participants; very low‐certainty evidence). We did not find any data on the impact of phenobarbital versus phenytoin as first‐line ASM for clinically diagnosed seizures on seizure control after the maximal loading dose of ASM and on important long‐term outcomes such as mortality or neurodevelopmental disability at 18 to 24 months or on cognitive impairment at two years or more. </p> <p>One trial (<a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>) compared phenobarbital versus lorazepam as first‐line ASM in clinically diagnosed neonatal seizures. We are uncertain as to the effect of phenobarbital versus lorazepam on achieving seizure control after the first loading dose (RR 0.71, 95% CI 0.53 to 0.94; 71 participants; very low‐certainty evidence); mortality before hospital discharge (RR 1.76, 95% CI 0.79 to 3.95; 71 participants; very low‐certainty evidence); and sedation or drowsiness (RR 5.66, 95% CI 1.35 to 23.71; 71 participants; very low‐certainty evidence). We did not find any data on the impact of phenobarbital versus lorazepam as first‐line ASM for clinically diagnosed seizures on seizure control after the maximal loading dose of ASM, risk of various adverse effects due to ASM, proportion of infants who develop epilepsy post‐discharge and on important long‐term outcomes such as mortality or neurodevelopmental disability at 18 to 24 months or cognitive impairment at two years or more. </p> <p>One trial (<a href="./references#CD014967-bbs2-0014" title="SolankiDI , GohilJR , PatelAP . Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. Journal of Clinical Neonatololgy2015;4(4):232-6. [DOI: 10.4103/2249‑4847.161696]">Solanki 2015</a>) compared phenytoin versus lorazepam as first‐line ASM in clinically diagnosed neonatal seizures. We are uncertain as to the effect of phenytoin versus lorazepam on achieving seizure control after the first loading dose (RR 0.77, 95% CI 0.60 to 0.99; 71 participants; very low‐certainty evidence); mortality before hospital discharge (RR 0.44, 95% CI 0.12 to 1.57; 71 participants; very low‐certainty evidence); and sedation or drowsiness (RR 0.21, 95% CI 0.01 to 4.13; 71 participants; very low‐certainty evidence). We did not find any data on the impact of phenytoin versus lorazepam as first‐line ASM for clinically diagnosed seizures on seizure control after the maximal loading dose of ASM, risk of various adverse effects due to ASM, proportion of infants who develop epilepsy post‐discharge and on important long‐term outcomes such as mortality or neurodevelopmental disability at 18 to 24 months or cognitive impairment at two years or more. </p> <p>One trial (<a href="./references#CD014967-bbs2-0015" title="SoulJS , BerginAM , StoppC , HayesB , SinghA , FortunoCR , et al, Boston Bumetanide Trial Group. A pilot randomized, controlled, double‐blind trial of bumetanide to treat neonatal seizures. Annals of Neurology2021;89(2):327-40. [DOI: 10.1002/ana.25959] [PMID: 33201535]">Soul 2021</a>) compared phenobarbital + bumetanide versus phenobarbital alone in EEG‐confirmed neonatal seizures. Phenobarbital + bumetanide when compared to phenobarbital alone may have little or no effect on seizure control after the first loading dose (RR 0.95, 95% CI 0.37 to 2.40; 43 participants; low‐certainty evidence). We are uncertain as to the effect of phenobarbital + bumetanide versus phenobarbital alone on mortality before hospital discharge (RR 0.20, 95% CI 0.02 to 1.74; 43 participants; very low‐certainty evidence); cognitive impairment at 18 to 24 months (RR 0.53, 95% CI 0.13 to 2.15; 43 participants; very low‐certainty evidence); and proportion of infants who develop epilepsy post‐discharge (RR 1.13, 95% CI 0.43 to 2.97; 43 participants; very low‐certainty evidence). We did not find any data on the effect of phenobarbital + bumetanide versus phenobarbital alone for EEG‐confirmed seizures on seizure control after the maximal loading dose of ASM, risk of various adverse effects due to ASM, and important long‐term outcomes such as mortality or neurodevelopmental disability at 18 to 24 months. </p> <p>One trial (<a href="./references#CD014967-bbs2-0002" title="BoylanGB , RennieJM , ChorleyG , PresslerRM , FoxGF , FarrerK , et al. Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study. Neurology2004;62(3):486-8. [DOI: 10.1212/01.wnl.0000106944.59990.e6] [PMID: 14872039]">Boylan 2004</a>) compared lignocaine versus benzodiazepines as second‐line ASM in clinically diagnosed neonatal seizures. We are uncertain about the effect of lignocaine versus benzodiazepines in achieving seizure control after the maximal loading dose (RR 8.17, 95% CI 0.52 to 128.42; 11 participants; very low‐certainty evidence); mortality or neurodevelopmental disability at 12 months (RR 1.00, 95% CI 0.71 to 1.41; 10 participants; very low‐certainty evidence); all‐cause mortality before hospital discharge (RR 1.20, 95% CI 0.25 to 5.71; 11 participants; very low‐certainty evidence); and neurodevelopmental disability at 12 months (RR 1.00, 95% CI 0.36 to 2.75; 10 participants; very low‐certainty evidence). We did not find any data on the effect of lignocaine versus benzodiazepines as second‐line ASM on seizure control after the first loading dose of ASM, risk of various adverse effects due to ASM, and proportion of infants who develop epilepsy post‐discharge. </p> <p>Two trials (<a href="./references#CD014967-bbs2-0016" title="SrinivasakumarP , ZempelJ , TrivediS , WallendorfM , RaoR , SmithB , et al. Treating EEG seizures in hypoxic ischemic encephalopathy: a randomized controlled trial. Pediatrics2015;136(5):e1302-9. [DOI: 10.1542/peds.2014-3777] [PMID: 26482675]">Srinivasakumar 2015</a>; <a href="./references#CD014967-bbs2-0018" title="Van RooijLG , ToetMC , Van HuffelenAC , GroenendaalF , LaanW , ZecicA , et al. Effect of treatment of subclinical neonatal seizures detected with aEEG: randomized, controlled trial. Pediatrics2010;125(2):e358-e66. [DOI: 10.1542/peds.2009-0136] [PMID: 20100767]">Van Rooji 2010</a>) compared the treatment of both clinical and electrographic seizures versus treating clinical seizures alone in neonates. Treatment of clinical and electrographic seizures when compared to treating clinical seizures alone may have little or no effect on seizure burden during hospitalisation (MD ‐1871.16, 95% CI ‐4525.05 to 782.73; 68 participants; low‐certainty evidence); mortality before hospital discharge (RR 0.59, 95% CI 0.28 to 1.27; 68 participants; low‐certainty evidence); and proportion of infants who develop epilepsy post‐discharge (RR 0.75, 95% CI 0.12 to 4.73; 35 participants; low‐certainty evidence). We found no data on the effect of treating clinical and electrographic seizures compared to treating clinical seizures alone on adverse effects due to ASM and other important long‐term outcomes such as mortality or neurodevelopmental disability at 18 to 24 months or cognitive impairment at two years or more. </p> <p>Two trials (<a href="./references#CD014967-bbs2-0006" title="JindalA , AnguranaSK , SutharR , KumarP , SundaramV . Effect of early withdrawal of phenobarbitone on the recurrence of neonatal seizures: an open-label randomized controlled trial. Epilepsy &amp; Behavior2021;117:107875. [DOI: 10.1016/j.yebeh.2021.107875] [PMID: 33706247]">Jindal 2021</a>; <a href="./references#CD014967-bbs2-0012" title="SaxenaP , SinghA , UpadhyayA , GuptaP , SharmaS , VishnubatlaS . Effect of withholding phenobarbitone maintenance in neonatal seizures: a randomized controlled trial. Indian Pediatrics2016;53(12):1069-73. [PMID: 27889710]">Saxena 2016</a>) compared maintenance therapy with ASM versus no maintenance therapy after achieving seizure control in neonatal seizures. We are uncertain about the effect of maintenance therapy with ASM versus no maintenance therapy on the recurrence of seizures before hospital discharge (RR 0.76, 95% CI 0.56 to 1.01; 373 participants; very low‐certainty evidence). Maintenance therapy with ASM compared to no maintenance therapy may have little or no effect on mortality before hospital discharge (RR 0.69, 95% CI 0.39 to 1.22; 373 participants; low‐certainty evidence); mortality by 18 to 24 months (RR 0.94, 95% CI 0.34 to 2.61; 111 participants; low‐certainty evidence); neurodevelopmental disability by 18 to 24 months (RR 0.89, 95% CI 0.13 to 6.12; 108 participants; low‐certainty evidence);‐and proportion of infants with epilepsy post discharge (RR 3.18, 95% CI 0.69 to 14.72; 126 participants; low‐certainty evidence). </p> </section> <section id="CD014967-sec-0247"> <h3 class="title" id="CD014967-sec-0247">Overall completeness and applicability of evidence</h3> <p>Phenobarbital is probably more effective than levetiracetam as first‐line ASM in achieving seizure control in neonates with EEG‐confirmed seizures after both the first loading dose and the maximal loading dose of ASM (moderate‐certainty evidence). Phenobarbital may be more effective than phenytoin as first‐line ASM in achieving seizure control in clinically diagnosed seizures after the first loading dose of ASM (low‐certainty evidence). Phenobarbital + bumetanide may have little or no difference in achieving seizure control when compared to phenobarbital alone in EEG‐confirmed seizures (low‐certainty evidence). These results apply to term and late preterm neonates who have seizures due to any aetiology other than hypoglycaemia and hypocalcaemia. None of the included studies had recruited preterm neonates born at &lt; 34 weeks' gestational age. Hence, the results cannot be used for this preterm population. For other comparisons of one ASM versus another to achieve seizure control, limited data and very low‐certainty evidence preclude us from drawing any reasonable conclusions. </p> <p>We are uncertain as to the effect of one ASM versus another on other short‐term outcomes including mortality before hospital discharge. Most of the trials have included neonates who required other ASMs as well for seizure control. Hence, all the short‐ and long‐term outcomes other than seizure control would have been influenced by other ASMs as well. We did not analyse monotherapy and polytherapy separately due to the non‐availability of adequate data. Most trials did not provide data on long‐term outcomes such as mortality, neurodevelopmental disability or cognitive impairment. As the long‐term neurodevelopmental outcomes are the major determinant for the choice of ASM, the lack of data on long‐term outcomes is a major drawback in interpreting the results of this review. </p> <p>It is well recognised that detection of neonatal seizures on a clinical observation basis alone is unreliable because most infants have only subtle clinical manifestations which are often missed in a clinical setting. In addition, clinical diagnosis has poor diagnostic accuracy as clinical behaviours are often misinterpreted as seizures (<a href="./references#CD014967-bbs2-0126" title="MurrayDM , BoylanGB , AliI , RyanCA , MurphyBP , ConnollyS . Defining the gap between electrographic seizure burden, clinical expression and staff recognition of neonatal seizures. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(3):F187-91. [DOI: 10.1136/adc.2005.086314] [PMID: 17626147]">Murray 2008</a>). In fact, one study revealed that even experts only correctly diagnosed 50% of events if relying on clinical observation only (<a href="./references#CD014967-bbs2-0118" title="MaloneA , RyanCA , FitzgeraldA , BurgoyneL , ConnollyS , BoylanGB . Interobserver agreement in neonatal seizure identification. Epilepsia2009;50(9):2097-101. [DOI: 10.1111/j.1528-1167.2009.02132.x] [PMID: 19490044]">Malone 2009</a>). It is also known that many seizures are electrographic‐only or subclinical, particularly after treatment with some types of ASM which are known to induce uncoupling (<a href="./references#CD014967-bbs2-0078" title="BoylanGB , RennieJM , PresslerRM , WilsonG , MortonM , BinnieCD . Phenobarbitone, neonatal seizures, and video-EEG. Archives of Disease in Childhood. Fetal and Neonatal Edition2002;86(3):F165-170. [DOI: 10.1136/fn.86.3.f165] [PMID: 11978746]">Boylan 2002</a>;<a href="./references#CD014967-bbs2-0100" title="HahnCD , RivielloJJ . Neonatal seizures and EEG: electroclinical dissociation and uncoupling. NeoReviews2004;5(8):e350-e5. [DOI: 10.1542/neo.5-8-e350]">Hahn 2004</a>; <a href="./references#CD014967-bbs2-0144" title="ScherMS , AlvinJ , GausL , MinnighB , PainterMJ . Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology2003;28(4):277-80. [DOI: 10.1016/s0887-8994(02)00621-5] [PMID: 12849880]">Scher 2003</a>). Electrographic seizures are also the most common seizure type in critical neonates as they are often on sedation, pain relief or muscle relaxation. In order for clinical trials to be meaningful and transferable, it is essential that outcome measures are well‐defined and can be measured accurately and precisely (<a href="./references#CD014967-bbs2-0102" title="HeneghanC , GoldacreB , MahtaniKR . Why clinical trial outcomes fail to translate into benefits for patients. Trials2017;18(1):122. [DOI: 10.1186/s13063-017-1870-2] [PMID: 28288676]">Heneghan 2017</a>). For the reasons outlined above, clinical diagnosis of seizures is neither. Thus, trials using clinical diagnosis should not be used for licencing ASM or to inform clinical guidelines or recommendations. Hence, the conclusions of this review are based on trials that used EEG‐confirmed seizures. </p> <p>Treatment of both clinical and electrographic seizures, when compared with treating clinical seizures alone, may have little or no effect on mortality before hospital discharge, seizure burden during hospitalisation, and the proportion of infants who develop epilepsy post‐discharge (low‐certainty evidence). Since both the trials included only neonates with HIE, the results are applicable only to this subgroup. There were no data on long‐term mortality or neurodevelopmental outcomes. </p> <p>Short‐term maintenance therapy with ASM after achieving seizure control when compared to no maintenance ASM may have little or no effect on mortality before hospital discharge, mortality by 18 to 24 months, neurodevelopmental disability by 18 to 24 months, and the proportion of infants with epilepsy post‐discharge (low‐certainty evidence). Both trials included only those neonates who achieved seizure control after the first loading dose of phenobarbital. Hence, the results do not apply to neonates who require more than one ASM for seizure control. </p> </section> <section id="CD014967-sec-0248"> <h3 class="title" id="CD014967-sec-0248">Quality of the evidence</h3> <p>For the comparison, phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures, the certainty of evidence was moderate for the outcomes: seizure control after first loading dose of ASM and seizure control after maximal loading dose of ASM (downgraded by one level for serious imprecision due to the small size not meeting the 'Optimal Information Size' criteria); and the certainty of evidence was very low for the outcomes: mortality before hospital discharge, requirement of mechanical ventilation, sedation or drowsiness, and proportion of infants with epilepsy post‐discharge (downgraded by one level for indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs as well and by two levels for very serious imprecision due to a wide confidence interval crossing the line of no difference, and sample size and event rate not meeting the 'Optimal Information Size' criteria). </p> <p>For the comparison, phenobarbital versus levetiracetam as first‐line ASM for clinically diagnosed neonatal seizures, the certainty of evidence was very low for the outcomes: seizure control after first loading dose of ASM (downgraded by two levels for very serious risk of bias due to 'high risk of bias' in two trials and some concerns in the other trial and by one level for serious imprecision due to small sample size not meeting the 'Optimal Information Size' criterion); seizure control after maximal loading dose of ASM (downgraded by two levels for very serious risk of bias due to high risk of bias in all the three included trials and by one level for serious imprecision due to small sample size not meeting the 'Optimal Information Size' criterion); requirement of mechanical ventilation (downgraded by two levels for very serious imprecision due to a single digit event rate and by one level for serious indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs as well); sedation or drowsiness (downgraded by two levels for very serious risk of bias due to high risk of bias in all included trials, and by one level for serious inconsistency, serious imprecision and serious indirectness); and proportion of infants with epilepsy post‐discharge (downgraded by two levels for very serious risk of bias due to high risk of bias in the only included trial and for very serious imprecision). The certainty of evidence was low for mortality before hospital discharge (downgraded by one level for serious indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs as well and by one level for serious imprecision due to a low event rate not meeting the 'Optimal Information Size' criteria). </p> <p>For the comparison, phenobarbital versus phenytoin as first‐line ASM for EEG‐confirmed neonatal seizures, the certainty of evidence was very low for the outcome: seizure control after maximal loading dose of ASM (downgraded by two levels for very serious risk of bias due to high risk of bias in the only included trial and by two levels for very serious imprecision due to a wide confidence interval crossing the line of no difference, and sample size and event rate not meeting the 'Optimal Information Size' criteria). </p> <p>For the comparison, phenobarbital versus phenytoin as first‐line ASM for clinically diagnosed neonatal seizures, the certainty of evidence was low for the outcome: seizure control after the first loading dose of ASM (downgraded by one level for serious risk of bias as the trial contributing &gt; 50% weighting to the estimate has a high risk of overall bias and by one level for serious inconsistency as there was considerable heterogeneity (I<sup>2</sup> = 96%)). The certainty of evidence was very low for mortality before hospital discharge (downgraded by one level for serious inconsistency as there was substantial heterogeneity (I<sup>2</sup> = 82%); by one level for serious indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs as well; and by one level for serious imprecision for sample size and event rate not meeting the 'Optimal Information Size' criteria); requirement for mechanical ventilation (downgraded by one level for serious indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs as well; and by two levels for very serious imprecision due to wide confidence interval crossing the line of no difference, and sample size and event rate not meeting the 'Optimal Information Size' criteria); sedation or drowsiness (downgraded by one level for serious indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs as well; by two levels for very serious imprecision due to wide confidence interval crossing the line of no difference, and sample size and event rate not meeting the 'Optimal Information Size' criteria; and by two levels for very serious risk of bias due to high risk of bias in the only included trial). </p> <p>For the comparison, phenobarbital versus lorazepam as first‐line ASM for clinically diagnosed neonatal seizures, the certainty of evidence was very low for all the outcomes: seizure control after the first loading dose of ASM (downgraded by two levels for very serious risk of bias due to high risk of bias in the only included trial and by one level for serious imprecision for sample size and event rate not meeting the 'Optimal Information Size' criteria); mortality before hospital discharge; and sedation or drowsiness (downgraded by two levels for very serious risk of bias due to high risk of bias in the only included trial, by one level for serious indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs, as well and by two levels for very serious imprecision due to wide confidence interval crossing the line of no difference, and sample size and event rate not meeting the 'Optimal Information Size' criteria). </p> <p>For the comparison, phenytoin versus lorazepam as first‐line ASM for clinically diagnosed neonatal seizures, the certainty of evidence was very low for all the outcomes: seizure control after the first loading dose of ASM (downgraded by two levels for very serious risk of bias due to high risk of bias in the only included trial and by one level for serious imprecision for sample size and event rate not meeting the 'Optimal Information Size' criteria); mortality before hospital discharge; and sedation or drowsiness (downgraded by two levels for very serious risk of bias due to high risk of bias in the only included trial, by one level for serious indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs as well and by two levels for very serious imprecision due to a wide confidence interval crossing the line of no difference, and sample size and event rate not meeting the 'Optimal Information Size' criteria). </p> <p>For the comparison, phenobarbital + bumetanide versus phenobarbital alone for EEG‐confirmed neonatal seizures, the certainty of evidence was low for the outcome: seizure control after the first loading dose of ASM (downgraded by two levels for very serious imprecision due to a wide confidence interval crossing the line of no difference, and sample size and event rate not meeting the 'Optimal Information Size' criteria); and very low for the outcomes: mortality before hospital discharge, cognitive impairment at 18 to 24 months and proportion of infants with epilepsy post‐discharge (downgraded by two levels for very serious imprecision due to a wide confidence interval crossing the line of no difference, and sample size and event rate not meeting the 'Optimal Information Size' criteria, and by one level for serious indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs, as well). </p> <p>For the comparison, lignocaine versus benzodiazepines as second‐line ASM for EEG‐confirmed neonatal seizures, the certainty of evidence was very low for all the outcomes: seizure control after maximal loading dose of ASM (downgraded by two levels for very serious risk of bias due to high risk of bias in the only included trial and by two levels for very serious imprecision due to a wide confidence interval crossing the line of no difference, and sample size and event rate not meeting the 'Optimal Information Size' criteria); mortality or neurodevelopmental disability at 12 months; all‐cause mortality before hospital discharge; and neurodevelopmental disability at 12 months (downgraded by two levels for very serious risk of bias due to high risk of bias in the only included trial and by two levels for very serious imprecision due to a wide confidence interval crossing the line of no difference, and sample size and event rate not meeting the 'Optimal Information Size' criteria, and by one level for serious indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs, as well). </p> <p>For the comparison, treating both clinical and electrographic seizures versus clinical seizures alone, the certainty of evidence was low for all the outcomes: mortality before hospital discharge, seizure burden during hospitalisation, and proportion of infants with epilepsy post‐discharge (downgraded by two levels for very serious imprecision due to a wide confidence interval crossing the line of no difference, and sample size and event rate not meeting the 'Optimal Information Size' criteria). </p> <p>For the comparison, maintenance therapy with ASM after achieving seizure control versus no maintenance ASM, the certainty of evidence was very low for repeat seizures before hospital discharge (downgraded by one level for risk of bias due to some concerns in the risk of bias in both the included studies, and by two levels for very serious imprecision due to a wide confidence interval crossing the line of no difference, and sample size and event rate not meeting the 'Optimal Information Size' criteria); and low for other outcomes: mortality before hospital discharge, mortality at 18 to 24 months, neurodevelopmental disability at 18 to 24 months and proportion of infants who develop epilepsy post‐discharge (downgraded by two levels for very serious imprecision due to a wide confidence interval crossing the line of no difference, and sample size and event rate not meeting the 'Optimal Information Size' criteria). </p> </section> <section id="CD014967-sec-0249"> <h3 class="title" id="CD014967-sec-0249">Potential biases in the review process</h3> <p>We performed a comprehensive search of the medical literature to identify all RCTs evaluating the role of ASMs for neonates with seizures. However, although it is unlikely that we missed large relevant studies, it is still possible that we failed to identify small studies whose results have been published in abstract proceedings or in less accessible literature. We made every effort to contact the authors of any included study asking them to provide missing data. Furthermore, some authors of the present review were inevitably already familiar with most of the included studies. </p> </section> <section id="CD014967-sec-0250"> <h3 class="title" id="CD014967-sec-0250">Agreements and disagreements with other studies or reviews</h3> <p>Other systematic reviews have previously addressed the topic of treatment of neonatal seizures. Only the previous Cochrane Review (<a href="./references#CD014967-bbs2-0077" title="BoothD , EvansDJ . Anticonvulsants for neonates with seizures. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD004218. [DOI: 10.1002/14651858.CD004218.pub2]">Booth 2004</a>), and the International League Against Epilepsy/World Health Organization (ILAE/WHO) guidelines (<a href="./references#CD014967-bbs2-0162" title="WHO. Guidelines on neonatal seizures. who.int/bitstream/handle/10665/77756/9789241548304_eng.pdf2011. [AVAILABLE FROM: apps.who.int/iris/bitstream/handle/10665/77756/9789241548304_eng.pdf;sequence=1]">WHO 2011</a>) adopted a similar comprehensive approach as our review. Both these previous reviews included only studies on EEG‐confirmed seizures. They concluded that phenobarbital is the recommended ASM in neonates, but the certainty of evidence was very low. Such a discrepancy in certainty of evidence is due to the inclusion of the recently published NEOLEV2 study (<a href="./references#CD014967-bbs2-0013" title="SharpeC , ReinerGE , DavisSL , NespecaM , GoldJJ , RasmussenM , et al, NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics2020;145(6):e20193182. [DOI: 10.1542/peds.2019-3182] [PMID: 32385134]">Sharpe 2020</a>) in our review. Other systematic reviews were limited to a literature search and, although they limited their search to EEG‐confirmed seizures, they did not synthesise results with meta‐analysis (<a href="./references#CD014967-bbs2-0092" title="FalsaperlaR , ScaliaB , GiugnoA , PavoneP , MottaM , CaccamoM , et al. Treating the symptom or treating the disease in neonatal seizures: a systematic review of the literature. Italian Journal of Pediatrics2021;47(1):85. [DOI: 10.1186/s13052-021-01027-2] [PMID: 33827647]">Falsaperla 2021</a>; <a href="./references#CD014967-bbs2-0101" title="Hellström-WestasL , BoylanG , ÅgrenJ . Systematic review of neonatal seizure management strategies provides guidance on anti-epileptic treatment. Acta Paediatrica2015;104(2):123-9. [DOI: 10.1111/apa.12812] [PMID: 25251733]">Hellström‐Westas 2015</a>; <a href="./references#CD014967-bbs2-0149" title="SlaughterLA , PatelAD , SlaughterJL . Pharmacological treatment of neonatal seizures: a systematic review. Journal of Child Neurology2013;28(3):351-64. [DOI: 10.1177/0883073812470734] [PMID: 23318696]">Slaughter 2013</a>). One other systematic review used a different approach (network meta‐analysis) and thus is not easily comparable with ours (<a href="./references#CD014967-bbs2-0165" title="XuZE , LiWB , QiaoMY , CuiHT , ZhaoLZ , ChenQX , et al. Comparative efficacy of anti-epileptic drugs for neonatal seizures: a network meta-analysis. Pediatrics and Neonatology2021;62(6):598-605. [DOI: 10.1016/j.pedneo.2021.06.005] [PMID: 34389261]">Xu 2021</a>). Most of the other reviews evaluated single ASMs such as levetiracetam (<a href="./references#CD014967-bbs2-0105" title="HooperRG , RamaswamyVV , WahidRM , SatodiaP , BhulaniA . Levetiracetam as the first-line treatment for neonatal seizures: a systematic review and meta-analysis. Developmental Medicine and Child Neurology2021;63(11):1283-93. [DOI: 10.1111/dmcn.14943] [PMID: 34124790]">Hooper 2021</a>; <a href="./references#CD014967-bbs2-0123" title="McHughDC , LancasterS , ManganasLN . A systematic review of the efficacy of levetiracetam in neonatal seizures. Neuropediatrics2018;49(1):12-7. [DOI: 10.1055/s-0037-1608653] [PMID: 29179233]">McHugh 2018</a>; <a href="./references#CD014967-bbs2-0146" title="SharmaD , HussainAM , SharmaSS . Efficacy of Levetiracetam in neonatal seizures: a systematic review. Journal of Maternal-Fetal &amp; Neonatal Medicine2022;35(20):3923-30. [DOI: 10.1080/14767058.2020.1844651] [PMID: 33172319]">Sharma 2022</a>), phenobarbital (<a href="./references#CD014967-bbs2-0113" title="KumarJ , MeenaJ , YadavJ , SainiL . Efficacy and safety of phenobarbitone as first-line treatment for neonatal seizure: a systematic review and meta-analysis. Journal of Tropical Pediatrics2021;67(1):fmab008. [DOI: 10.1093/tropej/fmab008] [PMID: 33598701]">Kumar 2021</a>), or levetiracetam versus phenobarbital (<a href="./references#CD014967-bbs2-0136" title="QiaoMY , CuiHT , ZhaoLZ , MiaoJK , ChenQX . Efficacy and safety of levetiracetam vs. phenobarbital for neonatal seizures: a systematic review and meta-analysis. Frontiers in Neurology2021;12:747745. [DOI: 10.3389/fneur.2021.747745] [PMID: 34867732]">Qiao 2021</a>), or they limited the review to a single aetiology such as stroke (<a href="./references#CD014967-bbs2-0150" title="SortinoV , PraticòA , MarinoS , CriscioneR , RuggieriM , PisaniF , et al. Efficacy of the anti-seizure medications in acute symptomatic neonatal seizures caused by stroke. A systematic review. Acta Bio-Medica2022;93(6):e2022328. [DOI: 10.23750/abm.v93i6.13440] [PMID: 36533757]">Sortino 2022</a>), and inborn errors of metabolism (<a href="./references#CD014967-bbs2-0092" title="FalsaperlaR , ScaliaB , GiugnoA , PavoneP , MottaM , CaccamoM , et al. Treating the symptom or treating the disease in neonatal seizures: a systematic review of the literature. Italian Journal of Pediatrics2021;47(1):85. [DOI: 10.1186/s13052-021-01027-2] [PMID: 33827647]">Falsaperla 2021</a>). All of these included only or mostly retrospective and uncontrolled studies. Thus, their evidence is of very low certainty and no strong recommendations can be based on this. </p> <p>The present systematic review is the first to evaluate evidence on the duration of treatment. The ILAE/WHO guidelines (<a href="./references#CD014967-bbs2-0162" title="WHO. Guidelines on neonatal seizures. who.int/bitstream/handle/10665/77756/9789241548304_eng.pdf2011. [AVAILABLE FROM: apps.who.int/iris/bitstream/handle/10665/77756/9789241548304_eng.pdf;sequence=1]">WHO 2011</a>) recommended stopping ASM before discharge, but this was an expert opinion not based on data from the literature. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD014967-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Flow diagram" data-id="CD014967-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full#CD014967-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Screen4Me 2022" data-id="CD014967-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Screen4Me 2022</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full#CD014967-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Screen4Me 2023" data-id="CD014967-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-FIG-03.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Screen4Me 2023</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full#CD014967-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-FIG-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures, Outcome 1: Proportion of infants who achieve seizure control after the first loading dose of ASM" data-id="CD014967-fig-0004" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures, Outcome 1: Proportion of infants who achieve seizure control after the first loading dose of ASM </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures, Outcome 2: Proportion of infants who achieve seizure control after the the maximal loading dose of ASM" data-id="CD014967-fig-0005" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures, Outcome 2: Proportion of infants who achieve seizure control after the the maximal loading dose of ASM </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures, Outcome 3: Mortality before hospital discharge" data-id="CD014967-fig-0006" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures, Outcome 3: Mortality before hospital discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures, Outcome 4: Requirement for mechanical ventilation" data-id="CD014967-fig-0007" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures, Outcome 4: Requirement for mechanical ventilation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures, Outcome 5: Proportion of infants who develop sedation or drowsiness" data-id="CD014967-fig-0008" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures, Outcome 5: Proportion of infants who develop sedation or drowsiness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures, Outcome 6: Bradycardia" data-id="CD014967-fig-0009" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures, Outcome 6: Bradycardia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures, Outcome 7: Hypotension requiring volume or inotropes" data-id="CD014967-fig-0010" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures, Outcome 7: Hypotension requiring volume or inotropes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures, Outcome 8: Shock requiring volume or inotropes" data-id="CD014967-fig-0011" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures, Outcome 8: Shock requiring volume or inotropes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures, Outcome 9: Recurrence of seizure before hospital discharge" data-id="CD014967-fig-0012" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures, Outcome 9: Recurrence of seizure before hospital discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures, Outcome 10: Proportion of infants with epilepsy post‐discharge" data-id="CD014967-fig-0013" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures, Outcome 10: Proportion of infants with epilepsy post‐discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 1: Proportion of infants who achieve seizure control after the first loading dose of ASM" data-id="CD014967-fig-0014" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 1: Proportion of infants who achieve seizure control after the first loading dose of ASM </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 2: Proportion of infants who achieve seizure control after the maximal loading dose of ASM" data-id="CD014967-fig-0015" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 2: Proportion of infants who achieve seizure control after the maximal loading dose of ASM </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 3: Mortality before hospital discharge" data-id="CD014967-fig-0016" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 3: Mortality before hospital discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 4: Requirement for mechanical ventilation" data-id="CD014967-fig-0017" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 4: Requirement for mechanical ventilation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 5: Proportion of infants who develop sedation or drowsiness" data-id="CD014967-fig-0018" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 5: Proportion of infants who develop sedation or drowsiness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 6: Bradycardia" data-id="CD014967-fig-0019" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 6: Bradycardia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 7: Hypotension requiring volume or inotropes" data-id="CD014967-fig-0020" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 7: Hypotension requiring volume or inotropes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 8: Shock requiring volume or inotropes" data-id="CD014967-fig-0021" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 8: Shock requiring volume or inotropes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 9: Proportion of infants with an abnormal background pattern in EEG during ASM treatment" data-id="CD014967-fig-0022" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 9: Proportion of infants with an abnormal background pattern in EEG during ASM treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 10: Proportion of infants with an abnormal background pattern in EEG after stopping ASM" data-id="CD014967-fig-0023" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 10: Proportion of infants with an abnormal background pattern in EEG after stopping ASM </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 11: Duration of hospital stay" data-id="CD014967-fig-0024" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 11: Duration of hospital stay </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 12: Recurrence of seizure before hospital discharge" data-id="CD014967-fig-0025" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 12: Recurrence of seizure before hospital discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 13: Proportion of infants with persistent seizures and/or requiring ASM at discharge" data-id="CD014967-fig-0026" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 13: Proportion of infants with persistent seizures and/or requiring ASM at discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 14: Proportion of infants discharged on gavage feeds" data-id="CD014967-fig-0027" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 14: Proportion of infants discharged on gavage feeds </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-002.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 15: Proportion of infants with an abnormal neurological examination at discharge" data-id="CD014967-fig-0028" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-002.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 15: Proportion of infants with an abnormal neurological examination at discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-002.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 16: Proportion of infants who develop epilepsy post discharge" data-id="CD014967-fig-0029" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-002.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2: Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 16: Proportion of infants who develop epilepsy post discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-002.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Phenobarbital versus phenytoin as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 1: Proportion of infants who achieve seizure control after the maximal loading dose of ASM" data-id="CD014967-fig-0030" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Phenobarbital versus phenytoin as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 1: Proportion of infants who achieve seizure control after the maximal loading dose of ASM </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Phenobarbital versus phenytoin as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 2: Arrythmias causing circulatory disturbance" data-id="CD014967-fig-0031" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Phenobarbital versus phenytoin as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 2: Arrythmias causing circulatory disturbance </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Phenobarbital versus phenytoin as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 3: Hypotension requiring volume or inotropes" data-id="CD014967-fig-0032" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Phenobarbital versus phenytoin as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 3: Hypotension requiring volume or inotropes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Phenobarbital versus phenytoin as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 4: Bradycardia" data-id="CD014967-fig-0033" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Phenobarbital versus phenytoin as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 4: Bradycardia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Phenobarbital versus phenytoin as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 1: Proportion of infants who achieve seizure control after the first loading dose of ASM" data-id="CD014967-fig-0034" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Phenobarbital versus phenytoin as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 1: Proportion of infants who achieve seizure control after the first loading dose of ASM </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Phenobarbital versus phenytoin as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 2: Mortality before hospital discharge" data-id="CD014967-fig-0035" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Phenobarbital versus phenytoin as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 2: Mortality before hospital discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Phenobarbital versus phenytoin as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 3: Requirement of mechanical ventilation" data-id="CD014967-fig-0036" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Phenobarbital versus phenytoin as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 3: Requirement of mechanical ventilation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Phenobarbital versus phenytoin as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 4: Proportion of infants who develop sedation or drowsiness" data-id="CD014967-fig-0037" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Phenobarbital versus phenytoin as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 4: Proportion of infants who develop sedation or drowsiness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Phenobarbital versus phenytoin as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 5: Bradycardia" data-id="CD014967-fig-0038" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Phenobarbital versus phenytoin as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 5: Bradycardia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Phenobarbital versus phenytoin as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 6: Proportion of infants with persistent seizures and/or requiring ASM at discharge" data-id="CD014967-fig-0039" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Phenobarbital versus phenytoin as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 6: Proportion of infants with persistent seizures and/or requiring ASM at discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Phenobarbital versus lorazepam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 1: Proportion of infants who achieve seizure control after the first loading dose of ASM" data-id="CD014967-fig-0040" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Phenobarbital versus lorazepam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 1: Proportion of infants who achieve seizure control after the first loading dose of ASM </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Phenobarbital versus lorazepam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 2: Mortality before hospital discharge" data-id="CD014967-fig-0041" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Phenobarbital versus lorazepam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 2: Mortality before hospital discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Phenobarbital versus lorazepam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 3: Proportion of infants who develop sedation or drowsiness" data-id="CD014967-fig-0042" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Phenobarbital versus lorazepam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 3: Proportion of infants who develop sedation or drowsiness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Phenobarbital versus lorazepam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 4: Proportion of infants with persistent seizures and/or requiring ASM at discharge" data-id="CD014967-fig-0043" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Phenobarbital versus lorazepam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 4: Proportion of infants with persistent seizures and/or requiring ASM at discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Phenytoin versus lorazepam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 1: Proportion of infants who achieve seizure control after the first loading dose of ASM" data-id="CD014967-fig-0044" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Phenytoin versus lorazepam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 1: Proportion of infants who achieve seizure control after the first loading dose of ASM </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Phenytoin versus lorazepam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 2: Mortality before hospital discharge" data-id="CD014967-fig-0045" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Phenytoin versus lorazepam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 2: Mortality before hospital discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Phenytoin versus lorazepam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 3: Proportion of infants who develop sedation or drowsiness" data-id="CD014967-fig-0046" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Phenytoin versus lorazepam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 3: Proportion of infants who develop sedation or drowsiness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Phenytoin versus lorazepam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 4: Proportion of infants with persistent seizures and/or requiring ASM at discharge" data-id="CD014967-fig-0047" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Phenytoin versus lorazepam as first‐line ASM in clinically diagnosed neonatal seizures, Outcome 4: Proportion of infants with persistent seizures and/or requiring ASM at discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Phenobarbital + bumetanide versus phenobarbital alone as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 1: Proportion of infants who achieve seizure control after the first loading dose of ASM" data-id="CD014967-fig-0048" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Phenobarbital + bumetanide versus phenobarbital alone as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 1: Proportion of infants who achieve seizure control after the first loading dose of ASM </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Phenobarbital + bumetanide versus phenobarbital alone as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 2: Mortality before hospital discharge" data-id="CD014967-fig-0049" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Phenobarbital + bumetanide versus phenobarbital alone as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 2: Mortality before hospital discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Phenobarbital + bumetanide versus phenobarbital alone as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 3: Proportion of infants with cognitive impairment at 18‐24 months" data-id="CD014967-fig-0050" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Phenobarbital + bumetanide versus phenobarbital alone as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 3: Proportion of infants with cognitive impairment at 18‐24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Phenobarbital + bumetanide versus phenobarbital alone as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 4: Seizure burden during hospitalisation" data-id="CD014967-fig-0051" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Phenobarbital + bumetanide versus phenobarbital alone as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 4: Seizure burden during hospitalisation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Phenobarbital + bumetanide versus phenobarbital alone as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 5: Requirement for mechanical ventilation" data-id="CD014967-fig-0052" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Phenobarbital + bumetanide versus phenobarbital alone as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 5: Requirement for mechanical ventilation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-007.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Phenobarbital + bumetanide versus phenobarbital alone as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 6: Hypotension requiring volume or inotropes" data-id="CD014967-fig-0053" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-007.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-007.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7: Phenobarbital + bumetanide versus phenobarbital alone as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 6: Hypotension requiring volume or inotropes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-007.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-007.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Phenobarbital + bumetanide versus phenobarbital alone as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 7: Proportion of infants with an abnormal background pattern in EEG during ASM treatment" data-id="CD014967-fig-0054" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-007.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-007.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7: Phenobarbital + bumetanide versus phenobarbital alone as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 7: Proportion of infants with an abnormal background pattern in EEG during ASM treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-007.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-007.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Phenobarbital + bumetanide versus phenobarbital alone as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 8: Proportion of infants who develop epilepsy post discharge" data-id="CD014967-fig-0055" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-007.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-007.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7: Phenobarbital + bumetanide versus phenobarbital alone as first‐line ASM in EEG‐confirmed neonatal seizures, Outcome 8: Proportion of infants who develop epilepsy post discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-007.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Lignocaine versus benzodiazepine as second‐line ASM in EEG‐confirmed neonatal seizures, Outcome 1: Proportion of infants who achieve seizure control after the maximal loading dose of ASM" data-id="CD014967-fig-0056" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Lignocaine versus benzodiazepine as second‐line ASM in EEG‐confirmed neonatal seizures, Outcome 1: Proportion of infants who achieve seizure control after the maximal loading dose of ASM </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Lignocaine versus benzodiazepine as second‐line ASM in EEG‐confirmed neonatal seizures, Outcome 2: Mortality or neurodevelopmental disability at 12 months' corrected age" data-id="CD014967-fig-0057" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Lignocaine versus benzodiazepine as second‐line ASM in EEG‐confirmed neonatal seizures, Outcome 2: Mortality or neurodevelopmental disability at 12 months' corrected age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Lignocaine versus benzodiazepine as second‐line ASM in EEG‐confirmed neonatal seizures, Outcome 3: Mortality before hospital discharge" data-id="CD014967-fig-0058" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Lignocaine versus benzodiazepine as second‐line ASM in EEG‐confirmed neonatal seizures, Outcome 3: Mortality before hospital discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Lignocaine versus benzodiazepine as second‐line ASM in EEG‐confirmed neonatal seizures, Outcome 4: Neurodevelopmental disability at 12 months' corrected age" data-id="CD014967-fig-0059" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: Lignocaine versus benzodiazepine as second‐line ASM in EEG‐confirmed neonatal seizures, Outcome 4: Neurodevelopmental disability at 12 months' corrected age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures, Outcome 1: Proportion of infants with repeat seizure before hospital discharge" data-id="CD014967-fig-0060" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures, Outcome 1: Proportion of infants with repeat seizure before hospital discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures, Outcome 2: Mortality before hospital discharge" data-id="CD014967-fig-0061" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures, Outcome 2: Mortality before hospital discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures, Outcome 3: Mortality at 18 to 24 months" data-id="CD014967-fig-0062" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures, Outcome 3: Mortality at 18 to 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures, Outcome 4: Neurodevelopmental disability at 18 to 24 months' corrected age" data-id="CD014967-fig-0063" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures, Outcome 4: Neurodevelopmental disability at 18 to 24 months' corrected age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-009.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures, Outcome 5: Requirement for mechanical ventilation" data-id="CD014967-fig-0064" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-009.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-009.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9: Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures, Outcome 5: Requirement for mechanical ventilation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-009.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-009.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures, Outcome 6: Shock requiring volume or inotropes" data-id="CD014967-fig-0065" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-009.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-009.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9: Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures, Outcome 6: Shock requiring volume or inotropes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-009.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-009.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures, Outcome 7: Abnormal background pattern in EEG after achieving seizure control" data-id="CD014967-fig-0066" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-009.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-009.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9: Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures, Outcome 7: Abnormal background pattern in EEG after achieving seizure control </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-009.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-009.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures, Outcome 8: Duration of hospital stay" data-id="CD014967-fig-0067" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-009.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-009.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.8</div> <div class="figure-caption"> <p>Comparison 9: Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures, Outcome 8: Duration of hospital stay </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-009.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-009.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures, Outcome 9: Proportion of infants with persistent seizures and/or requiring ASM at discharge" data-id="CD014967-fig-0068" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-009.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-009.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.9</div> <div class="figure-caption"> <p>Comparison 9: Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures, Outcome 9: Proportion of infants with persistent seizures and/or requiring ASM at discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-009.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-009.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures, Outcome 10: Abnormal neurological examination at discharge" data-id="CD014967-fig-0069" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-009.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-009.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.10</div> <div class="figure-caption"> <p>Comparison 9: Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures, Outcome 10: Abnormal neurological examination at discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-009.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-009.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures, Outcome 11: Proportion of infants who develop epilepsy post‐discharge" data-id="CD014967-fig-0070" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-009.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-009.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.11</div> <div class="figure-caption"> <p>Comparison 9: Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures, Outcome 11: Proportion of infants who develop epilepsy post‐discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-009.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Treatment of both clinical and electrographic seizures versus treatment of clinical seizures alone in neonates, Outcome 1: Seizure burden during hospitalisation" data-id="CD014967-fig-0071" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Treatment of both clinical and electrographic seizures versus treatment of clinical seizures alone in neonates, Outcome 1: Seizure burden during hospitalisation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Treatment of both clinical and electrographic seizures versus treatment of clinical seizures alone in neonates, Outcome 2: Mortality before hospital discharge" data-id="CD014967-fig-0072" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Treatment of both clinical and electrographic seizures versus treatment of clinical seizures alone in neonates, Outcome 2: Mortality before hospital discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014967-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/urn:x-wiley:14651858:media:CD014967:CD014967-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Treatment of both clinical and electrographic seizures versus treatment of clinical seizures alone in neonates, Outcome 3: Proportion of infants who develop epilepsy post‐discharge" data-id="CD014967-fig-0073" src="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_t/tCD014967-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: Treatment of both clinical and electrographic seizures versus treatment of clinical seizures alone in neonates, Outcome 3: Proportion of infants who develop epilepsy post‐discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/media/CDSR/CD014967/image_n/nCD014967-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD014967-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates with EEG‐confirmed seizures<br/><b>Setting:</b> Neonatal intensive care unit<br/><b>Intervention:</b> phenobarbital as first‐line ASM<br/><b>Comparison:</b> levetiracetam as first‐line ASM </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with levetiracetam as first‐line ASM</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with phenobarbital as first‐line ASM</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after the first loading dose of ASM </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>359 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>834 per 1000</b><br/>(586 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.32</b><br/>(1.63 to 3.30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after the maximal loading dose of ASM </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>283 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>801 per 1000</b><br/>(504 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.83</b><br/>(1.78 to 4.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality or neurodevelopment disability at 18 to 24 months' corrected age ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality before hospital discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b><br/>(3 to 197) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.30</b><br/>(0.04 to 2.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Requirement of mechanical ventilation</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>375 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>454 per 1000</b><br/>(285 to 716) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.21</b><br/>(0.76 to 1.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who develop sedation or drowsiness</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>190 per 1000</b><br/>(74 to 486) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.74</b><br/>(0.68 to 4.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who develop epilepsy post‐discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>481 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>443 per 1000</b><br/>(231 to 847) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b><br/>(0.48 to 1.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438900176882570386" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438900176882570386</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by one level for serious imprecision due to small small size not meeting the 'Optimal Information Size' criteria<br/><sup>b</sup> Downgraded by one level for indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs as well.<br/><sup>c</sup> Downgraded by two levels for very serious imprecision due to very low sample size and event rate not meeting the 'Optimal Information Size' criteria </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full#CD014967-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014967-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ Phenobarbital versus levetiracetam as first‐line ASM for clinically diagnosed neonatal seizures</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbital versus levetiracetam as first‐line ASM for clinically diagnosed neonatal seizures</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> clinically diagnosed neonatal seizures<br/><b>Setting:</b> Neonatal intensive care unit<br/><b>Intervention:</b> phenobarbital as first‐line ASM<br/><b>Comparison:</b> levetiracetam as first‐line ASM </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with levetiracetam as first‐line ASM</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with phenobarbital as first‐line ASM</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after first loading dose of ASM</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>443 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>306 per 1000</b><br/>(244 to 381) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.69</b><br/>(0.55 to 0.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>286<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after maximal loading dose of ASM</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>777 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>451 per 1000</b><br/>(365 to 559) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.58</b><br/>(0.47 to 0.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality or neurodevelopment disability at 18 to 24 months' corrected age ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported in any included trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality before hospital discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>116 per 1000</b><br/>(67 to 200) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.41</b><br/>(0.82 to 2.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>452<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d,</sup><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Requirement of mechanical ventilation</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b><br/>(3 to 49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.20</b><br/>(0.50 to 9.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>394<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,</sup><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who develop sedation or drowsiness</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b><br/>(36 to 292) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.88</b><br/>(0.66 to 5.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c,</sup><sup>d,</sup><sup>e,</sup><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who develop epilepsy post discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>133 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b><br/>(7 to 659) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.50</b><br/>(0.05 to 4.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>f,</sup><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_442643727142716799" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_442643727142716799</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for very serious risk of bias due to 'high risk of bias' in 2 trials and some concerns in the other trial<br/><sup>b</sup> Downgraded by one level for serious imprecision due to small sample size not meeting the 'Optimal Information Size' criterion<br/><sup>c</sup> Downgraded by two levels for very serious risk of bias due to high risk of bias in all included studies<br/><sup>d</sup> Downgraded by one level for serious indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs as well<br/><sup>e</sup> Downgraded by one level for serious imprecision due to low event rate not meeting the 'Optimal Information Size' criteria <br/><sup>f</sup> Downgraded by two levels for very serious imprecision due to single digit event rate<br/><sup>g</sup> Downgraded by one level for serious inconsistency due to substantial heterogeneity<br/><sup>h</sup> Downgraded by two levels for very serious risk of bias due to high risk of bias in the only included study </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ Phenobarbital versus levetiracetam as first‐line ASM for clinically diagnosed neonatal seizures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full#CD014967-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014967-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings table ‐ Phenobarbital versus phenytoin as first‐line ASM for EEG‐confirmed neonatal seizures</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbital versus phenytoin as first‐line ASM for EEG‐confirmed neonatal seizures</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates with EEG‐confirmed seizures<br/><b>Setting:</b> Neonatal intensive care unit<br/><b>Intervention:</b> phenobarbital as first‐line ASM<br/><b>Comparison:</b> phenytoin as first‐line ASM </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with phenytoin as first‐line ASM</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with phenobarbital as first‐line ASM</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after the first loading dose of ASM ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial did not report this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after the maximal loading dose of ASM </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>448 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>435 per 1000</b><br/>(242 to 771) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.97</b><br/>(0.54 to 1.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial did not report this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438951560046041157" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438951560046041157</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for very serious risk of bias due to high risk of bias in the only included trial<br/><sup>b</sup> Downgraded by two levels for very serious imprecision due to very low sample size and event rate not meeting the 'Optimal Information Size' criteria </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings table ‐ Phenobarbital versus phenytoin as first‐line ASM for EEG‐confirmed neonatal seizures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full#CD014967-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014967-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings table ‐ Phenobarbital versus phenytoin as first‐line ASM for clinically diagnosed neonatal seizures</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbital versus phenytoin as first‐line ASM for clinically diagnosed neonatal seizures</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates with clinically diagnosed seizures<br/><b>Setting:</b> Neonatal intensive care unit<br/><b>Intervention:</b> phenobarbital as first‐line ASM<br/><b>Comparison:</b> phenytoin as first‐line ASM </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with phenytoin as first‐line ASM</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with phenobarbital as first‐line ASM</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after first loading dose of ASM</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>356 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>683 per 1000</b><br/>(498 to 939) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.92</b><br/>(1.40 to 2.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after maximal loading dose ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neither of the two included trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neither of the two included trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality before hospital discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>211 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>281 per 1000</b><br/>(167 to 477) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.33</b><br/>(0.79 to 2.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c,</sup><sup>d,</sup><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Requirement of mechanical ventilation</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 7.13</b><br/>(0.38 to 134.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,</sup><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who develop sedation or drowsiness</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 23.00</b><br/>(1.41 to 375.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,</sup><sup>f,</sup><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438949398863786458" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438949398863786458</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by one level for serious risk of bias as the trial contributing &gt; 50% weighting to the estimate has a high risk of overall bias<br/><sup>b</sup> Downgraded by one level for serious inconsistency as there was considerable heterogeneity (I2 = 96%)<br/><sup>c</sup> Downgraded by one level for serious inconsistency as there was substantial heterogeneity (I2=82%)<br/><sup>d</sup> Downgraded by one level for serious indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs as well<br/><sup>e</sup> Downgraded by one level for serious imprecision for sample size and event rate not meeting the 'Optimal Information Size' criteria <br/><sup>f</sup> Downgraded by two levels for very serious imprecision due to very low sample size and event rate not meeting the 'Optimal Information Size' criteria<br/><sup>g</sup> Downgraded by two levels for very serious risk of bias due to high risk of bias in the only included trial </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings table ‐ Phenobarbital versus phenytoin as first‐line ASM for clinically diagnosed neonatal seizures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full#CD014967-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014967-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings table ‐ Phenobarbital versus Lorazepam as first‐line ASM for clinically diagnosed neonatal seizures</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbital versus Lorazepam as first‐line ASM for clinically diagnosed neonatal seizures</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Neonates with clinically diagnosed seizures<br/><b>Setting:</b> Neonatal intensive care unit<br/><b>Intervention:</b> Phenobarbital as first‐line ASM<br/><b>Comparison:</b> Lorazepam as first‐line ASM </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Lorazepam as first‐line ASM</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Phenobarbital as first‐line ASM</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after the first loading dose of ASM </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>889 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>631 per 1000</b><br/>(471 to 836) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.71</b><br/>(0.53 to 0.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after the maximal loading dose of ASM ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality before hospital discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>194 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>342 per 1000</b><br/>(154 to 768) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.76</b><br/>(0.79 to 3.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who develop sedation or drowsiness</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>314 per 1000</b><br/>(75 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5.66</b><br/>(1.35 to 23.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438956545731624502" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438956545731624502</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for very serious risk of bias due to high risk of bias in the only included trial<br/><sup>b</sup> Downgraded by one level for serious imprecision for sample size and event rate not meeting the 'Optimal Information Size' criteria<br/><sup>c</sup> Downgraded by one level for serious indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs as well<br/><sup>d</sup> Downgraded by two levels for very serious imprecision due to very low sample size and event rate not meeting the 'Optimal Information Size' criteria </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings table ‐ Phenobarbital versus Lorazepam as first‐line ASM for clinically diagnosed neonatal seizures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full#CD014967-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014967-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings table ‐ Phenytoin versus lorazepam as first‐line ASM for clinically diagnosed neonatal seizures</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenytoin versus lorazepam as first‐line ASM for clinically diagnosed neonatal seizures</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates with clinically diagnosed seizures<br/><b>Setting:</b> Neonatal intensive care unit<br/><b>Intervention:</b> phenytoin as first‐line ASM<br/><b>Comparison:</b> lorazepam as first‐line ASM </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with lorazepam as first‐line ASM</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with phenytoin as first‐line ASM</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after the first loading dose of ASM </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>889 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>684 per 1000</b><br/>(533 to 880) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.77</b><br/>(0.60 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after the maximal loading dose of ASM ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality before hospital discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>194 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>86 per 1000</b><br/>(23 to 305) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.44</b><br/>(0.12 to 1.57) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who develop sedation or drowsiness</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b><br/>(1 to 229) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.21</b><br/>(0.01 to 4.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438956906630512363" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438956906630512363</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for very serious risk of bias due to high risk of bias in the only included trial<br/><sup>b</sup> Downgraded by one level for serious imprecision for sample size and event rate not meeting the 'Optimal Information Size' criteria<br/><sup>c</sup> Downgraded by one level for serious indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs as well.<br/><sup>d</sup> Downgraded by two levels for very serious imprecision due to very low sample size and event rate not meeting the 'Optimal Information Size' criteria </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings table ‐ Phenytoin versus lorazepam as first‐line ASM for clinically diagnosed neonatal seizures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full#CD014967-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014967-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Summary of findings table ‐ Phenobarbital + bumetanide versus phenobarbital alone for EEG‐confirmed neonatal seizures</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbital + bumetanide versus phenobarbital alone for EEG‐confirmed neonatal seizures</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates with EEG‐confirmed seizures<br/><b>Setting:</b> Neonatal intensive care unit<br/><b>Intervention:</b> phenobarbital + bumetanide<br/><b>Comparison:</b> phenobarbital alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with phenobarbital alone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with phenobarbital + bumetanide</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after the first loading dose of ASM </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>313 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>297 per 1000</b><br/>(116 to 750) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b><br/>(0.37 to 2.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after the maximal loading dose of the ASM ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality before hospital discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>188 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b><br/>(4 to 326) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.20</b><br/>(0.02 to 1.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive impairment at 18‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>159 per 1000</b><br/>(39 to 645) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.53</b><br/>(0.13 to 2.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Requirement of mechanical ventilation</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who develop epilepsy post‐discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>308 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>348 per 1000</b><br/>(132 to 914) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b><br/>(0.43 to 2.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438957230819281917" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438957230819281917</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for very serious imprecision due to very low sample size and event rate not meeting the 'Optimal Information Size' criteria<br/><sup>b</sup> Downgraded by one level for serious indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs as well </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Summary of findings table ‐ Phenobarbital + bumetanide versus phenobarbital alone for EEG‐confirmed neonatal seizures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full#CD014967-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014967-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Summary of findings table ‐ Lignocaine versus benzodiazepines as second‐line ASM for EEG‐confirmed neonatal seizures</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lignocaine versus benzodiazepines as second‐line ASM for EEG‐confirmed neonatal seizures</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates with EEG‐confirmed seizures<br/><b>Setting:</b> Neonatal intensive care unit<br/><b>Intervention:</b> lignocaine as second‐line ASM<br/><b>Comparison:</b> benzodiazepines as second‐line ASM </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with benzodiazepines as second‐line ASM</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with lignocaine as second‐line ASM</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after first loading dose of ASM ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who achieve seizure control after maximal loading dose of ASM</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 8.17</b><br/>(0.52 to 128.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality or neurodevelopmental disability at 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b><br/>(710 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/>(0.71 to 1.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality before hospital discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>333 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b><br/>(83 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.20</b><br/>(0.25 to 5.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurodevelopmental disability at 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>600 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>600 per 1000</b><br/>(216 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/>(0.36 to 2.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438957465149804345" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438957465149804345</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for very serious risk of bias due to high risk of bias in the only included trial<br/><sup>b</sup> Downgraded by two levels for very serious imprecision due to very low sample size and event rate not meeting the 'Optimal Information Size' criteria<br/><sup>c</sup> Downgraded by one level for serious indirectness of the intervention as the study population included neonates who required second‐ and third‐line ASMs as well </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Summary of findings table ‐ Lignocaine versus benzodiazepines as second‐line ASM for EEG‐confirmed neonatal seizures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full#CD014967-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014967-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Summary of findings table ‐ Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates with clinically diagnosed seizures<br/><b>Setting:</b> Neonatal intensive care unit<br/><b>Intervention:</b> maintenance ASM after achieving seizure control<br/><b>Comparison:</b> no maintenance ASM after achieving seizure control </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no maintenance ASM after achieving seizure control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with maintenance ASM after achieving seizure control</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants with repeat seizure before hospital discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>353 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>268 per 1000</b><br/>(198 to 356) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.76</b><br/>(0.56 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>373<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neither of the two included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality before hospital discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>96 per 1000</b><br/>(54 to 170) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.69</b><br/>(0.39 to 1.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>373<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality at 18‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>121 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>113 per 1000</b><br/>(41 to 315) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b><br/>(0.34 to 2.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurodevelopmental disability at 18‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>35 per 1000</b><br/>(5 to 240) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b><br/>(0.13 to 6.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who develop epilepsy post‐discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>106 per 1000</b><br/>(23 to 491) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.18</b><br/>(0.69 to 14.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438158727822576253" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438158727822576253</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by one level for risk of bias due to 'some concerns' in the risk of bias in both the included studies<br/><sup>b</sup> Downgraded by two levels for very serious imprecision due to very low sample size and event rate not meeting the 'Optimal Information Size' criteria </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Summary of findings table ‐ Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full#CD014967-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014967-tbl-0010"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Summary of findings table ‐ Treatment of clinical and electrographic seizures versus treatment of clinical seizures alone in neonates</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Treatment of clinical and electrographic seizures versus treatment of clinical seizures alone in neonates</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates<br/><b>Setting:</b> Neonatal intensive care unit<br/><b>Intervention:</b> treatment of clinical and electrographic seizures<br/><b>Comparison:</b> treatment of clinical seizures alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with treatment of clinical seizures alone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with treatment of clinical and electrographic seizures</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seizure burden during hospitalisation</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean seizure burden during hospitalisation was <b>0</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>1871.16 lower</b><br/>(4525.05 lower to 782.73 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality before hospital discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>345 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>203 per 1000</b><br/>(97 to 438) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.59</b><br/>(0.28 to 1.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of infants who develop epilepsy post‐discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>133 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><br/>(16 to 631) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.75</b><br/>(0.12 to 4.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438901735468111265" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438901735468111265</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for very serious imprecision due to very low sample size and event rate not meeting the 'Optimal Information Size' criteria </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Summary of findings table ‐ Treatment of clinical and electrographic seizures versus treatment of clinical seizures alone in neonates</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/full#CD014967-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014967-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Proportion of infants who achieve seizure control after the first loading dose of ASM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Proportion of infants who achieve seizure control after the the maximal loading dose of ASM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Mortality before hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Requirement for mechanical ventilation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Proportion of infants who develop sedation or drowsiness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Bradycardia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Hypotension requiring volume or inotropes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Shock requiring volume or inotropes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Recurrence of seizure before hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Proportion of infants with epilepsy post‐discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Phenobarbital versus levetiracetam as first‐line ASM for EEG‐confirmed neonatal seizures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014967-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Proportion of infants who achieve seizure control after the first loading dose of ASM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.55, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Proportion of infants who achieve seizure control after the maximal loading dose of ASM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.47, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Mortality before hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.82, 2.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Requirement for mechanical ventilation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [0.50, 9.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Proportion of infants who develop sedation or drowsiness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [0.66, 5.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Bradycardia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.00 [0.74, 48.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Hypotension requiring volume or inotropes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Shock requiring volume or inotropes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.30, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Proportion of infants with an abnormal background pattern in EEG during ASM treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Proportion of infants with an abnormal background pattern in EEG after stopping ASM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Duration of hospital stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [0.54, 4.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Recurrence of seizure before hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.42, 6.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Proportion of infants with persistent seizures and/or requiring ASM at discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Proportion of infants discharged on gavage feeds <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.15 Proportion of infants with an abnormal neurological examination at discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.51, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.16 Proportion of infants who develop epilepsy post discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Phenobarbital versus levetiracetam as first‐line ASM in clinically diagnosed neonatal seizures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014967-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Phenobarbital versus phenytoin as first‐line ASM in EEG‐confirmed neonatal seizures</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Proportion of infants who achieve seizure control after the maximal loading dose of ASM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Arrythmias causing circulatory disturbance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Hypotension requiring volume or inotropes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Bradycardia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Phenobarbital versus phenytoin as first‐line ASM in EEG‐confirmed neonatal seizures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014967-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Phenobarbital versus phenytoin as first‐line ASM in clinically diagnosed neonatal seizures</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Proportion of infants who achieve seizure control after the first loading dose of ASM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [1.40, 2.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Mortality before hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.79, 2.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Requirement of mechanical ventilation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Proportion of infants who develop sedation or drowsiness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Bradycardia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Proportion of infants with persistent seizures and/or requiring ASM at discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Phenobarbital versus phenytoin as first‐line ASM in clinically diagnosed neonatal seizures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014967-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Phenobarbital versus lorazepam as first‐line ASM in clinically diagnosed neonatal seizures</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Proportion of infants who achieve seizure control after the first loading dose of ASM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Mortality before hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Proportion of infants who develop sedation or drowsiness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Proportion of infants with persistent seizures and/or requiring ASM at discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Phenobarbital versus lorazepam as first‐line ASM in clinically diagnosed neonatal seizures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014967-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Phenytoin versus lorazepam as first‐line ASM in clinically diagnosed neonatal seizures</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Proportion of infants who achieve seizure control after the first loading dose of ASM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Mortality before hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Proportion of infants who develop sedation or drowsiness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Proportion of infants with persistent seizures and/or requiring ASM at discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Phenytoin versus lorazepam as first‐line ASM in clinically diagnosed neonatal seizures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014967-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Phenobarbital + bumetanide versus phenobarbital alone as first‐line ASM in EEG‐confirmed neonatal seizures</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Proportion of infants who achieve seizure control after the first loading dose of ASM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Mortality before hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Proportion of infants with cognitive impairment at 18‐24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Seizure burden during hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Requirement for mechanical ventilation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.6 Hypotension requiring volume or inotropes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.7 Proportion of infants with an abnormal background pattern in EEG during ASM treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.8 Proportion of infants who develop epilepsy post discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Phenobarbital + bumetanide versus phenobarbital alone as first‐line ASM in EEG‐confirmed neonatal seizures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014967-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Lignocaine versus benzodiazepine as second‐line ASM in EEG‐confirmed neonatal seizures</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Proportion of infants who achieve seizure control after the maximal loading dose of ASM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Mortality or neurodevelopmental disability at 12 months' corrected age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Mortality before hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 Neurodevelopmental disability at 12 months' corrected age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Lignocaine versus benzodiazepine as second‐line ASM in EEG‐confirmed neonatal seizures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014967-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Proportion of infants with repeat seizure before hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.56, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Mortality before hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.39, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Mortality at 18 to 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 Neurodevelopmental disability at 18 to 24 months' corrected age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.5 Requirement for mechanical ventilation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.6 Shock requiring volume or inotropes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.67, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.7 Abnormal background pattern in EEG after achieving seizure control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.8 Duration of hospital stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.44, 0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.9 Proportion of infants with persistent seizures and/or requiring ASM at discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.10 Abnormal neurological examination at discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.62, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.11 Proportion of infants who develop epilepsy post‐discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.18 [0.69, 14.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Maintenance ASM versus no maintenance ASM after achieving seizure control in clinically diagnosed neonatal seizures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014967-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Treatment of both clinical and electrographic seizures versus treatment of clinical seizures alone in neonates</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Seizure burden during hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1871.16 [‐4525.05, 782.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Mortality before hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.28, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Proportion of infants who develop epilepsy post‐discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Treatment of both clinical and electrographic seizures versus treatment of clinical seizures alone in neonates</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#CD014967-tbl-0020">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-1"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 Proportion of infants who achieve seizure control after the first loading dose of ASM</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Sharpe 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though there was missing data analysis methods that correct for bias such as sensitivity analyses showing that results are little changed under a range of plausible assumptions about the relationship between missingness in the outcome and its true value was performed </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>aEEG was utilised to detect seizures which is a reliable method when compared to clinical diagnosis of seizures. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 Proportion of infants who achieve seizure control after the first loading dose of ASM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-1">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-2"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 Proportion of infants who achieve seizure control after the the maximal loading dose of ASM</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Sharpe 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though there was missing data analysis methods that correct for bias such as sensitivity analyses showing that results are little changed under a range of plausible assumptions about the relationship between missingness in the outcome and its true value was performed </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>aEEG was utilised to detect seizures which is a reliable method when compared to clinical diagnosis of seizures </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 Proportion of infants who achieve seizure control after the the maximal loading dose of ASM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-2">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-3"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 Mortality before hospital discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Sharpe 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though there was missing data analysis methods that correct for bias such as sensitivity analyses showing that results are little changed under a range of plausible assumptions about the relationship between missingness in the outcome and its true value was performed </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 Mortality before hospital discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-3">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-4"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 Requirement for mechanical ventilation</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Sharpe 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though there was missing data analysis methods that correct for bias such as sensitivity analyses showing that results are little changed under a range of plausible assumptions about the relationship between missingness in the outcome and its true value was performed </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>aEEG was utilised to detect seizures which is a reliable method when compared to clinical diagnosis of seizures </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 Requirement for mechanical ventilation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-4">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-5"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Proportion of infants who develop sedation or drowsiness</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Sharpe 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though there was missing data analysis methods that correct for bias such as sensitivity analyses showing that results are little changed under a range of plausible assumptions about the relationship between missingness in the outcome and its true value was performedThough there was missing data analysis methods that correct for bias such as sensitivity analyses showing that results are little changed under a range of plausible assumptions about the relationship between missingness in the outcome and its true value was performed </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Proportion of infants who develop sedation or drowsiness</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-5">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-6"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.6 Bradycardia</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Sharpe 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though there was missing data analysis methods that correct for bias such as sensitivity analyses showing that results are little changed under a range of plausible assumptions about the relationship between missingness in the outcome and its true value was performed </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>aEEG was utilised to detect seizures which is a reliable method when compared to clinical diagnosis of seizures </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.6 Bradycardia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-6">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-7"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.7 Hypotension requiring volume or inotropes</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Sharpe 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though there was missing data analysis methods that correct for bias such as sensitivity analyses showing that results are little changed under a range of plausible assumptions about the relationship between missingness in the outcome and its true value was performed </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.7 Hypotension requiring volume or inotropes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-7">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-8"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.8 Shock requiring volume or inotropes</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Sharpe 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though there was missing data analysis methods that correct for bias such as sensitivity analyses showing that results are little changed under a range of plausible assumptions about the relationship between missingness in the outcome and its true value was performed </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.8 Shock requiring volume or inotropes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-8">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-9"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.9 Recurrence of seizure before hospital discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Sharpe 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though there was missing data analysis methods that correct for bias such as sensitivity analyses showing that results are little changed under a range of plausible assumptions about the relationship between missingness in the outcome and its true value was performed </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>aEEG was utilised to detect seizures which is a reliable method when compared to clinical diagnosis of seizures </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.9 Recurrence of seizure before hospital discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-9">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-10"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.10 Proportion of infants with epilepsy post‐discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Sharpe 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though there was missing data analysis methods that correct for bias such as sensitivity analyses showing that results are little changed under a range of plausible assumptions about the relationship between missingness in the outcome and its true value was performed </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.10 Proportion of infants with epilepsy post‐discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-10">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-11"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.1 Proportion of infants who achieve seizure control after the first loading dose of ASM</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Akeel 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since clinical judgement was used to ascertain seizure control, and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group. The authors have given details of the seizure definition used and who diagnosed the seizures. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial protocol not available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain.</p> </td> </tr> <tr class="study-data"> <td> <p>Gowda 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Single blinded study with the personnel aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group. There is no clear definition for different seizure types, how it was differentiated from non‐epiletic events and how it was assesed and by whom. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk in one domain</p> </td> </tr> <tr class="study-data"> <td> <p>Susnerwala 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since clinical judgement was used to ascertain seizure control, and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group. The authors have given details of the seizure definition used and who diagnosed the seizures. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in one domain.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.1 Proportion of infants who achieve seizure control after the first loading dose of ASM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-11">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-12"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.2 Proportion of infants who achieve seizure control after the maximal loading dose of ASM</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Ghaffar 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealment not specified and not enough data provided for baseline characteristics evaluation </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding or if any deviations arouse outside the trial context</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for all enrolled patients available</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group. There is no clear definition for different seizure types, how it was differentiated from non‐epiletic events and how it was assesed and by whom. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No registered protocol accessible</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk in one domain</p> </td> </tr> <tr class="study-data"> <td> <p>Gowda 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Single blinded study with the personnel aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group. There is no clear definition for different seizure types, how it was differentiated from non‐epiletic events and how it was assesed and by whom. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk in one domain</p> </td> </tr> <tr class="study-data"> <td> <p>Khan 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group. There is no clear definition for different seizure types, how it was differentiated from non‐epiletic events and how it was assesed and by whom. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk in one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.2 Proportion of infants who achieve seizure control after the maximal loading dose of ASM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-12">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-13"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.3 Mortality before hospital discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Falsaperla 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Single blinded study with the personnel aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> <tr class="study-data"> <td> <p>Gowda 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Single blinded study with the personnel aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias across all domains</p> </td> </tr> <tr class="study-data"> <td> <p>Khan 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> <tr class="study-data"> <td> <p>Perveen 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients at the time of discharge. Significant attrition at 3 and 6 months, though no outcomes assessed during this period was included in this analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> <tr class="study-data"> <td> <p>Prakash 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial protocol not available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in one domain.</p> </td> </tr> <tr class="study-data"> <td> <p>Susnerwala 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk in all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.3 Mortality before hospital discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-13">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-14"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.4 Requirement for mechanical ventilation</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Akeel 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial protocol not available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in one domain.</p> </td> </tr> <tr class="study-data"> <td> <p>Falsaperla 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Single blinded study with the personnel aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> <tr class="study-data"> <td> <p>Gowda 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Single blinded study with the personnel aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias across all domains</p> </td> </tr> <tr class="study-data"> <td> <p>Khan 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> <tr class="study-data"> <td> <p>Perveen 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients at the time of discharge. Significant attrition at 3 and 6 months, though no outcomes assessed during this period was included in this analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.4 Requirement for mechanical ventilation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-14">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-15"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.5 Proportion of infants who develop sedation or drowsiness</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Khan 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk of bias in one domain</p> </td> </tr> <tr class="study-data"> <td> <p>Prakash 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and the assessors were aware of the intervention allocation, there is a likelihood of assessment being influenced by the knowledge of the allocation group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial protocol not available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk of bias in one domain.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.5 Proportion of infants who develop sedation or drowsiness</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-15">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-16"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.6 Bradycardia</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Akeel 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial protocol not available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in one domain.</p> </td> </tr> <tr class="study-data"> <td> <p>Falsaperla 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Single blinded study with the personnel aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> <tr class="study-data"> <td> <p>Gowda 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Single blinded study with the personnel aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias across all domains</p> </td> </tr> <tr class="study-data"> <td> <p>Khan 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.6 Bradycardia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-16">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-17"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.7 Hypotension requiring volume or inotropes</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Falsaperla 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Single blinded study with the personnel aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> <tr class="study-data"> <td> <p>Khan 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.7 Hypotension requiring volume or inotropes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-17">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-18"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.8 Shock requiring volume or inotropes</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Falsaperla 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Single blinded study with the personnel aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> <tr class="study-data"> <td> <p>Khan 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> <tr class="study-data"> <td> <p>Perveen 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients at the time of discharge. Significant attrition at 3 and 6 months, though no outcomes assessed during this period was included in this analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.8 Shock requiring volume or inotropes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-18">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-19"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.9 Proportion of infants with an abnormal background pattern in EEG during ASM treatment</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Falsaperla 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Single blinded study with the personnel aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.9 Proportion of infants with an abnormal background pattern in EEG during ASM treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-19">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-20"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.10 Proportion of infants with an abnormal background pattern in EEG after stopping ASM</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Falsaperla 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Single blinded study with the personnel aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.10 Proportion of infants with an abnormal background pattern in EEG after stopping ASM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-20">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-21"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.11 Duration of hospital stay</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Falsaperla 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Single blinded study with the personnel aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> <tr class="study-data"> <td> <p>Perveen 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients at the time of discharge. Significant attrition at 3 and 6 months, though no outcomes assessed during this period was included in this analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.11 Duration of hospital stay</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-21">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-22"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.12 Recurrence of seizure before hospital discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Falsaperla 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Single blinded study with the personnel aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group. There is no clear definition for different seizure types, how it was differentiated from non‐epiletic events and how it was assesed and by whom. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk in one domain</p> </td> </tr> <tr class="study-data"> <td> <p>Khan 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group. There is no clear definition for different seizure types, how it was differentiated from non‐epiletic events and how it was assesed and by whom. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk in one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.12 Recurrence of seizure before hospital discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-22">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-23"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.13 Proportion of infants with persistent seizures and/or requiring ASM at discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Falsaperla 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Single blinded study with the personnel aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group. There is no clear definition for different seizure types, how it was differentiated from non‐epiletic events and how it was assesed and by whom. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk in one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.13 Proportion of infants with persistent seizures and/or requiring ASM at discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-23">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-24"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.14 Proportion of infants discharged on gavage feeds</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Falsaperla 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Single blinded study with the personnel aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> <tr class="study-data"> <td> <p>Khan 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.14 Proportion of infants discharged on gavage feeds</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-24">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-25"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.15 Proportion of infants with an abnormal neurological examination at discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Falsaperla 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Single blinded study with the personnel aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> <tr class="study-data"> <td> <p>Khan 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> <tr class="study-data"> <td> <p>Perveen 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients at the time of discharge. Significant attrition at 3 and 6 months, though no outcomes assessed during this period was included in this analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in one domain</p> </td> </tr> <tr class="study-data"> <td> <p>Susnerwala 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and the assessors were aware of the intervention allocation, there is a likelihood of assessment being influenced by the knowledge of the allocation group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk of bias in one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.15 Proportion of infants with an abnormal neurological examination at discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-25">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-26"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.16 Proportion of infants who develop epilepsy post discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Falsaperla 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Single blinded study with the personnel aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.16 Proportion of infants who develop epilepsy post discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-26">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-27"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.1 Proportion of infants who achieve seizure control after the maximal loading dose of ASM</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Painter 1999</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups, except in gender. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>aEEG was utilised to detect seizures which is a reliable method.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial protocol not available</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.1 Proportion of infants who achieve seizure control after the maximal loading dose of ASM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-27">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-28"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.2 Arrythmias causing circulatory disturbance</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Painter 1999</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups, except in gender. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group, <i>It was a double blinded RCT and hence the outcome assessors are blinded to allocation;</i> EEG was used to diagnose abnormal activity </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial protocol not available</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.2 Arrythmias causing circulatory disturbance</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-28">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-29"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.3 Hypotension requiring volume or inotropes</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Painter 1999</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups, except in gender. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group, <i>It was a double blinded RCT and hence the outcome assessors are blinded to allocation;</i> EEG was used to diagnose abnormal activity </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial protocol not available</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.3 Hypotension requiring volume or inotropes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-29">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-30"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.4 Bradycardia</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Painter 1999</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups, except in gender. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>aEEG was utilised to detect seizures which is a reliable method.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial protocol not available</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.4 Bradycardia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-30">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-31"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.1 Proportion of infants who achieve seizure control after the first loading dose of ASM</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Pathak 2013</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though EEG was performed, it was done after 48‐72 hours of clinical resolution of seizures. Since clinical judgement was used to ascertain seizure control, and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group. The authors have given details of the seizure definition used and who diagnosed the seizures. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in one domain</p> </td> </tr> <tr class="study-data"> <td> <p>Solanki 2015</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-high col2" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information on allocation concealment and baseline characteristics suggest a mismatch between the two groups despite randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group. The authors have given details of the seizure definition used and who diagnosed the seizures. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk in one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.1 Proportion of infants who achieve seizure control after the first loading dose of ASM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-31">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-32"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.2 Mortality before hospital discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Pathak 2013</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> <tr class="study-data"> <td> <p>Solanki 2015</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-high col2" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information on allocation concealment and baseline characteristics suggest a mismatch between the two groups despite randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk in one of the domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.2 Mortality before hospital discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-32">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-33"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.3 Requirement of mechanical ventilation</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Pathak 2013</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.3 Requirement of mechanical ventilation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-33">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-34"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.4 Proportion of infants who develop sedation or drowsiness</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Solanki 2015</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-high col2" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information on allocation concealment and baseline characteristics suggest a mismatch between the two groups despite randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk in one of the domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.4 Proportion of infants who develop sedation or drowsiness</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-34">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-35"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.5 Bradycardia</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Pathak 2013</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.5 Bradycardia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-35">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-36"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.6 Proportion of infants with persistent seizures and/or requiring ASM at discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Solanki 2015</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-high col2" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information on allocation concealment and baseline characteristics suggest a mismatch between the two groups despite randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group. The authors have given details of the seizure definition used and who diagnosed the seizures. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk in one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.6 Proportion of infants with persistent seizures and/or requiring ASM at discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-36">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-37"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.1 Proportion of infants who achieve seizure control after the first loading dose of ASM</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Solanki 2015</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-high col2" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information on allocation concealment and baseline characteristics suggest a mismatch between the two groups despite randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group. The authors have given details of the seizure definition used and who diagnosed the seizures. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk in one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.1 Proportion of infants who achieve seizure control after the first loading dose of ASM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-37">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-38"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.2 Mortality before hospital discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Solanki 2015</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-high col2" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information on allocation concealment and baseline characteristics suggest a mismatch between the two groups despite randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk in one of the domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.2 Mortality before hospital discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-38">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-39"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.3 Proportion of infants who develop sedation or drowsiness</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Solanki 2015</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-high col2" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information on allocation concealment and baseline characteristics suggest a mismatch between the two groups despite randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk in one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.3 Proportion of infants who develop sedation or drowsiness</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-39">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-40"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.4 Proportion of infants with persistent seizures and/or requiring ASM at discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Solanki 2015</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-high col2" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information on allocation concealment and baseline characteristics suggest a mismatch between the two groups despite randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group. The authors have given details of the seizure definition used and who diagnosed the seizures. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk in one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.4 Proportion of infants with persistent seizures and/or requiring ASM at discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-40">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-41"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.1 Proportion of infants who achieve seizure control after the first loading dose of ASM</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Solanki 2015</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-high col2" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information on allocation concealment and baseline characteristics suggest a mismatch between the two groups despite randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group. The authors have given details of the seizure definition used and who diagnosed the seizures. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk in one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.1 Proportion of infants who achieve seizure control after the first loading dose of ASM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-41">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-42"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.2 Mortality before hospital discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Solanki 2015</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-high col2" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information on allocation concealment and baseline characteristics suggest a mismatch between the two groups despite randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk in one of the domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.2 Mortality before hospital discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-42">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-43"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.3 Proportion of infants who develop sedation or drowsiness</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Solanki 2015</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-high col2" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information on allocation concealment and baseline characteristics suggest a mismatch between the two groups despite randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk in one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.3 Proportion of infants who develop sedation or drowsiness</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-43">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-44"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.4 Proportion of infants with persistent seizures and/or requiring ASM at discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Solanki 2015</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-high col2" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information on allocation concealment and baseline characteristics suggest a mismatch between the two groups despite randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that the assessors were aware of the intervention, there is a likelihood of assessment being influenced by the knowledge of the allocation group. The authors have given details of the seizure definition used and who diagnosed the seizures. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk in one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.4 Proportion of infants with persistent seizures and/or requiring ASM at discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-44">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-45"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.1 Proportion of infants who achieve seizure control after the first loading dose of ASM</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Soul 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Triple‐masked, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blinded study and neither the participants nor the treating physicians were aware of the allocation </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Triple‐masked trial</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.1 Proportion of infants who achieve seizure control after the first loading dose of ASM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-45">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-46"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.2 Mortality before hospital discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Soul 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Triple‐masked, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blinded study and neither the participants nor the treating physicians were aware of the allocation </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Triple‐masked trial</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.2 Mortality before hospital discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-46">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-47"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.3 Proportion of infants with cognitive impairment at 18‐24 months</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Soul 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Triple‐masked, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blinded study and neither the participants nor the treating physicians were aware of the allocation </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Triple‐masked trial</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.3 Proportion of infants with cognitive impairment at 18‐24 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-47">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-48"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.4 Seizure burden during hospitalisation</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Soul 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Triple‐masked, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blinded study and neither the participants nor the treating physicians were aware of the allocation </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>aEEG was utilised to detect seizures which is a reliable method when compared to clinical diagnosis of seizures </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.4 Seizure burden during hospitalisation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-48">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-49"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.5 Requirement for mechanical ventilation</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Soul 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Triple‐masked, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blinded study and neither the participants nor the treating physicians were aware of the allocation </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Triple‐masked trial</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.5 Requirement for mechanical ventilation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-49">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-50"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.6 Hypotension requiring volume or inotropes</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Soul 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Triple‐masked, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blinded study and neither the participants nor the treating physicians were aware of the allocation </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Triple‐masked trial</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.6 Hypotension requiring volume or inotropes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-50">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-51"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.7 Proportion of infants with an abnormal background pattern in EEG during ASM treatment</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Soul 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Triple‐masked, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blinded study and neither the participants nor the treating physicians were aware of the allocation </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Triple‐masked trial</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.7 Proportion of infants with an abnormal background pattern in EEG during ASM treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-51">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-52"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.8 Proportion of infants who develop epilepsy post discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Soul 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Triple‐masked, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blinded study and neither the participants nor the treating physicians were aware of the allocation </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Triple‐masked trial</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.8 Proportion of infants who develop epilepsy post discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-52">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-53"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 8.2 Mortality or neurodevelopmental disability at 12 months' corrected age</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Boylan 2004</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though there is no information on whether the allocation was blinded to participants or treating physicians, there were no significant deviations outside the trial context. Analysis was also as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 8.2 Mortality or neurodevelopmental disability at 12 months' corrected age</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-53">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-54"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 8.3 Mortality before hospital discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Boylan 2004</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though there is no information on whether the allocation was blinded to participants or treating physicians, there were no significant deviations outside the trial context. Analysis was also as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 8.3 Mortality before hospital discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-54">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-55"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 8.4 Neurodevelopmental disability at 12 months' corrected age</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Boylan 2004</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on allocation concealment, but baseline characteristics do not show any differences between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though there is no information on whether the allocation was blinded to participants or treating physicians, there were no significant deviations outside the trial context. Analysis was also as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A trial protocol is not available for assessment</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in more than one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 8.4 Neurodevelopmental disability at 12 months' corrected age</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-55">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-56"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.1 Proportion of infants with repeat seizure before hospital discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Jindal 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Diagnosis of seizures was based on clinical assessment and not EEG. Hence, there is a likelihood that assessment might have been influenced by knowledge of allocation. There is no clear definition for different seizure types, how it was differentiated from non‐epiletic events and how it was assesed and by whom. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk in one domain</p> </td> </tr> <tr class="study-data"> <td> <p>Saxena 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blinded study and neither the participants nor the treating physicians were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients till hospital discharge,Though many of the enrolled patients were lost to follow up, it was balanced between the two groups. Hence, it seems that the result is not biased as reasons for lost to follow up does not differ significantly between the groups. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Diagnosis of seizures was based on clinical assessment and not EEG. Hence, there is a likelihood that assessment might have been influenced by knowledge of allocation. There is no clear definition for different seizure types, how it was differentiated from non‐epiletic events and how it was assesed and by whom. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk in one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.1 Proportion of infants with repeat seizure before hospital discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-56">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-57"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.2 Mortality before hospital discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Jindal 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> <tr class="study-data"> <td> <p>Saxena 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blinded study and neither the participants nor the treating physicians were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients till hospital discharge</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group, </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.2 Mortality before hospital discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-57">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-58"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.3 Mortality at 18 to 24 months</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Saxena 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blinded study and neither the participants nor the treating physicians were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though many of the enrolled patients were lost to follow up, it was balanced between the two groups. Hence, it seems that the result is not biased as reasons for lost to follow up does not differ significantly between the groups. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group, </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.3 Mortality at 18 to 24 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-58">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-59"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.4 Neurodevelopmental disability at 18 to 24 months' corrected age</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Saxena 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blinded study and neither the participants nor the treating physicians were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though many of the enrolled patients were lost to follow up, it was balanced between the two groups. Hence, it seems that the result is not biased as reasons for lost to follow up does not differ significantly between the groups. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>It was a double blinded RCT and hence the outcome assessors are blinded to allocation</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.4 Neurodevelopmental disability at 18 to 24 months' corrected age</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-59">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-60"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.5 Requirement for mechanical ventilation</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Jindal 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.5 Requirement for mechanical ventilation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-60">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-61"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.6 Shock requiring volume or inotropes</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Jindal 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> <tr class="study-data"> <td> <p>Saxena 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blinded study and neither the participants nor the treating physicians were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients till hospital discharge,</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group, </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.6 Shock requiring volume or inotropes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-61">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-62"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.7 Abnormal background pattern in EEG after achieving seizure control</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Saxena 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blinded study and neither the participants nor the treating physicians were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients till hospital discharge,Though many of the enrolled patients were lost to follow up, it was balanced between the two groups. Hence, it seems that the result is not biased as reasons for lost to follow up does not differ significantly between the groups. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>EEG was used to diagnose abnormal activity</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.7 Abnormal background pattern in EEG after achieving seizure control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-62">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-63"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.8 Duration of hospital stay</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Jindal 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias across all domains</p> </td> </tr> <tr class="study-data"> <td> <p>Saxena 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blinded study and neither the participants nor the treating physicians were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients till hospital discharge,Though many of the enrolled patients were lost to follow up, it was balanced between the two groups. Hence, it seems that the result is not biased as reasons for lost to follow up does not differ significantly between the groups. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group, <i>It was a double blinded RCT and hence the outcome assessors are blinded to allocation.</i> </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.8 Duration of hospital stay</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-63">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-64"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.9 Proportion of infants with persistent seizures and/or requiring ASM at discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Jindal 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Diagnosis of seizures was based on clinical assessment and not EEG. Hence, there is a likelihood that assessment might have been influenced by knowledge of allocation. There is no clear definition for different seizure types, how it was differentiated from non‐epiletic events and how it was assesed and by whom. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk in one domain</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.9 Proportion of infants with persistent seizures and/or requiring ASM at discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-64">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-65"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.10 Abnormal neurological examination at discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Jindal 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the outcome is a subjective one and that there is no information on whether assessors were aware of the intervention allocation and there is a likelihood of assessment being influenced by the knowledge of the allocation group, a high risk was adjudged for this domain. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns in one domain</p> </td> </tr> <tr class="study-data"> <td> <p>Saxena 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blinded study and neither the participants nor the treating physicians were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients till hospital discharge</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>It was a double blinded RCT and hence the outcome assessors are blinded to allocation</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.10 Abnormal neurological examination at discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-65">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-66"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.11 Proportion of infants who develop epilepsy post‐discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Saxena 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blinded study and neither the participants nor the treating physicians were aware of the allocation. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though many of the enrolled patients were lost to follow up, it was balanced between the two groups. Hence, it seems that the result is not biased as reasons for lost to follow up does not differ significantly between the groups. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group, </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.11 Proportion of infants who develop epilepsy post‐discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-66">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-67"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 10.1 Seizure burden during hospitalisation</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Srinivasakumar 2015</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome (EEG used), it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> <tr class="study-data"> <td> <p>Van Rooji 2010</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though 9 out of 42 patients randomised were excluded, the reasons for the same are stated and they do not differ substantially between the groups, thus indicating that the results might not be biased. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 10.1 Seizure burden during hospitalisation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-67">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-68"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 10.2 Mortality before hospital discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Srinivasakumar 2015</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> <tr class="study-data"> <td> <p>Van Rooji 2010</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though 9 out of 42 patients randomised were excluded, the reasons for the same are stated and they do not differ substantially between the groups, thus indicating that the results might not be biased. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 10.2 Mortality before hospital discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-68">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-69"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 10.3 Proportion of infants who develop epilepsy post‐discharge</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Srinivasakumar 2015</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Allocation concealed, sequence generation random and baseline characteristics does not reveal any imbalance between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Though the personnel were aware of the intervention allocation, but there seems to be no deviations that arouse outside the trial context. Also all patients analysed as randomised. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data reasonably complete for all the included patients</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Being an objective outcome, it is unlikely that assessment of the outcome would be influenced by knowledge of allocation group </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial analysed as per a priori registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk across all domains</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 10.3 Proportion of infants who develop epilepsy post‐discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014967.pub2/references#riskOfBias2Table-69">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD014967.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD014967-note-0015">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD014967-note-0025">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD014967-note-0021">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD014967-note-0024">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD014967-note-0020">Hrvatski</a> </li> <li class="section-language"> <a class="" href="id#CD014967-note-0022">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ms#CD014967-note-0019">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD014967-note-0023">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD014967-note-0018">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD014967-note-0016">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD014967-note-0017">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014967\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014967\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014967\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014967\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014967\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014967\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014967\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014967\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014967\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014967\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014967\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014967\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014967\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014967\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014967\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014967\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014967\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014967\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XHP2gG4h&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014967.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014967.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD014967.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD014967.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014967.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719157812"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014967.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719157816"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014967.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de1e62feb1be4',t:'MTc0MDcxOTE1OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 